CD33-specific chimeric antigen receptor
A CD33-targeting chimeric antigen receptor (CAR) is engineered into immune cells to address the limitations of current AML treatments, enhancing the immune response against AML cells and improving treatment efficacy by targeting leukemic stem cells.
Patent Information
- Application Number
- JP2018564239
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-06-08
- Filing Date
- 2017-06-07
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2037-06-07
AI Technical Summary
Current treatments for acute myeloid leukemia (AML) are limited, especially in older patients, with poor response rates and high mortality, and there is a need for new agents with a favorable safety profile that can target leukemic stem cells to prevent relapse.
Development of a chimeric antigen receptor (CAR) comprising a CD33 antigen binding domain, stalk domain, transmembrane domain, costimulatory signaling domain (4-1BB or CD28), and CD3 zeta signaling domain, engineered into immune effector cells to stimulate a T cell-mediated immune response against AML cells.
The CAR-engineered immune cells effectively target and kill AML cells, including those resistant to chemotherapy, potentially improving treatment outcomes and survival rates by eliminating leukemic stem cells.
Smart Images

Figure 0007591342000022 
Figure 0007591342000023 
Figure 0007591342000024
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 347,503, filed Jun. 8, 2016, the entire contents of which are incorporated herein by reference.
[0002] Reference to sequence listing This application contains a Sequence Listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on Jun. 6, 2017, is named "50471_709_601_SL.txt" and is 103,120 bytes in size. [Background technology]
[0003] Provided herein are compositions and methods for treating cancer in humans. The present invention further relates to specific chimeric antigen receptors and vectors for treating myeloid malignancies, such as acute myeloid leukemia.
[0004] Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow produces abnormal myeloblasts. AML is the most common form of acute leukemia in adults (Siegel, R., et al., Cancer Statistics, CA Cancer J Clin, 64(1):9-29 (2014)). AML is a rapidly progressive disease with a median age at onset of 65-70 years. AML is known by many names, including acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. The "acute" refers to the aggressive nature of the disease, which can progress quickly and, if untreated, can be fatal within months of diagnosis. The cancer originates in the bone marrow but spreads rapidly via the blood to other anatomical sites. The disease is observed in both children and adults, but is more common in the elderly. The likelihood of developing AML increases with age, but people of any age can develop AML. Approximately 8 in 10 adults with acute leukemia are expected to have AML, and approximately 1 in 6 children with leukemia are expected to have AML. In the United States, an average of 12,000 new cases of AML are currently expected annually, with approximately 30,000 patients surviving or experiencing remission.
[0005] In older AML patients (≥65 years), median survival is short (3.9 months for patients aged 65-74 years to 1.4 months for patients ≥85 years). Treatment options for AML patients are limited and outcomes are typically poor, with a median 5-year survival rate of 20% and a 5-year survival rate of less than 5% for patients over 65 years (Thein, M. et al., Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades, Cancer, 119(15):2720-7 (2013)). Certain subgroups of AML have poorer outcomes, especially patients with relapsed and / or refractory AML and AML resulting from abnormalities within chromosome 7, complex karyotypes, prior myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN). Patients ≥65 years with AML are more likely to exhibit unfavorable risk cytogenetics than younger patients. These cytogenetic factors are associated with resistance to chemotherapy and show significantly lower response rates to treatment. In addition to response rates, elderly patients with AML are often not considered candidates for or selected to receive standard induction chemotherapy due to poor tolerability and treatment outcomes. Induction chemotherapy is associated with high rates of treatment-related mortality and low complete response (CR) rates in this patient subset. Currently, there are no approved therapies for AML patients who do not receive standard induction chemotherapy. Due to the lack of treatments and cytogenetics associated with poor response rates, AML has an unmet medical need for new agents that support clinical benefit with a favorable safety profile.
[0006] Hematopoiesis is characterized by tissue-specific hierarchical differentiation from pluripotent stem cells to more mature differentiated cell phenotypes. Similar to homeostatic hematopoiesis, AML is thought to arise from mutations that result in leukemic stem cells (LSCs) accumulating within this dormant stem cell population. The inability to eliminate this AML LSC population results in relapse and treatment failure.
[0007] Most patients with AML achieve remission with induction chemotherapy, but many relapse despite administration of post-remission consolidation therapy. Relapses can occur after weeks to years. Up to 10% of patients become resistant to induction chemotherapy. Both of these groups of patients (relapsed / refractory) constitute a particularly poor risk group. Allogeneic stem cell transplantation is considered the recommended procedure for the majority of these patients, but is feasible in only a minority of patients and is associated with significant morbidity and mortality (Hamadani, M., Awan, F. & Copelan, E., Hematopoietic stem cell transplantation in adults with acute myeloid leukemia, Biol Blood Marrow Transplant, 5:556-67 (2008)). In addition, the outcome of transplanted patients with refractory disease is also poor (Duval, M. et al., Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure, J Clin Oncol, 28(23):3730-8 (2010)), and almost half of patients with recurrent disease are chemotherapy resistant and therefore not suitable for transplantation (Hamadani, M., Awan, F. & Copelan, E., Hematopoietic stem cell transplantation in adults with acute myeloid leukemia Biol Blood Marrow Transplant, 5:556-67 (2008); Estey, E., 2013. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol, 88(4), pp. 318-27). Many new drugs and approaches are being explored for this group of patients.However, the CR rate is generally less than 30% (Litzow, M. et al., Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group, Br J Haemotol, 148:217-25 (2010), Cortes, J. et al., Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia, Cancer, 118(2):418-27 (2012), Kirschbaum, M. et al., A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia, Leukemia, 25(10):1543-7 (2011)).
[0008] In patients with AML, cytogenetics is an important prognostic factor in predicting response to treatment (Grimwade, D. et al., The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties, Blood, 92(7):2322-33 (1998)). Patients with AML whose leukemic cells have t(8;21), t(15;17), t(16;16), or inv(16) translocations have a good outcome with induction chemotherapy and intensive postremission consolidation chemotherapy. However, abnormalities of chromosomes 5 or 7, 11q23, or complex karyotypes have a very poor outcome even with currently available induction and postremission chemotherapy. Patients with normal karyotype or trisomy 8 have an intermediate prognosis. Among adults with AML, t(9;22) or t(4;11) confers an extremely poor prognosis. Patients with AML due to t(9;22) are rarely, if ever, cured with chemotherapy alone. Immunophenotyping of surface antigens expressed on leukemic blasts may aid in diagnosis and has important implications for the treatment and prognosis of myeloid, T-cell, and B-cell leukemias. Given the difficulty in achieving long-term survival in AML using conventional therapies, novel treatment strategies are needed. Summary of the Invention
[0009] One aspect of the present disclosure is an isolated nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises: (a) a CD33 antigen-binding domain; (b) a stalk domain; (c) a transmembrane domain; (d) a costimulatory signaling domain comprising at least one of 4-1BB and CD28, or a fragment thereof; (e) a CD3 zeta signaling domain; and, optionally, (f) a truncated epitheliumThe present invention relates to an isolated nucleic acid comprising a growth factor receptor (HER1t or HER1t-1).
[0010] Provided herein is a vector comprising a scaffold and a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain. In certain embodiments, a truncated epithelium Vectors are provided which further comprise a nucleic acid encoding a growth factor receptor (HER1t or HER1t-1), or full-length or truncated CD20.
[0011] As used herein, the term "scaffold" refers to a structure having: (1) a truncated form; epithelium Vectors are provided that contain a growth factor receptor or a functional variant thereof, and (2) a nucleic acid sequence encoding a chimeric antigen receptor (CAR) that contains (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0012] In certain embodiments, vectors are provided that comprise a scaffold and a nucleic acid sequence encoding (1) full-length CD20 and its functional variants, and (2) a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0013] In certain embodiments, the scaffold comprises: (a) a CD33 antigen-binding domain; (b) a stalk domain; (c) a transmembrane domain; (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; (e) a CD3 zeta signaling domain; and (f) a truncated epitheliumEngineered cells, e.g., immune effector cells, are provided that contain a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising at least one of a growth factor receptor (HER1t or HER1t-1), full-length CD20, and a truncated CD20 (CD20t-1).
[0014] In certain embodiments, (1) a truncated epithelium Provided are engineered cells, e.g., immune effector cells, comprising a growth factor receptor (HER1t or HER1t-1) and (2) a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0015] In certain embodiments, modified cells, e.g., immune effector cells, are provided that include (1) a cell tag for use as a kill switch, a selection marker, a biomarker, or a combination thereof, and (2) a chimeric antigen receptor (CAR) that includes (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain, and (e) a CD3 zeta signaling domain. In certain embodiments, the costimulatory signaling domain includes at least one of 4-1BB and CD28. In some embodiments, the cell tag is HER1t, HER1t-1, CD20, or CD20t-1.
[0016] Provided herein is a method for stimulating a T cell-mediated immune response in a human against a target cell population or tissue, comprising administering to the human an effective amount of a cell genetically modified to express a CAR, the CAR comprising: (a) a CD33 antigen-binding domain; (b) a stalk domain; (c) a transmembrane domain; (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; (e) a CD3 zeta signaling domain; and (f) a truncated T cell-mediated immune response in a human. epitheliumA method is presented that involves a growth factor receptor (HER1t or HER1t-1).
[0017] Provided herein is an isolated nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises: (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0018] In some embodiments, the CD33 antigen-binding domain is (a) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 8 (hM195scFv); (b) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 9 and 10 (M2H12). (c) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 11 and 12 (DRB2); and (d) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 14 and 15 (My9-6).
[0019] Optionally, the CD33 antigen-binding domain is a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 8 (hM195scFv). Optionally, the stalk domain is a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 22 (CD8 alpha hinge).
[0020] In some embodiments, the costimulatory signaling domain comprises 4-1BB. Optionally, the costimulatory signaling domain of 4-1BB comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:24. Optionally, the costimulatory signaling domain comprises CD28. In some embodiments, the costimulatory signaling domain of CD28 comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:28.
[0021] In some embodiments, the CD3 zeta signaling domain comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 26. In some embodiments, the isolated nucleic acid comprises a truncated form epithelium Further comprising a growth factor receptor. Optionally, a truncated form epithelium The growth factor receptor is HER1t and comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 32. epithelium The growth factor receptor is HER1t-1 and comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:54.
[0022] In some embodiments, the CAR comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an amino acid sequence comprising SEQ ID NO: 39, 41, 43, 45, 47, 49, 51, 53, or 55.
[0023] As used herein, the invention relates to a scaffold and (1) a truncated form of HER1t, HER1t-1, or at least one of functional variants thereof. epithelium Provided is a vector comprising a growth factor receptor and (2) a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0024] Provided herein are vectors comprising a scaffold and a nucleic acid sequence encoding (1) full-length CD20, a truncated CD20 (CD20t-1), or a functional variant thereof, and (2) a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0025] In some embodiments, the vector is a lentiviral vector, a retroviral vector, or a non-viral vector. epithelium The growth factor receptor comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 32 or SEQ ID NO: 54. Optionally, the vector comprises a nucleotide sequence encoding a truncated CD20 (CD20t-1), or a functional variant thereof, said CD20t-1 comprising a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 56.
[0026] In some embodiments, the full length CD20 comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 36. Optionally, the vector further comprises a nucleotide sequence encoding a self-cleaving Thosea asigna virus (T2A) peptide. Optionally, the backbone of the vector is a DNA plasmid of the Sleeping Beauty transposon or pFUGW.
[0027] Optionally, the vector further comprises a promoter. Optionally, the promoter is hEF1a1. Optionally, the CD33 antigen binding domain is (a) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 8 (hM195scFv), (b) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 9 and 10 (M2H12). , (c) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 11 and 12 (DRB2), and (d) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 14 and 15 (My9-6).
[0028] In some embodiments, the CD33 antigen-binding domain is a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 8. Optionally, the stalk domain comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 22 (CD8 alpha hinge). Optionally, the costimulatory signaling domain comprises 4-1BB. In some embodiments, the costimulatory signaling domain of 4-1BB comprises a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 24.
[0029] Optionally, the costimulatory signaling domain of the vector comprises CD28. Optionally, the costimulatory signaling domain of CD28 comprises a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:28. Optionally, the CD3 zeta signaling domain comprises a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:26.
[0030] In some embodiments, the vector comprises a plasmid. Optionally, each of the vectors comprises an expression plasmid. Optionally, the non-viral vector is a Sleeping Beauty transposon. In some embodiments, the immune effector cell can comprise a nucleotide sequence disclosed herein.
[0031] As used herein, the term "scaffold" refers to a structure having: (1) a truncated form; epitheliumImmune effector cells are provided that comprise a vector comprising a growth factor receptor (HER1t) and (2) a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0032] Also provided herein are (1) cell tags for use as a kill switch, a selection marker, a biomarker, or a combination thereof, and (2) immune effector cells comprising a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0033] In some embodiments, the cell tag comprises HER1t, HER1t-1, CD20t-1, or CD20. Optionally, the cell tag comprises HER1t, said HER1t comprising the polypeptide sequence of SEQ ID NO: 32. Optionally, the cell tag comprises HER1t-1, said HER1t-1 comprising the polypeptide sequence of SEQ ID NO: 54. Optionally, the immune effector cell comprises a vector disclosed herein. In some embodiments, the cell is a T cell, a natural killer (NK) cell, a cytotoxic T lymphocyte (CTL), or a regulatory T cell. Optionally, the cell exhibits anti-tumor immunity when the CD33 antigen-binding domain binds to CD33.
[0034] Provided herein is a method for stimulating a T cell-mediated immune response against a target cell population or target tissue in a human subject in need thereof, comprising administering to the human subject an effective amount of a cell genetically modified to express a CAR, the CAR comprising: (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, (e) a CD3 zeta signaling domain, and (f) a truncated form of a CAR. epithelium A method is presented, comprising: detecting a HER1t-dependent marker for the proliferation and differentiation of a HER1t-dependent marker.
[0035] In some embodiments, the human has been diagnosed with acute myeloid leukemia (AML). Optionally, the acute myeloid leukemia is relapsed or refractory AML.
[0036] An isolated nucleic acid is provided that encodes a chimeric antigen receptor (CAR), the CAR comprising: (a) a CD33 antigen-binding domain with the amino acid sequence of SEQ ID NO:8; (b) a stalk domain with the amino acid sequence of SEQ ID NO:22; (c) a costimulatory signaling domain comprising a CD28 with the amino acid sequence of SEQ ID NO:28; (d) a HER1 tag comprising at least one of HER1t with the amino acid sequence of SEQ ID NO:32 and HER1t-1 with the amino acid sequence of SEQ ID NO:54; and (e) a CD3 zeta signaling domain with the amino acid sequence of SEQ ID NO:26.
[0037] Also provided herein is an isolated nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises: (a) a CD33 antigen-binding domain with the amino acid sequence of SEQ ID NO:8; (b) a stalk domain with the amino acid sequence of SEQ ID NO:22; (c) a costimulatory signaling domain comprising 4-1BB with the amino acid sequence of SEQ ID NO:24; (d) a HER1 tag comprising at least one of HER1t with the amino acid sequence of SEQ ID NO:32 and HER1t-1 with the amino acid sequence of SEQ ID NO:54; and (e) a CD3 zeta signaling domain with the amino acid sequence of SEQ ID NO:26.
[0038] In some embodiments, the vector comprises one or more of the polynucleotides disclosed herein. Optionally, the vector is a lentiviral vector, a retroviral vector, or a non-viral vector. Optionally, the non-viral vector is a Sleeping Beauty transposon. In some embodiments, the vector is a plurality of vectors.
[0039] A system for expressing a CAR in an immune effector cell is provided, the system comprising one or more vectors encoding the isolated nucleic acid disclosed herein. In some embodiments, the immune effector cell is a T cell or a NK cell. Optionally, the system further comprises a nucleic acid encoding at least one additional gene. Optionally, the additional gene comprises a cytokine. In some embodiments, the cytokine comprises at least one of IL-2, IL-15, IL-12, IL-21, and a fusion of IL-15 with IL-15Rα. Optionally, the cytokine is in a secreted form. In some embodiments, the cytokine is in a membrane-bound form.
[0040] Optionally, the system comprises a vector. Optionally, the one or more vectors are lentiviral vectors, retroviral vectors, or non-viral vectors. In some embodiments, the non-viral vector is a Sleeping Beauty transposon. Optionally, the system further comprises a Sleeping Beauty transposase. Optionally, the Sleeping Beauty transposase is SB11, SB100X, or SB110. Optionally, the immune effector cell is a mammalian cell. In some embodiments, the method of expressing a CAR in an immune effector cell comprises contacting the immune effector cell with the system disclosed herein.
[0041] Provided herein is a method of stimulating the proliferation and / or survival of modified T cells, the method comprising: (a) obtaining a sample of cells from a subject, the sample comprising T cells or progenitor cells of T cells; (b) transfecting the cells with one or more vectors encoding the isolated nucleic acid of any one of claims 1-13 and 44-45, and a vector encoding a transposase, resulting in a population of modified CD33 CAR-expressing T cells; and (c) optionally culturing the population of CD33 CAR T cells ex vivo for two days or less.
[0042] In some embodiments, the method further comprises transfecting the cell with a vector encoding a cytokine. Optionally, the cytokine is a fusion protein comprising IL-15 and IL-15Rα. Optionally, the one or more vectors are lentiviral vectors, retroviral vectors, or non-viral vectors. In some embodiments, the non-viral vector is a Sleeping Beauty transposon. Optionally, the method further comprises a Sleeping Beauty transposase. Optionally, the Sleeping Beauty transposase is SB11, SB100X, or SB110.
[0043] The features of the present disclosure are pointed out with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings. [Brief description of the drawings]
[0044] [Figure 1] FIG. 1 is a schematic diagram depicting the structure of CD33 isoforms. [Diagram 2] FIG. 1 depicts the CD33 CAR lentiviral vector map. [Diagram 3]FIG. 1 is an exemplary schematic diagram for the Sleeping Beauty transposon system. [Figure 4] FIG. 1 is an exemplary schematic diagram for lentiviral transduction to generate CAR-T cells. [Diagram 5] FIG. 1 depicts the expression of CD33 CAR and HER1t on adoptively transferred T cells. [Figure 6] FIG. 14 confirms Western blot confirmation of CD33 CAR expression from lentiviral transduced cells. [Figure 7] Figure 1 shows the kinetics of absolute number expansion of in vitro cultured CD33 CAR-T cells and fold increase of total T cell population from untransduced T cells (UNT) and CD33 CAR-T cells (CD33 CARLV) after stimulation with CD3 / CD28 beads. [Figure 8] FIG. 1 provides an assessment of CD33 CAR-T cell copy number after lentiviral transduction. [Figure 9-1] Figures 9A, 9B, and 9C: Figures supporting the target-specific in vitro cytotoxicity of CD33 CAR-T cells. CD33-specific cytotoxicity was measured by europium-labeled target cells (EL4, EL4 / CD33, and MOLM-13) (Figure 9A). Surface expression levels of CD33 on the tested cell lines were measured by flow cytometry. Bold shaded lines indicate staining with an isotype control antibody, and light shaded lines indicate staining with an anti-human CD33 antibody (Figures 9B and 9C). [Figure 9-2]Figures 9A, 9B, and 9C: Figures supporting the target-specific in vitro cytotoxicity of CD33 CAR-T cells. CD33-specific cytotoxicity was measured by europium-labeled target cells (EL4, EL4 / CD33, and MOLM-13) (Figure 9A). Surface expression levels of CD33 on the tested cell lines were measured by flow cytometry. Bold shaded lines indicate staining with an isotype control antibody, and light shaded lines indicate staining with an anti-human CD33 antibody (Figures 9B and 9C). [Figure 10A] Figures confirm the production of cytokines (IFNγ (Figure 10A), IL-2 (Figure 10B), and TNF (Figure 10C)) from ex vivo expanded CD33 CAR-T cells. [Figure 10B] Figures confirm the production of cytokines (IFNγ (Figure 10A), IL-2 (Figure 10B), and TNF (Figure 10C)) from ex vivo expanded CD33 CAR-T cells. [Figure 10C] Figures confirm the production of cytokines (IFNγ (Figure 10A), IL-2 (Figure 10B), and TNF (Figure 10C)) from ex vivo expanded CD33 CAR-T cells. [Figure 11] FIG. 1 shows cetuximab-induced antibody-dependent cell-mediated cytotoxicity (ADCC) of HER1t-expressing CD33 CAR-T cells. [Figure 12] FIG. 14 supports survival curves of NSG mice by treatment group in an AML tumor model. [Figure 13] Figures 13A and 13B: Quantitative analysis of tumor burden as measured by fLUC bioluminescence is presented: Figure 13A: ventral view and Figure 13B: dorsal view. [Figure 14A] FIG. 13 presents flow cytometry analysis of blood, bone marrow, and spleen samples from NSG mice treated with CD33 CAR-T cells. [Figure 14B]FIG. 13 presents flow cytometry analysis of blood, bone marrow, and spleen samples from NSG mice treated with CD33 CAR-T cells. [Figure 15] Figures 15A and 15B: Figures demonstrating the expression of CD33 CAR and HER1t on diverse human T cells transduced with LV. [Figure 16A] 16A depicts a graph depicting flow cytometry results for CD33 expression on various AML cell lines (FIG. 16A). FIG. 16B depicts a graph depicting the results of a 2-hour europium release assay for various LV CD33 CARs on various CD33-expressing AML cell lines (FIG. 16B). FIG. 16C depicts the results of expression of cytokines released by T cells upon recognition of various CD33-expressing AML cell lines by LV CD33 CARs (FIG. 16C). [Figure 16B] 16A depicts a graph depicting flow cytometry results for CD33 expression on various AML cell lines (FIG. 16A). FIG. 16B depicts a graph depicting the results of a 2-hour europium release assay for various LV CD33 CARs on various CD33-expressing AML cell lines (FIG. 16B). FIG. 16C depicts the results of expression of cytokines released by T cells upon recognition of various CD33-expressing AML cell lines by LV CD33 CARs (FIG. 16C). [Figure 16C] 16A depicts a graph depicting flow cytometry results for CD33 expression on various AML cell lines (FIG. 16A). FIG. 16B depicts a graph depicting the results of a 2-hour europium release assay for various LV CD33 CARs on various CD33-expressing AML cell lines (FIG. 16B). FIG. 16C depicts the results of expression of cytokines released by T cells upon recognition of various CD33-expressing AML cell lines by LV CD33 CARs (FIG. 16C). [Figure 17]FIG. 1 presents a graph depicting lysis of CD33-expressing leukemia cell lines by CAR33-CD8a-CD28m-Z (Sleeping Beauty) T cells. [Figure 18] FIG. 13 presents graphs depicting flow cytometry results demonstrating the effect of CAR33-CD8a-CD28m-Z (Sleeping Beauty) T cells on CD107a degranulation and IFNγ production in the presence of CD33-expressing target cells. [Figure 19] FIG. 1 presents graphs depicting flow cytometry results supporting expression of CD33 CAR (Sleeping Beauty) and HER1t on genetically modified T cells. [Figure 20A] 20A depicts the effect of the CAR described herein in CD33-expressing AML cells. Figure 20A presents a graph depicting the flow cytometry results for CD33 expression on various AML cell lines. Figure 20B presents a graph depicting the results of a 2-hour europium release assay for CAR33-CD8a-CD28m-Z (Sleeping Beauty) on various CD33-expressing AML cell lines. [Figure 20B] 20A depicts the effect of the CAR described herein in CD33-expressing AML cells. Figure 20A presents a graph depicting the flow cytometry results for CD33 expression on various AML cell lines. Figure 20B presents a graph depicting the results of a 2-hour europium release assay for CAR33-CD8a-CD28m-Z (Sleeping Beauty) on various CD33-expressing AML cell lines. [Figure 21-1] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-2] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-3]FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-4] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-5] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-6] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-7] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-8] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-9] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-10] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-11] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-12] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-13] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-14] FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 21-15]FIG. 1 provides a sequence listing illustrating nucleic acid and polypeptide sequences for the methods and compositions described herein. [Figure 22A-1]Figures 22A and 22B present the effect of compositions described herein when contacted with tumor cells, including in vivo results in mice. Figure 22A presents a graph depicting cytokine analysis from plasma of mice administered CAR-T cells on day 11 of the study (3 days after CAR-T cell administration). Plasma from mice was collected and human cytokines were assessed by a multiplex analyte platform. Mean values ± SEM are shown for several analytes measured (GM-CSF, IFNγ, TNFα, IL-10, IL-18, and IP-10). N=11-15 mice per group, including mice that were part of satellite groups for tissue collection at the specified time points. *p<0.05; **p<0.01; ***p<0.001; One-way analysis of variance (ANOVA) with Tukey's multiple comparison test for saline, non-transduced T cells, and CD19-CAR-T cells for each treatment group. FIG. 22B presents a graph depicting a representative sampling of blood samples taken from AML tumor-bearing mice after treatment with CAR T cells. AML tumor-bearing mice were treated with saline, non-transduced T cells, a single dose of CD19-CAR-T cells, or CD33-CAR-T cells on day 8. The group noted as dose 2 received a second dose of equal doses of CD33-CAR-T cells alone on day 15 of the study. Blood samples were obtained from mice to assess the presence and persistence of CAR T cells, as well as the presence of MOLM-13 tumor cells (based on expression of CD123). (A) On day 16, when the mice became moribund, blood samples were taken from mice treated with saline alone, non-transduced T cells, or CD19-CAR-T cells. (B) On day 18, blood samples were taken from the remaining mice treated with CD33-CAR-T cells. Data shown was gated on FSC / SSC / human CD45+ cells. Figure 22C: Graph depicting cytotoxic activity against ALM tumor cell lines (THP1 and HL60). [Figure 22A-2]Figures 22A and 22B present the effect of compositions described herein when contacted with tumor cells, including in vivo results in mice. Figure 22A presents a graph depicting cytokine analysis from plasma of mice administered CAR-T cells on day 11 of the study (3 days after CAR-T cell administration). Plasma from mice was collected and human cytokines were assessed by a multiplex analyte platform. Mean values ± SEM are shown for several analytes measured (GM-CSF, IFNγ, TNFα, IL-10, IL-18, and IP-10). N=11-15 mice per group, including mice that were part of satellite groups for tissue collection at the specified time points. *p<0.05; **p<0.01; ***p<0.001; One-way analysis of variance (ANOVA) with Tukey's multiple comparison test for saline, non-transduced T cells, and CD19-CAR-T cells for each treatment group. FIG. 22B presents a graph depicting a representative sampling of blood samples taken from AML tumor-bearing mice after treatment with CAR T cells. AML tumor-bearing mice were treated with saline, non-transduced T cells, a single dose of CD19-CAR-T cells, or CD33-CAR-T cells on day 8. The group noted as dose 2 received a second dose of equal doses of CD33-CAR-T cells alone on day 15 of the study. Blood samples were obtained from mice to assess the presence and persistence of CAR T cells, as well as the presence of MOLM-13 tumor cells (based on expression of CD123). (A) On day 16, when the mice became moribund, blood samples were taken from mice treated with saline alone, non-transduced T cells, or CD19-CAR-T cells. (B) On day 18, blood samples were taken from the remaining mice treated with CD33-CAR-T cells. Data shown was gated on FSC / SSC / human CD45+ cells. Figure 22C: Graph depicting cytotoxic activity against ALM tumor cell lines (THP1 and HL60). [Figure 22B-1]Figures 22A and 22B present the effect of compositions described herein when contacted with tumor cells, including in vivo results in mice. Figure 22A presents a graph depicting cytokine analysis from plasma of mice administered CAR-T cells on day 11 of the study (3 days after CAR-T cell administration). Plasma from mice was collected and human cytokines were assessed by a multiplex analyte platform. Mean values ± SEM are shown for several analytes measured (GM-CSF, IFNγ, TNFα, IL-10, IL-18, and IP-10). N=11-15 mice per group, including mice that were part of satellite groups for tissue collection at the specified time points. *p<0.05; **p<0.01; ***p<0.001; One-way analysis of variance (ANOVA) with Tukey's multiple comparison test for saline, non-transduced T cells, and CD19-CAR-T cells for each treatment group. FIG. 22B presents a graph depicting a representative sampling of blood samples taken from AML tumor-bearing mice after treatment with CAR T cells. AML tumor-bearing mice were treated with saline, non-transduced T cells, a single dose of CD19-CAR-T cells, or CD33-CAR-T cells on day 8. The group noted as dose 2 received a second dose of equal doses of CD33-CAR-T cells alone on day 15 of the study. Blood samples were obtained from mice to assess the presence and persistence of CAR T cells, as well as the presence of MOLM-13 tumor cells (based on expression of CD123). (A) On day 16, when the mice became moribund, blood samples were taken from mice treated with saline alone, non-transduced T cells, or CD19-CAR-T cells. (B) On day 18, blood samples were taken from the remaining mice treated with CD33-CAR-T cells. Data shown was gated on FSC / SSC / human CD45+ cells. Figure 22C: Graph depicting cytotoxic activity against ALM tumor cell lines (THP1 and HL60). [Figure 22B-2]Figures 22A and 22B present the effect of compositions described herein when contacted with tumor cells, including in vivo results in mice. Figure 22A presents a graph depicting cytokine analysis from plasma of mice administered CAR-T cells on day 11 of the study (3 days after CAR-T cell administration). Plasma from mice was collected and human cytokines were assessed by a multiplex analyte platform. Mean values ± SEM are shown for several analytes measured (GM-CSF, IFNγ, TNFα, IL-10, IL-18, and IP-10). N=11-15 mice per group, including mice that were part of satellite groups for tissue collection at the specified time points. *p<0.05; **p<0.01; ***p<0.001; One-way analysis of variance (ANOVA) with Tukey's multiple comparison test for saline, non-transduced T cells, and CD19-CAR-T cells for each treatment group. FIG. 22B presents a graph depicting a representative sampling of blood samples taken from AML tumor-bearing mice after treatment with CAR T cells. AML tumor-bearing mice were treated with saline, non-transduced T cells, a single dose of CD19-CAR-T cells, or CD33-CAR-T cells on day 8. The group noted as dose 2 received a second dose of equal doses of CD33-CAR-T cells alone on day 15 of the study. Blood samples were obtained from mice to assess the presence and persistence of CAR T cells, as well as the presence of MOLM-13 tumor cells (based on expression of CD123). (A) On day 16, when the mice became moribund, blood samples were taken from mice treated with saline alone, non-transduced T cells, or CD19-CAR-T cells. (B) On day 18, blood samples were taken from the remaining mice treated with CD33-CAR-T cells. Data shown was gated on FSC / SSC / human CD45+ cells. Figure 22C: Graph depicting cytotoxic activity against ALM tumor cell lines (THP1 and HL60). [Figure 22C]Figures 22A and 22B present the effect of compositions described herein when contacted with tumor cells, including in vivo results in mice. Figure 22A presents a graph depicting cytokine analysis from plasma of mice administered CAR-T cells on day 11 of the study (3 days after CAR-T cell administration). Plasma from mice was collected and human cytokines were assessed by a multiplex analyte platform. Mean values ± SEM are shown for several analytes measured (GM-CSF, IFNγ, TNFα, IL-10, IL-18, and IP-10). N=11-15 mice per group, including mice that were part of satellite groups for tissue collection at the specified time points. *p<0.05; **p<0.01; ***p<0.001; One-way analysis of variance (ANOVA) with Tukey's multiple comparison test for saline, non-transduced T cells, and CD19-CAR-T cells for each treatment group. FIG. 22B presents a graph depicting a representative sampling of blood samples taken from AML tumor-bearing mice after treatment with CAR T cells. AML tumor-bearing mice were treated with saline, non-transduced T cells, a single dose of CD19-CAR-T cells, or CD33-CAR-T cells on day 8. The group noted as dose 2 received a second dose of equal doses of CD33-CAR-T cells alone on day 15 of the study. Blood samples were obtained from mice to assess the presence and persistence of CAR T cells, as well as the presence of MOLM-13 tumor cells (based on expression of CD123). (A) On day 16, when the mice became moribund, blood samples were taken from mice treated with saline alone, non-transduced T cells, or CD19-CAR-T cells. (B) On day 18, blood samples were taken from the remaining mice treated with CD33-CAR-T cells. Data shown was gated on FSC / SSC / human CD45+ cells. Figure 22C: Graph depicting cytotoxic activity against ALM tumor cell lines (THP1 and HL60). [Figure 23-1]Figures 23A-23E: Describe the generation of CD33-CAR-T cells from T cells of an AML patient and support the cytotoxic activity against AML tumor cells. Figure 23A: PBMCs from an AML donor were obtained and phenotypically characterized for expression of CD33 and CD3. Figure 23B: T cells were isolated from the PBMC fraction using a bead-based method and the unlabeled fraction was characterized for CD33+ tumor cells. Figure 23C: T cells were transduced with LV-CD33-CAR construct and show expression of the CAR at day 14 of culture. Figure 23D: Shows co-culture of CD33-CAR-T cells from an AML donor with MOLM-13 tumor cells or AML donor tumor cells at day 0 (when the assay was ready) and day 3. All cells were gated for FSC / SSC / viable cells. Figure 23E: Cytokine expression of CD33-CAR-T cells from an AML patient after co-culture with CD33-expressing tumor cells. Intracellular cytokine staining was performed on CD33-CAR-T cells (derived from AML donor E261) 18 hours after co-culture with the indicated tumor cells. T cells were cell surface stained and then stained for the cytokines IFNγ and IL-2 following fixation / permeabilization. Cells were gated based on FSC / SSC / Live / CD3 T cells. AML E261 cells refer to the patient's autologous CD33 tumor cells present in the sample. [Figure 23-2]Figures 23A-23E: Describe the generation of CD33-CAR-T cells from T cells of an AML patient and support the cytotoxic activity against AML tumor cells. Figure 23A: PBMCs from an AML donor were obtained and phenotypically characterized for expression of CD33 and CD3. Figure 23B: T cells were isolated from the PBMC fraction using a bead-based method and the unlabeled fraction was characterized for CD33+ tumor cells. Figure 23C: T cells were transduced with LV-CD33-CAR construct and show expression of the CAR at day 14 of culture. Figure 23D: Shows co-culture of CD33-CAR-T cells from an AML donor with MOLM-13 tumor cells or AML donor tumor cells at day 0 (when the assay was ready) and day 3. All cells were gated for FSC / SSC / viable cells. Figure 23E: Cytokine expression of CD33-CAR-T cells from an AML patient after co-culture with CD33-expressing tumor cells. Intracellular cytokine staining was performed on CD33-CAR-T cells (derived from AML donor E261) 18 hours after co-culture with the indicated tumor cells. T cells were cell surface stained and then stained for the cytokines IFNγ and IL-2 following fixation / permeabilization. Cells were gated based on FSC / SSC / Live / CD3 T cells. AML E261 cells refer to the patient's autologous CD33 tumor cells present in the sample. [Figure 23-3]Figures 23A-23E: Describe the generation of CD33-CAR-T cells from T cells of an AML patient and support the cytotoxic activity against AML tumor cells. Figure 23A: PBMCs from an AML donor were obtained and phenotypically characterized for expression of CD33 and CD3. Figure 23B: T cells were isolated from the PBMC fraction using a bead-based method and the unlabeled fraction was characterized for CD33+ tumor cells. Figure 23C: T cells were transduced with LV-CD33-CAR construct and show expression of the CAR at day 14 of culture. Figure 23D: Shows co-culture of CD33-CAR-T cells from an AML donor with MOLM-13 tumor cells or AML donor tumor cells at day 0 (when the assay was ready) and day 3. All cells were gated for FSC / SSC / viable cells. Figure 23E: Cytokine expression of CD33-CAR-T cells from an AML patient after co-culture with CD33-expressing tumor cells. Intracellular cytokine staining was performed on CD33-CAR-T cells (derived from AML donor E261) 18 hours after co-culture with the indicated tumor cells. T cells were cell surface stained and then stained for the cytokines IFNγ and IL-2 following fixation / permeabilization. Cells were gated based on FSC / SSC / Live / CD3 T cells. AML E261 cells refer to the patient's autologous CD33 tumor cells present in the sample. [Figure 24] FIG. 1 describes the expression of CD33 CAR and HER1t on NK cells. [Diagram 25] FIG. 1 describes the expression of HER1t and HER1t-1 tags on CD33 CAR NK cells. [Figure 26] FIG. 1 discloses the expression of CD20t-1 tag on CD33 CAR NK cells. [Figure 27] FIG. 14 demonstrates that CD33-CAR NK cells efficiently lyse NK-resistant CD33+ AML cells (ML-2, KG-1). [Figure 28]FIG. 14 demonstrates that CD33-CAR NK cells efficiently lyse an NK-resistant AML cell line (KG-1) at low E:T ratios. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In describing and claiming the invention, the following terminology is used.
[0046] definition In the claims and / or this specification, the use of the words "a" or "an" when used in conjunction with the term "comprising" can mean "one," but is also consistent with the meanings of "one or more," "at least one," and "one or more than one."
[0047] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, method utilized to determine the value, or the variation that exists among study subjects. Typically, the term is intended to encompass a variation of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%, or less, depending on the context.
[0048] Although the term "or" in the claims is used to mean "and / or" unless expressly indicated to refer to alternatives only or that the alternatives are mutually exclusive, the present disclosure supports the definition that refers to alternatives only and the definition that refers to "and / or."
[0049] As used in the specification and claims, the words "comprising" (any form of "comprising", such as "comprise" and "comprises"), "having" (any form of "having", such as "have" and "has"), "including" (any form of "including", such as "include" and "includes"), or "containing" (any form of "containing", such as "contain" and "contains") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed herein can be implemented with respect to any method or composition of the invention, and vice versa. Additionally, the compositions of the invention can be used to achieve the methods of the invention.
[0050] As used herein, "synthetic" or "modified" refers to a compound formed or developed through chemical processes and / or human intervention, as opposed to a naturally occurring compound.
[0051] "Isolated" refers to the removal of a nucleic acid from its natural environment. "Purified" refers to the increased purity of a given nucleic acid, whether it is removed from nature (including genomic DNA and mRNA), synthesized (including cDNA), and / or amplified under laboratory conditions, where "purity" is a relative term and not "absolute purity". On the other hand, it should be understood that nucleic acids and proteins may be formulated with diluents or adjuvants, but for practical purposes may be considered to be isolated. For example, nucleic acids are typically mixed with acceptable carriers or diluents when used for introduction into cells.
[0052] As used herein, "polynucleotide" or "oligonucleotide" refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. The term refers only to the primary structure of the molecule. Thus, the term includes double-stranded and single-stranded DNA, triplex DNA, as well as double-stranded and single-stranded RNA. The term can also include modified forms of polynucleotides, for example, by methylation and / or capping, as well as unmodified forms of polynucleotides. The term is also intended to include molecules that contain non-natural or synthetic nucleotides, as well as nucleotide analogs.
[0053] "Polypeptide" is used interchangeably with the terms "polypeptide," "peptide," and "protein," and refers to a polymer of amino acid residues. A "mature protein" is a full-length protein, optionally including glycosylation or other modifications typical of proteins in a given intracellular environment.
[0054] Nucleic acids and / or nucleic acid sequences are "homologous" if they are derived from a common ancestral nucleic acid or ancestral nucleic acid sequence, natural or artificial. Proteins and / or protein sequences are homologous if their coding DNA is derived from a common ancestral nucleic acid or ancestral nucleic acid sequence, natural or artificial. Homologous molecules may be referred to as homologs. For example, any natural protein described herein can be modified by any available mutagenesis method. When expressed, this mutant nucleic acid encodes a polypeptide that is homologous to the protein encoded by the original nucleic acid. Homology is generally inferred from the sequence identity between two or more nucleic acids or proteins (or sequences thereof). The exact percentage of identity between sequences useful for establishing homology varies with the nucleic acid and protein in question, but a sequence identity of at least 25% is used to establish homology. Higher levels of sequence identity, such as 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% or more, can also be used to establish homology. Methods for determining percentage sequence identity (e.g., BLASTP and BLASTN, using default parameters) are described herein and are publicly available.
[0055] The term "identical" or "sequence identity" in the context of two nucleic acid or amino acid sequences of a polypeptide refers to residues in the two sequences that are the same when aligned for maximum correspondence over a designated comparison window. As used herein, a "comparison window" refers to a segment of at least about 20, usually about 50 to about 200, more usually about 100 to about 150 contiguous positions within which a sequence may be compared to a reference sequence over the same number of contiguous positions after optimal alignment of the two sequences. Methods of sequence alignment for comparison are well known in the art.Optimal sequence alignment for comparison can be achieved by the local homology algorithm of Smith and Waterman, Adv. Appl. Math., 2:482 (1981); the alignment algorithm of Needleman and Wunsch, J. Mol. Biol., 48:443 (1970); the search for similarity method of Pearson and Lipman, Proc. Nat. Acad. Sci USA, 85:2444 (1988); computerized implementations of these algorithms (including, but not limited to, GAP, BESTFIT, BLAST, FASTA, and TFASTA in the PC / Gene program by Intelligentics, Mountain View Calif., Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis., USA), and the CLUSTAL program can be found in Higgins and Sharp, Gene, 73:237-244. (1988) and Higgins and Sharp, CABIOS, 5:151-153 (1989), Corpet et al., Nucleic Acids Res., 16:10881-10890 (1988), Huang et al., Computer Applications in the Biosciences, 8:155-165 (1992), and Pearson et al., Methods in Molecular Biology, 24:307-331 (1994). Alignment is also often performed by visual and manual alignment.
[0056] In one class of embodiments, the polypeptides herein are at least 80%, 85%, 90%, 98% 99%, or 100% identical to a reference polypeptide or fragment thereof, e.g., as measured by BLASTP (or CLUSTAL, or any other available alignment software) using default parameters. Similarly, nucleic acids can also be described in terms of a starting nucleic acid, e.g., they can be 50%, 60%, 70%, 75%, 80%, 85%, 90%, 98%, 99%, or 100% identical to a reference nucleic acid or fragment thereof, e.g., as measured by BLASTN (or CLUSTAL, or any other available alignment software) using default parameters. When one molecule is said to have a certain percentage of sequence identity to a larger molecule, what is meant is that when the two molecules are optimally aligned, that percentage of residues in the smaller molecule will find matching residues in the larger molecule in the order in which the two molecules are optimally aligned.
[0057] The term "substantially identical" as applied to a nucleic acid or amino acid sequence means that the nucleic acid or amino acid sequence includes sequences having at least 90% sequence identity, or more, at least 95%, at least 98%, and at least 99% sequence identity, as compared to a reference sequence using the programs described above, e.g., BLAST using standard parameters. For example, the BLASTN program (for nucleotide sequences) uses as default a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as default a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1992)). Percentage sequence identity is determined by comparing two optimally aligned sequences over a comparison window, where a portion of the polynucleotide sequence within the comparison window may contain additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions) due to optimal alignment of the two sequences. The percentage is calculated by determining the number of positions where identical nucleic acid bases or amino acid residues occur in both sequences to determine the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to determine the percentage sequence identity. In some embodiments, substantial identity exists over a region of the sequences at least about 50 residues long, over a region of at least about 100 residues, and in some embodiments, the sequences are substantially identical over at least about 150 residues. In some embodiments, the sequences are substantially identical over the entire length of the coding regions.
[0058] A "functional variant" of a protein disclosed herein may include, for example, an amino acid sequence of a reference protein with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 conservative amino acid substitutions, or approximately these numbers of conservative amino acid substitutions. The phrase "conservative amino acid substitution" or "conservative mutation" refers to the replacement of one amino acid with another amino acid with common characteristics. A functional method of defining common characteristics between individual amino acids is to analyze the normalized frequency of amino acid changes between corresponding proteins of homologous organisms (Schulz, GE and Schirmer, RH, Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such analysis, it is possible to define amino acid groups in which the amino acids in the group are preferentially exchanged with each other, and thus are most similar to each other in their effect on the overall protein structure (Schulz, GE and Schirmer, RH, supra). Examples of conservative mutations include amino acid substitutions of amino acids in the above subgroups, such as substitution of arginine with lysine, and vice versa, to maintain a positive charge; substitution of aspartic acid with glutamic acid, and vice versa, to maintain a negative charge; substitution of threonine with serine, to maintain a free -OH; and substitution of asparagine with glutamine, to maintain a free -NH2.
[0059] Alternatively or in addition, functional variants may comprise the amino acid sequence of a reference protein with at least one non-conservative amino acid substitution. "Non-conservative mutation" involves amino acid substitution between different groups, such as substitution of lysine with tryptophan or substitution of phenylalanine with serine. In this case, non-conservative amino acid substitutions preferably do not interfere with or inhibit the biological activity of the functional variant. Non-conservative amino acid substitutions may enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased compared to the parent CAR.
[0060] The proteins disclosed herein (including functional parts and functional variants thereof) may contain synthetic amino acids instead of one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, norleucine, α-amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3-hydroxyproline and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexylalanine, cyclohexylglycine. , indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, α-aminocyclopentanecarboxylic acid, α-aminocyclohexanecarboxylic acid, α-aminocycloheptanecarboxylic acid, α-(2-amino-2-norbornane)-carboxylic acid, α,γ-diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine, and α-tert-butylglycine.
[0061] "CD33" is a 67 kDa single-pass transmembrane glycoprotein and a member of the sialic acid-binding immunoglobulin-like lectin (Siglecs) superfamily. CD33 is characterized by a V-set Ig-like domain, responsible for binding to sialic acid, and a C2-set Ig-like domain in its extracellular domain. Alternative splicing of CD33 mRNA results in a short chain isoform (CD33m) that lacks the V-set Ig-like domain as well as the disulfide bond linking the V-set Ig-like domain and the C2-set Ig-like domain, as shown in FIG. 1. In healthy subjects, CD33 is expressed primarily as a myeloid differentiation antigen found on normal multipotent myeloid progenitor cells, unipotent colony forming cells, monocytes, and mature granulocytes. CD33 is expressed on more than 80% of myeloid leukemia cells, but not on normal hematopoietic stem cells or mature granulocytes (Andrews, R. et al., The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors, Blood, 68(5):1030-5 (1986)). CD33 has been reported to be expressed on malignant myeloid cells, activated T cells, and activated NK cells, and is found on at least a subset of blasts in the majority of AML patients (Pollard, J. et al., Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML, Blood, 119(16):3705-11 (2012)). In addition to widespread expression on AML blasts, CD33 can also be expressed on the stem cells underlying AML.
[0062] The term "substantially purified" refers to a nucleic acid sequence, polypeptide, protein, or other compound that is essentially free, i.e., greater than about 50% free, greater than about 70% free, or greater than about 90% free, from polynucleotides, proteins, polypeptides, and other molecules with which it is naturally associated.
[0063] As used herein, a "coding sequence" refers to a segment of a polynucleotide that codes for a protein. A region or sequence is bounded near the 5' end by an initiation codon and near the 3' end by a termination codon. A coding sequence can also be referred to as an open reading frame.
[0064] As used herein, "operably linked" refers to the physical and / or functional linkage of a DNA segment to another DNA segment, such that the segments can function in their intended manner. A DNA sequence encoding a gene product is operably linked to a regulatory sequence, for example, a promoter, an enhancer, and / or a silencer, when it is linked to the regulatory sequence in a manner that allows the transcription of the DNA sequence to be modulated, directly or indirectly. For example, a DNA sequence is operably linked to a promoter. When it is ligated to a promoter downstream of the transcription start site of the promoter and in the correct reading frame with respect to the transcription start site, it allows the elongation of transcription to proceed through the DNA sequence. An enhancer or silencer is operably linked to a DNA sequence encoding a gene product when it is ligated to the DNA sequence so that it increases or decreases the transcription of the DNA sequence, respectively. Enhancers and silencers can be located upstream, downstream, or embedded in the coding region of a DNA sequence. A signal sequence DNA is operably linked to a DNA encoding a polypeptide if the signal sequence is expressed as a preprotein that participates in the secretion of the polypeptide. Linkage of a DNA sequence to a regulatory sequence is typically accomplished via adapters or linkers inserted within the sequence by ligation at appropriate restriction sites or using restriction endonucleases known to those skilled in the art.
[0065] The term "transcriptional regulator" refers to a biochemical element that acts to prevent or inhibit transcription of a promoter-driven DNA sequence under certain environmental conditions (e.g., a repressor protein or nuclear inhibitory protein) or a biochemical element that acts to enable or stimulate transcription of a promoter-driven DNA sequence under certain environmental conditions (e.g., an inducer or enhancer).
[0066] The term "induction" refers to an increase in transcription of a nucleic acid sequence, promoter activity, and / or promoter expression conferred by a transcriptional regulator, relative to some basal level of transcription.
[0067] "Promoter" refers to a region of a polynucleotide that induces transcription of a coding sequence. A promoter is located near and upstream (towards the 5' region of the sense strand) of a gene's transcription start site, on the same strand of DNA. Some promoters are constitutive, since they are active in all circumstances within a cell, whereas other promoters, e.g., inducible promoters, are regulated and active in response to specific stimuli.
[0068] The term "promoter activity" refers to the degree of expression of a nucleotide sequence operably linked to a promoter whose activity is measured. Promoter activity can be measured directly by determining the amount of RNA transcript produced, for example, by Northern blot analysis, or indirectly by determining the amount of a product encoded by a linked nucleic acid sequence, such as a reporter nucleic acid sequence linked to the promoter.
[0069] As used herein, "inducible promoter" refers to a promoter that is induced to be active by the presence or absence of a transcriptional regulator, such as a biotic or non-biotic factor. Inducible promoters are useful because the expression of genes operably linked to them can be turned on or off at certain stages of the development of an organism or, in particular, a tissue. Examples of inducible promoters are alcohol-regulated promoters, tetracycline-regulated promoters, steroid-regulated promoters, metal-regulated promoters, pathogenesis-regulated promoters, temperature-regulated promoters, and light-regulated promoters. In one embodiment, the inducible promoter is part of a gene switch.
[0070] The term "enhancer" as used herein refers to a DNA sequence that, for example, increases the transcription of a nucleic acid sequence to which it is operably linked. Enhancers can be located many kilobases away from the coding region of a nucleic acid sequence and can mediate the binding of regulatory factors, DNA methylation patterns, or changes in DNA structure. Numerous enhancers are known in the art from a variety of different sources and are available as or within cloned polynucleotides (e.g., from depositories such as ATCC, as well as other commercial or personal sources). Many polynucleotides that contain a promoter (such as the commonly used CMV promoter) also contain enhancer sequences. Enhancers can be located upstream, within, or downstream of a coding sequence. The term "Ig enhancer" refers to an enhancer element derived from an enhancer region mapped within the immunoglobulin (Ig) locus, including, for example, the heavy chain (mu) 5' enhancer, the light chain (kappa) 5' enhancer, the kappa intronic enhancer and the mu intronic enhancer, and the 3' enhancer (see generally, Paul WE (ed), Fundamental Immunology, 3rd Edition, Raven Press, New York (1993), pages 353-363, and U.S. Pat. No. 5,885,827).
[0071] An "expression vector" or "vector" is any genetic element, e.g., a plasmid, chromosome, virus, transposon, to which another polynucleotide segment has been attached so as to cause the replication and / or expression of the attached segment, that behaves as an autonomous unit of polynucleotide replication in a cell (i.e., capable of replication under its own control) or is capable of replication by insertion into a host cell chromosome. Suitable vectors include, but are not limited to, plasmids, transposons, bacteriophages, and cosmids. A vector may contain polynucleotide sequences necessary to effect ligation or insertion of the vector into a desired host cell and to effect expression of the attached segment. Such sequences vary depending on the host organism and include promoter sequences to effect transcription, enhancer sequences to increase transcription, sequences of ribosome binding sites, and transcription-translation termination sequences. Alternatively, an expression vector may be capable of directly expressing the product of a nucleic acid sequence encoded therein, without ligation or integration of the vector into a DNA sequence of the host cell.
[0072] A vector may also contain a "selectable marker gene." As used herein, the term "selectable marker gene" refers to a nucleic acid sequence that allows cells expressing the nucleic acid sequence to be specifically selected in the presence of a corresponding selection agent, either forward or reverse. Suitable selectable marker genes are known in the art and are described, for example, in International Patent Applications WO 1992 / 08796 and WO 1994 / 28143, Wigler et al., Proc. Natl. Acad. Sci. USA, 77: 3567 (1980), O'Hare et al., Proc. Natl. Acad. Sci. USA, 78: 1527 (1981), Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78: 2072 (1981), Colberre-Garapin et al., J. Mol. Biol., 150:1 (1981), Santerre et al., Gene, 30: 147 (1984), Kent et al., Science, 237: 901-903 (1984), and the like. (1987), Wigler et al., Cell, 11: 223 (1977), Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48: 2026 (1962), Lowy et al., Cell, 22: 817 (1980), and U.S. Pat. Nos. 5,122,464 and 5,770,359.
[0073] In some embodiments, the vector is an "episomal expression vector" or "episome" that is capable of replicating in a host cell and persists as an extrachromosomal segment of DNA in the host cell under appropriate selective pressure (see, e.g., Conese et al., Gene Therapy, 11:1735-1742 (2004)). Representative, commercially available episomal expression vectors include, but are not limited to, episomal plasmids that use the Epstein-Barr nuclear antigen 1 (EBNA1) and Epstein-Barr virus (EBV) origin of replication (oriP). The vectors pREP4, pCEP4, pREP7, and pcDNA3.1 from Invitrogen (Carlsbad, Calif.) and pBK-CMV from Stratagene (LaJolla, Calif.) represent non-limiting examples of episomal vectors that use T antigen and the SV40 origin of replication instead of EBNA1 and oriP.
[0074] A "transposon" or "transposable element" (TE) is a vector DNA sequence that changes its location in the genome, possibly creating or storing mutations and altering the genome size of a cell. Transposition often results in duplication of the TE. Class I TEs are copied in two steps: first, they are transcribed from DNA to RNA, and then the RNA produced is reverse transcribed into DNA. This copied DNA is then inserted into the new location in the genome. The reverse transcription step is catalyzed by a reverse transcriptase enzyme, which may be encoded by the TE itself. The characteristics of retrotransposons are similar to retroviruses such as HIV. The cut-and-paste transposition mechanism by class II TEs does not involve an RNA intermediate. Transposition is catalyzed by several transposase enzymes. Some transposases bind nonspecifically to any target site in DNA, whereas others bind to specific DNA sequence targets. Transposases make staggered cuts at the target site resulting in single-stranded DNA overhangs (sticky ends) at the 5' or 3' side. This step excises the DNA transposon, which is then ligated to a new target site, a process that involves the activity of DNA polymerase to fill in the gaps and DNA ligase to close the sugar-phosphate backbone. This results in duplication of the target site. The insertion site of the DNA transposon can be identified by the short direct repeats that can be created by staggered cuts in the target DNA and filling in by DNA polymerase, followed by a series of inverted repeats that are important for excision of the TE by the transposase. Cut-and-paste TEs are duplicated when transposition occurs during the S phase of the cell cycle when the donor site has already been duplicated but the target site has not yet been duplicated. Metastases, both in class I and class II TEs, can be classified as "autonomous" or "non-autonomous." Autonomous TEs can move on their own, whereas non-autonomous TEs require the presence of another TE to move.This is because non-autonomous TEs often lack transposase (in the case of class II) or reverse transcriptase (in the case of class I).
[0075] "Transposase" refers to an enzyme that binds to the ends of a transposon and catalyzes the movement of the transposon to another part of the genome by either a cut-and-paste mechanism or a replicative transposition mechanism.
[0076] "Sleeping Beauty (SB) transposon system" refers to a synthetic DNA transposon system for introducing DNA sequences into vertebrate chromosomes. Some exemplary embodiments of the system are described, for example, in U.S. Pat. Nos. 6,489,458, 8,227,432, 9,228,180 and WO 2016 / 145146. The Sleeping Beauty transposon system is composed of Sleeping Beauty (SB) transposase and SB transposon. In some embodiments, the Sleeping Beauty transposon system can include SB11 transposon system, SB100X transposon system, or SB110 transposon system.
[0077] The nucleic acid sequences and vectors disclosed or contemplated herein can be introduced into a cell by "transfection," "transformation," or "transduction." As used herein, "transfection," "transformation," or "transduction" refers to the introduction of one or more exogenous polynucleotides into a host cell by using physical or chemical methods. Many transfection methods are known in the art, including, for example, calcium phosphate DNA co-precipitation (see, e.g., Murray EJ (ed.), Methods in Molecular Biology, Vol. 7, Gene Transfer and Expression Protocols, Humana Press (1991)); DEAE-dextran; electroporation; cationic liposome-mediated transfection; tungsten particle-promoted gene gun (Johnston, Nature, 346: 776-777 (1990)); and strontium phosphate DNA co-precipitation (Brash et al., Mol. Cell Biol., 7: 2031-2034 (1987)). Phage or viral vectors can be introduced into host cells after propagation of infectious particles in suitable packaging cells, many of which are commercially available.
[0078] As used herein, a "T cell" or "T lymphocyte" is a type of lymphocyte that plays a central role in cell-mediated immunity. A "T cell" or "T lymphocyte" can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T cell receptor (TCR) on the cell surface.
[0079] "Helper T cells" (TH cells) assist other white blood cells in immune processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. These cells are also known as CD4+ T cells because they express the CD4 glycoprotein on their surface. Helper T cells become activated when presented with peptide antigens by MHC class II molecules expressed on the surface of antigen-presenting cells (APCs). Upon activation, helper T cells divide rapidly and secrete small proteins called cytokines that regulate or support active immune responses. These cells can differentiate into one of several subtypes, including TH1, TH2, TH3, TH17, Th9, or TFH, which secrete different cytokines to facilitate different kinds of immune responses. Signaling from APCs directs T cells toward specific subtypes.
[0080] "Cytotoxic T cells" (TC cells or CTLs) destroy virus-infected and tumor cells and are also involved in graft rejection. These cells are also known as CD8+ T cells because they express the CD8 glycoprotein on their surface. These cells recognize their targets by binding to antigens associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, CD8+ cells can be inactivated into an anergic state, thereby preventing autoimmune diseases.
[0081] "Memory T cells" are a subset of antigen-specific T cells that persist for a long time after an infection has cleared. Upon re-exposure to their cognate antigen, memory T cells rapidly expand into large numbers of effector T cells, thereby providing the immune system with a "memory" for past infections. Memory T cells are of three subtypes: central memory T cells (TCs) M cells) and two types of effector memory T cells (T EM Cells and TEMRA Memory cells include CD4+ or CD8+ cells. Memory T cells typically express the cell surface proteins CD45RO, CD45RA, and / or CCR7.
[0082] "Regulatory T cells" (Treg cells), formerly known as suppressor T cells, play a role in maintaining immune tolerance. The primary role of regulatory T cells is to block T cell-mediated immunity, terminating immune responses and suppressing autoreactive T cells that have escaped the negative selection process in the thymus.
[0083] "Natural killer T cells" (NKT cells; not to be confused with natural killer cells of the innate immune system) bridge the adaptive immune system with the innate immune system. Unlike conventional T cells, which recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigens presented by a molecule called CD1d. Upon activation, these cells can perform functions ascribed to both Th and Tc cells (i.e., production of cytokines and release of cytolytic / cell-killing molecules). NKT cells can also recognize and eliminate some tumor cells and cells infected with herpes viruses.
[0084] As used herein, "tumor antigen" refers to any antigenic substance that is produced or overexpressed in tumor cells. Tumor antigens can, for example, induce an immune response in the host. Alternatively, for the purposes of this disclosure, tumor antigens can be proteins that are expressed by both healthy and tumor cells, but are suitable therapeutic targets for identifying certain tumor types. In one embodiment, tumor antigen is CD33, which is a target of CAR T cell therapy for treating myeloid malignancies, such as acute myeloid leukemia (AML).
[0085] "AML" as used herein refers to acute myeloid leukemia, also known as acute myeloid leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. AML is distinguished from other major forms of leukemia because it has eight different subtypes based on the cell type from which the leukemia develops. Thus, the term "AML" refers to all subtypes, including myeloblastic (M0), myeloblastic without maturation (M1), myeloblastic with maturation (M2), promyelocytic (M3), myelomonocytic (M4), monocytic (M5), erythroleukemia (M6), and megakaryocytic (M7), depending on the specific analysis. "AML" as used herein also refers to acute myeloid leukemia, which is a cancer in which the bone marrow produces abnormal myeloblasts. AML is the most common form of acute leukemia in adults (Siegel, R., Ma, J., Zou, Z. & Jemal, A., Cancer statistics, 2014, CA Cancer J Clin, 64(1):9-29 (2014)). "Relapsed AML" refers to a subject who has experienced a period of remission of AML. "Refractory AML" refers to a patient whose disease does not respond to a first cycle of initial standard induction therapy (e.g., anthracycline- and / or cytarabine-based therapy). In embodiments, "refractory AML" refers to a patient whose disease does not respond to one or two or more cycles of standard induction therapy.
[0086] "Adoptive T cell transfer" refers to the isolation and ex vivo expansion of tumor-specific T cells, achieving a greater number of T cells than can be obtained by vaccination alone or the patient's natural tumor response.Tumor-specific T cells are then infused into patients with cancer in an attempt to give their immune system the ability to overwhelm the remaining tumor through T cells that can attack and kill the cancer.Many forms of T cell therapy have been used for cancer treatment, including culturing tumor-infiltrating lymphocytes or TILs, isolating and expanding one specific T cell or clone, and also using T cells that are modified to strongly recognize and attack tumors.
[0087] "Antigen recognition moiety or antigen recognition domain" refers to a molecule or a portion of a molecule that specifically binds to an antigen. In one embodiment, the antigen recognition moiety is an antibody, an antibody-like molecule, or a fragment thereof, and the antigen is a tumor antigen.
[0088] As used herein, "antibody" refers to a monoclonal or polyclonal antibody. As used herein, the term "monoclonal antibody" refers to an antibody produced by a single clone of B cells and binding to the same epitope. In contrast, a "polyclonal antibody" refers to a population of antibodies produced by different B cells and binding to different epitopes of the same antigen. A whole antibody typically consists of four polypeptides: two identical copies of a heavy (H) chain polypeptide and two identical copies of a light (L) chain polypeptide. Each of the heavy chains contains an N-terminal variable (VH) region and three C-terminal constant (CH1, CH2, and CH3) regions, and each light chain contains an N-terminal variable (VL) region and a C-terminal constant (CL) region. The variable regions of each pair of light and heavy chains form the antigen-binding site of the antibody. The VH and VL regions share a common general structure, each region containing four framework regions whose sequences are relatively conserved. The framework regions are connected by three complementarity determining regions (CDRs). The three CDRs, known as CDR1, CDR2, and CDR3, form the "hypervariable region" of the antibody that is responsible for binding to the antigen.
[0089] An "antibody-like molecule" can be, for example, a protein that is a member of the Ig superfamily, capable of selectively binding to a partner. MHC molecules and T cell receptors are such molecules. In one embodiment, the antibody-like molecule is a TCR. In one embodiment, the TCR is modified to increase its binding affinity to the MHC.
[0090] The terms "fragment of an antibody," "antibody fragment," "functional fragment of an antibody," and "antigen-binding portion" are used interchangeably herein to mean one or more fragments or portions of an antibody that retain the ability to specifically bind to an antigen (see generally Holliger et al., Nat. Biotech., 23(9):1126-1129 (2005)). Antibody fragments desirably include, for example, one or more CDRs, a variable region (or a portion thereof), a constant region (or a portion thereof), or a combination thereof. Examples of antibody fragments include (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge in the stalk region; (iii) an Fv fragment, which consists of the VL and VH domains of a single arm of an antibody; and (iv) a single-chain Fv (scFv), which is a monovalent molecule consisting of the two domains (i.e., VL and VH) of an Fv fragment joined by a synthetic linker that allows the two domains to be synthesized as a single polypeptide chain (see, e.g., Bird et al., Science, 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA, 85: 5879-5883 (1988); and Osbourn et al., Nat. Biotechnol., 16: 778-789 (1989)). (1998); and (v) diabodies, which are dimers of polypeptide chains in which each polypeptide chain comprises a VH connected to a VL by a peptide linker that is too short to allow pairing between the VH and VL on the same polypeptide chain, thereby driving pairing between complementary domains on different VH-VL polypeptide chains to create a dimeric molecule with two functional antigen-binding sites. Antibody fragments are known in the art and are described in more detail, for example, in U.S. Patent Application Publication No. 2009 / 0093024A1.
[0091] "Chimeric antigen receptor" is also known as artificial T cell receptor, chimeric T cell receptor, chimeric immune receptor. Chimeric antigen receptor (CAR) is an engineered receptor that grafts any specificity onto immune effector cells. CAR typically has an extracellular domain (ectodomain) that includes an antigen-binding domain and a stalk region, a transmembrane domain, and an intracellular domain (endodomain).
[0092] The "stalk" region, which encompasses the terms "spacer" or "hinge" regions, is used to link the antigen-binding domain with the transmembrane domain. The term "stalk domain" as used herein generally refers to any oligonucleotide or polypeptide that functions to link the transmembrane domain with the extracellular or cytoplasmic domain within a polypeptide chain. In embodiments, the stalk domain is flexible enough to allow the antigen-binding domain to orient in different directions to facilitate antigen recognition. In one embodiment, the stalk domain is a hinge region from IgG1. Alternatives include, but are not limited to, the CH2CH3 region of an immunoglobulin and a portion of CD3. In an embodiment, the stalk region is a CD8 alpha hinge (SEQ ID NO: 22). The term "functional portion" when used in reference to a CAR refers to any portion or fragment of a CAR described herein that retains the biological activity of the CAR of which the functional portion is a part (parent CAR). With respect to the nucleic acid sequence encoding the parent CAR, the nucleic acid sequence encoding a functional portion of the CAR can encode a protein that comprises, for example, about 10%, 25%, 30%, 50%, 68%, 80%, 90%, 95% or more of the parent CAR.
[0093] The term "functional variant" as used herein refers to a polypeptide or protein that has substantial or significant sequence identity or sequence similarity to a reference polypeptide and retains the biological activity of the reference polypeptide of which it is a variant. Functional variants include, for example, variants of a CAR (parent CAR) described herein that retain the ability to recognize target cells to a similar extent, to the same extent, or to a greater extent than the parent CAR. In the context of a nucleic acid sequence encoding a parent CAR, a nucleic acid sequence encoding a functional variant of a CAR can be, for example, about 10% identical, about 25% identical, about 30% identical, about 50% identical, about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, about 95% identical, or about 99% identical to the nucleic acid sequence encoding the parent CAR.
[0094] As used herein, "inducible promoter" refers to a promoter that is induced to activity by the presence or absence of a transcriptional regulator, such as a biotic or abiotic factor. Inducible promoters are useful because the expression of genes operably linked to them can be turned on or off at certain stages of the development of an organism or, in particular, a tissue. Examples of inducible promoters are alcohol-regulated promoters, tetracycline-regulated promoters, steroid-regulated promoters, metal-regulated promoters, pathogenesis-regulated promoters, temperature-regulated promoters, and light-regulated promoters. An inducible promoter can be part of a gene switch. An inducible promoter can be a gene switch ligand inducible promoter. In some cases, an inducible promoter can be a small molecule ligand-induced, two-polypeptide, ecdysone receptor-based gene switch, such as the RHEOSWITCH® gene switch. In some cases, the gene switch may be any of the methods described, without limitation, in PCT / US Appln. No. 2001 / 009050 (WO 2001 / 070816), U.S. Pat. Nos. 7,091,038, 7,776,587, 7,807,417, 8,202,718, PCT / US Appln. No. 2001 / 030608 (WO 2002 / 029075), U.S. Pat. Nos. 8,105,825, 8,168,426, each of which is incorporated by reference in its entirety. Detailed description: PCT / 1J52002 / 005235 (International Publication No. 2002 / 066613), U.S. Application No. 10 / 468,200 (U.S. Publication No. 20120167239), PCT / U.S. Application No. 2002 / 005706 (International Publication No. 2002 / 066614), U.S. Patent Nos. 7,531,326, 8,236,556, 8,598,409, PCT / U52002 / 005090 (International Publication No. 2002 / 066612), U.S. Patent No. 8,715,959 (U.S. Publication No. 20060100416), PCT / U.S. Application No. 2002 / 005234 (International Publication No. 2003 / 027266), U.S. Patent Nos. 7,601,508, 7,829,676, 7,919,269, 8,030,067, PCT / U52002 / 005708 (International Publication No. 2002 / 066615), U.S. Application No. 10 / 468,192 (U.S. Publication No. 2011021252 No. 8, PCT / US Application No. 2002 / 005026 (WO 2003 / 027289), U.S. Patent Nos. 7,563,879, 8,021,878, and 8,497,093, PCT / US Application No. 2005 / 015089 (WO 2005 / 108617), U.S. Patent Nos. 7,935,510, 8,076,454, PCT / U52008 / 011270 (WO 2009 / 04537 No. 0), U.S. Application No. 12 / 241,018 (U.S. Publication No. 20090136465), PCT / U.S. Application No. 2008 / 011563 (WO 2009 / 048560), U.S. Application No. 12 / 247,738 (U.S. Publication No. 20090123441), PCT / U.S. Application No. 2009 / 005510 (WO 2010 / 042189), U.S. Application No. 13 / 123,129 (U.S. Publication No. 2011026 The receptor may be selected from ecdysone-based receptor components including any of the systems described in PCT / US Appl. No. 8766, PCT / US Appl. No. 2011 / 029682 (WO 2011 / 119773), US Appl. No. 13 / 636,473 (US Publication No. 20130195800), PCT / US Appl. No. 2012 / 027515 (WO 2012 / 122025), and U.S. Pat. No. 9,402,919.
[0095] "Proliferative disease" as referred to in this specification means that a unifying concept has been presented in which excessive cell proliferation and excessive intracellular matrix turnover contribute significantly to the pathogenesis of several diseases, including cancer.
[0096] As used herein, "patient" refers to a mammalian subject diagnosed with or suspected of having or developing a proliferative disorder, such as cancer. In some embodiments, the term "patient" refers to a mammalian subject with a higher than average likelihood of developing a proliferative disorder, such as cancer. Exemplary patients may be humans, apes, dogs, pigs, cows, cats, horses, goats, sheep, rodents, and other mammals that may benefit from the therapies disclosed herein. Exemplary human patients may be male and / or female.
[0097] As used herein, "administering" refers to administering one or more compositions described herein to a patient or subject. By way of example and not limitation, administration, e.g., injection, of a composition can be performed by intravenous (iv), subcutaneous (sc), intradermal (id), intraperitoneal (ip), or intramuscular (im) injection. One or more such routes can be utilized. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time. Alternatively, or contemporaneously, administration can be by oral route. In addition, administration can also be by bolus or cell pellet depot surgery, or by placement of a medical device.
[0098] As used herein, a "patient in need thereof" or a "subject in need thereof" refers to a patient diagnosed with or suspected of having a proliferative disorder, such as cancer. In one embodiment, the patient has or may develop a leukemia, such as, but not limited to, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).
[0099] In certain embodiments, the compositions described herein may comprise modified or host cells expressing a nucleic acid sequence described herein, or a vector comprising at least one nucleic acid sequence described herein, in an amount effective to treat or prevent a proliferative disorder. As used herein, the terms "treatment," "treating," and the like refer to obtaining a desired pharmacological and / or physiological effect. In some embodiments, the effect is therapeutic, i.e., the effect partially or completely cures the disease and / or adverse symptoms attributable to the disease. To this end, the methods of the invention comprise administering a "therapeutically effective amount" of a composition comprising a host cell expressing a nucleic acid sequence of the invention, or a vector comprising a nucleic acid sequence of the invention.
[0100] "Therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compositions described herein to elicit a desired response in one or more subjects.
[0101] Alternatively, the pharmacological and / or physiological effect may be "prophylactic," ie, the effect prevents, either completely or partially, a disease or its symptoms.
[0102] A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result (eg, prevention of disease onset).
[0103] Chimeric Antigen Receptor In some embodiments described herein, the CAR can include an extracellular single chain variable domain (scFv) from an antibody for target recognition, and the scFv can be connected by a flexible linker to a transmembrane domain and / or an intracellular signaling domain, including, for example, CD3ζ, for T cell activation. Normally, in vivo, when T cells can be activated, they receive an antigen-induced primary TCR signal along with a secondary costimulatory signaling from CD28 that induces the production of cytokines (i.e., IL-2 and IL-21), which then feed back into a signaling loop in an autocrine / paracrine manner. With this in mind, the CAR can include a signaling domain, for example, a CD28 cytoplasmic signaling domain, or a signaling domain from other costimulatory molecules, such as a 4-1BB signaling domain. Costimulation by chimeric CD28 improves T cell survival by upregulating anti-apoptotic molecules and producing IL-2, as well as expanding and proliferating T cells derived from peripheral blood mononuclear cells (PBMCs).
[0104] In one embodiment, the CAR is a fusion of a single chain variable fragment (scFv) derived from a monoclonal antibody specific for the tumor-associated antigen CD33, for example, fused to the transmembrane domain and endodomain of CD3 zeta. Such a molecule results in the transmission of a zeta signal in response to the recognition of its target by the scFv.
[0105] In some embodiments, the CAR may have an ectodomain (extracellular), a transmembrane domain, and an endodomain (intracellular). In one embodiment for the CAR ectodomain, the signal peptide directs the nascent protein to the endoplasmic reticulum. This is the case, for example, when the receptor is glycosylated and anchored in the cell membrane. Any eukaryotic signal peptide sequence is assumed to be functional. In general, the signal peptide that is naturally attached to the most amino-terminal component is used (e.g., in scFvs with a light chain-linker-heavy chain orientation, the natural signal of the light chain is used). In some embodiments, the signal peptide is GM-CSFRa (SEQ ID NO: 16) or IgK (SEQ ID NO: 34). Other signal peptides that may be used include signal peptides from CD8 alpha and CD28.
[0106] The antigen recognition domain may be an scFv. However, alternatives may exist. Antigen recognition domains derived from the natural T cell receptor (TCR) alpha and beta single chains are envisaged, as are simple ectodomains (e.g., the CD4 ectodomain, which recognizes HIV-infected cells) as well as other recognition components linked thereto, e.g., cytokines (resulting in recognition of cells bearing cytokine receptors). Almost anything that binds with high affinity to a given target, e.g., tumor-associated antigens, may be used as an antigen recognition region.
[0107] Generally, CARs exist in a dimerized form and are expressed as fusion proteins linking an extracellular scFv (VH linked to VL) region, a stalk domain, a transmembrane domain, and an intracellular signaling motif. The endodomain of the first generation CAR induces T cell activation only through signaling by CD3zeta. The second generation CARs provide activation signaling through other endodomains, such as CD3zeta and CD28, or 4-1BB or OX40. The third generation CARs activate T cells through a combination of three signaling motifs, such as CD28, 4-1BB, or OX40, that contain CD3zeta.
[0108] In some embodiments, the present invention provides a chimeric antigen receptor (CAR) comprising an extracellular domain, a transmembrane domain, and an intracellular signaling domain. In some embodiments, the extracellular domain comprises a target-specific binding element, otherwise referred to as an antigen-binding moiety or scFv, and a stalk domain. In some embodiments, the intracellular signaling domain, or otherwise, the cytoplasmic signaling domain, comprises a costimulatory signaling region and a zeta chain portion.
[0109] The costimulatory signaling region refers to the portion of the CAR that contains the intracellular signaling domain of a costimulatory molecule, which is a cell surface molecule other than an antigen receptor or its ligand, that is required for an efficient response of lymphocytes to antigens.
[0110] In some embodiments, a stalk domain is incorporated between the extracellular domain and the transmembrane domain of the CAR. The term "stalk domain" as used herein generally refers to any oligonucleotide or polypeptide that functions to link a transmembrane domain to a cytoplasmic domain in an scFv or polypeptide chain. The stalk domain may include a flexible hinge, such as an Fc hinge, and optionally one or two constant domains of Fc. In some cases, the stalk region includes a hinge region from IgG1. In alternative cases, the stalk region includes an immunoglobulin CH2CH3 region and, optionally, a portion of CD3. In some cases, the stalk region includes a CD8α hinge region, a 12 amino acid hinge region of IgG4-Fc (ESKYGPPCPPCP) (SEQ ID NO: 62), or an IgG4 hinge region, as described in WO2016 / 073755.
[0111] The transmembrane domain may be derived from a natural or recombinant source. If the source is natural, the domain may be derived from any membrane-associated or transmembrane protein. Suitable transmembrane domains may include the transmembrane regions of the alpha, beta, or zeta chains of the T-cell receptor, or may include transmembrane regions from CD28, CD3 epsilon, CD3 zeta, CD45, CD4, CD5, CD8 alpha, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154. Alternatively, the transmembrane domain may be synthetic and may include hydrophobic residues such as leucine and valine. In some embodiments, triplets of phenylalanine, tryptophan, and valine are found at one or both ends of the synthetic transmembrane domain. Optionally, in some embodiments, a short oligonucleotide or polypeptide linker, between 2-10 amino acids in length, may form the link between the transmembrane domain and the cytoplasmic signaling domain of the CAR. In some embodiments, the linker is a glycine-serine linker. In some embodiments, the transmembrane domain comprises a CD8α transmembrane domain or a CD3ζ transmembrane domain. In some embodiments, the transmembrane domain comprises a CD8α transmembrane domain. In other embodiments, the transmembrane domain comprises a CD3ζ transmembrane domain.
[0112] The intracellular domain may include one or more costimulatory domains. Exemplary costimulatory domains include, but are not limited to, CD8, CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134), CD3 zeta, or fragments or combinations thereof. In some cases, the CARs described herein include one or more, or two or more, of the costimulatory domains selected from CD8, CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134), or fragments or combinations thereof. In some cases, the CARs described herein include one or more, or two or more, of the costimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, OX40 (CD134), or fragments or combinations thereof. In some cases, the CARs described herein comprise one or more, or two or more, of the costimulatory domains selected from CD8, CD28, 4-1BB (CD137), DAP10, DAP12, or fragments or combinations thereof. In some cases, the CARs described herein comprise one or more, or two or more, of the costimulatory domains selected from CD28, 4-1BB (CD137), or fragments or combinations thereof. In some cases, the CARs described herein comprise the costimulatory domains CD28 and 4-1BB (CD137), or their respective fragments. In some cases, the CARs described herein comprise the costimulatory domains CD28 and OX40 (CD134), or their respective fragments. In some cases, the CARs described herein comprise the costimulatory domains CD8 and CD28, or their respective fragments. In some cases, the CARs described herein comprise the costimulatory domain CD28, or their respective fragments. In some cases, the CARs described herein include the costimulatory domain 4-1BB (CD137), or a fragment thereof. In some cases, the CARs described herein include the costimulatory domain OX40 (CD134), or a fragment thereof.In some cases, the CAR described herein comprises a costimulatory domain CD8, or a fragment thereof.In some cases, the CAR described herein comprises at least one costimulatory domain DAP10, or a fragment thereof.In some cases, the CAR described herein comprises at least one costimulatory domain DAP12, or a fragment thereof.
[0113] The intracellular signaling domain, also known as the cytoplasmic domain, of the CAR of the present disclosure contributes to the activation of at least one of the normal effector functions of the immune cell in which the CAR is placed. The term "effector function" refers to a specialized cellular function. The effector function of a T cell can be, for example, cytolytic activity or helper activity, including secretion of cytokines. Thus, the term "intracellular signaling domain" refers to a portion of a protein that transmits an effector function signal and directs the cell to perform a specialized function. Typically, the entire intracellular signaling domain can be utilized, but in many cases it is not necessary to use the entire chain. A truncated portion of the intracellular signaling domain can be used in place of the complete chain, so long as it transmits an effector function signal. Thus, the term intracellular signaling domain is intended to include any truncated portion of the intracellular signaling domain sufficient to transmit an effector function signal. In some embodiments, the intracellular domain further comprises a signaling domain for T cell activation. In some cases, the signaling domain for T cell activation comprises a domain derived from TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, or CD66d. In some cases, the signaling domain for T cell activation comprises a domain derived from CD3 zeta.
[0114] In embodiments herein, an isolated nucleic acid encoding a chimeric antigen receptor (CAR) is provided, the CAR comprising: (a) a CD33 antigen-binding domain; (b) a stalk domain; (c) a transmembrane domain; (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; (e) a CD3 zeta signaling domain; and, optionally, (f) a truncated epithelium An isolated nucleic acid is presented that includes a growth factor receptor (HER1t or HER1t-1).
[0115] The scope of the present invention includes nucleic acid sequences that encode functional portions of the CARs described herein. Functional portions include, for example, portions of the CAR that retain the ability to recognize target cells or detect, treat, or prevent disease to a similar, comparable, or greater extent than the parent CAR.
[0116] In some embodiments, CAR contains additional amino acids at the amino or carboxy end of the moiety, or at both ends, that are not found in the amino acid sequence of parent CAR.It is desirable that the additional amino acids do not interfere with the biological function of the functional moiety, such as recognizing target cells, detecting cancer, treating or preventing cancer, etc.It is more desirable that the additional amino acids enhance the biological activity of CAR compared to the biological activity of parent CAR.
[0117] The term "functional variant" as used herein refers to a CAR, polypeptide, or protein having substantial or significant sequence identity or sequence similarity to a CAR encoded by a nucleic acid sequence of the present invention, where the functional variant retains the biological activity of the CAR of which it is a variant. Functional variants include, for example, variants of a CAR (parent CAR) described herein that retain the ability to recognize target cells to a similar extent, to the same extent, or to a greater extent than the parent CAR. In the context of a nucleic acid sequence encoding a parent CAR, a nucleic acid sequence encoding a functional variant of a CAR can be, for example, about 10% identical, about 25% identical, about 30% identical, about 50% identical, about 65% identical, about 80% identical, about 90% identical, about 95% identical, or about 99% identical to the nucleic acid sequence encoding the parent CAR.
[0118] The CARs described herein (including functional portions and functional variants thereof) include CARs that are glycosylated, amidated, carboxylated, phosphorylated, esterified, N-acylated, cyclized, or converted into acid addition salts, for example, via disulfide bridges, and / or, optionally, dimerized or polymerized, or conjugated CARs.
[0119] antigen binding portion In some embodiments, the CARs described herein comprise a target-specific binding element, otherwise referred to as an antigen-binding moiety. In some embodiments, the CARs described herein are modified to target a tumor antigen of interest by modifying a desired antigen-binding moiety that specifically binds to an antigen on a tumor cell. In the context of the present invention, "tumor antigen" or "hyperproliferative disorder antigen" or "antigen associated with a hyperproliferative disorder" refers to an antigen that is common to a specific hyperproliferative disorder, such as cancer.
[0120] In some embodiments, the antigen-binding portion of the CAR described herein is specific for CD33 (CD33 CAR). When expressed on the cell surface, the CD33-specific CAR redirects the specificity of T cells to human CD33. In some embodiments, the antigen-binding domain comprises a single-chain antibody fragment (scFv) comprising a variable domain light chain (VL) and a variable domain heavy chain (VH) of a target antigen-specific anti-CD33 monoclonal antibody, the VL and VH being connected by a flexible linker, such as a glycine-serine linker or a Whitlow linker. In some embodiments, the scFv is M195, m2H12, DRB2, and / or My9-6. In some embodiments, the scFv is a humanized scFv, e.g., hM195. In some embodiments, the antigen-binding portion may comprise a VH and a VL directionally linked, e.g., from the N-terminus to the C-terminus, with a VH-linker-VL or a VL-linker-VH.
[0121] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a VL polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:1 (hM195 VL).
[0122] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a VH polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:3 (hM195 VH).
[0123] In embodiments, the CAR described herein comprises the VL (SEQ ID NO: 1) and VH (SEQ ID NO: 3) of the antigen-binding portion of hM195, a clone of a humanized anti-CD33 mAb, with a Gly-Ser linker (SEQ ID NO: 6) or a functional variant of the linker.
[0124] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:8 (hM195 VH, VL, and linker).
[0125] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a VH polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:9 (M2H12 VH).
[0126] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a VL polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 10 (M2H12 VL).
[0127] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a VH polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 11 (DRB2 VH).
[0128] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a VL polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 12 (DRB2 VL).
[0129] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a VH polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 13 (My9-6 VH).
[0130] In embodiments, the CAR described herein comprises an antigen-binding portion comprising a VL polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 14 (My9-6 VL).
[0131] In several embodiments, the antigen-binding portion has a GM-CSFRa signal peptide that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:16.
[0132] Stork Domain In some embodiments, the CD33 CAR of the present invention comprises a stalk domain that provides separation of the antigen-binding portion from the T cell membrane. In some embodiments, the stalk domain establishes an optimal intermembrane distance between the effector and the target. In some embodiments, the stalk domain provides flexibility for the antigen-binding domain to reach its target. In one embodiment, the stalk domain is a CD8 alpha hinge domain.
[0133] In several embodiments, the CD8 alpha hinge domain comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:22.
[0134] Transmembrane domain In some embodiments, the CAR comprises a transmembrane domain fused to the extracellular domain of the CAR stalk domain. In one embodiment, a transmembrane domain that naturally associates with one of the domains in the CAR is used. In some embodiments, the transmembrane domain is a hydrophobic alpha helix that spans the membrane.
[0135] The transmembrane domain may be derived from a natural or synthetic source. If the source is natural, the domain may be derived from any membrane-associated or transmembrane protein. The transmembrane region of particular use in the present invention may be derived from (i.e., at least comprising the transmembrane region of) the alpha, beta, or zeta chains of the T-cell receptor, CD28, CD3 epsilon, CD3 zeta, CD45, CD4, CD5, CD8 alpha, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. Alternatively, the transmembrane domain may be synthetic, in which case the transmembrane domain will include hydrophobic residues such as leucine and valine. In some embodiments, a triplet of phenylalanine, tryptophan, and valine will be found at each end of the synthetic transmembrane domain. Optionally, in some embodiments, a short oligonucleotide or polypeptide linker, between 2-10 amino acids in length, can form the link between the transmembrane domain and the cytoplasmic signaling domain of the CAR. In some embodiments, the linker is a glycine-serine linker.
[0136] In some embodiments, the transmembrane domain in the CAR described herein is a CD8 alpha transmembrane domain. In some embodiments, the CD8 alpha transmembrane domain comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 18.
[0137] In some embodiments, the transmembrane domain in the CAR described herein is a CD28 transmembrane domain. In some embodiments, the CD28 transmembrane domain comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:20.
[0138] Cytoplasmic domain (costimulatory and signaling domains) The cytoplasmic domain, also known as the intracellular signaling domain, of the CAR described herein contributes to the activation of at least one of the normal effector functions of the immune cell in which the CAR is placed. The term "effector function" refers to a specialized cellular function. The effector function of a T cell can be, for example, cytolytic activity or helper activity, including secretion of cytokines. Thus, the term "intracellular signaling domain" refers to a portion of a protein that transmits an effector function signal and directs the cell to perform a specialized function. Typically, the entire intracellular signaling domain can be utilized, but in many cases it is not necessary to use the entire chain. A truncated portion of the intracellular signaling domain can be used in place of the complete chain, so long as it transmits an effector function signal. Thus, the term intracellular signaling domain is intended to include any truncated portion of the intracellular signaling domain sufficient to transmit an effector function signal.
[0139] Examples of intracellular signaling domains for use in the CARs described herein can include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to trigger signal transduction following antigen receptor binding, as well as any derivatives or variants of these sequences, and any synthetic sequences that have the same functional capabilities.
[0140] Signals generated via the TCR alone are generally insufficient for full activation of T cells; secondary or costimulatory signals are also required. Thus, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that induce antigen-dependent primary activation via the TCR (primary cytoplasmic signaling sequences), and those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic signaling sequences).
[0141] Primary cytoplasmic signaling sequences regulate the primary activation of the TCR complex in a stimulatory or inhibitory manner. Primary cytoplasmic signaling sequences that act in a stimulatory manner may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs or ITAMs.
[0142] Examples of ITAM-containing primary cytoplasmic signaling sequences of particular use in the present invention include primary cytoplasmic signaling sequences derived from TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. In embodiments, the cytoplasmic signaling molecule in the CAR described herein comprises a cytoplasmic signaling sequence derived from CD3 zeta.
[0143] In some embodiments, the cytoplasmic domain of the CAR can be designed to include a CD3 zeta signaling domain, either by itself or in combination with any other desired cytoplasmic domain useful in the context of the CAR described herein. For example, the cytoplasmic domain of the CAR can include a CD3 zeta chain portion and a costimulatory signaling region. The costimulatory signaling region refers to the portion of the CAR that includes the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligand that is required for an efficient response of lymphocytes to antigens. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds to CD83, and the like. In embodiments, costimulatory molecules can be used, for example, CD28 in conjunction with 4-1BB or CD28 in conjunction with OX40. Thus, although the invention is exemplified with 4-1BB and CD28 as costimulatory signaling elements, other costimulatory elements are within the scope of the invention.
[0144] The cytoplasmic signaling sequences within the cytoplasmic signaling portion of the CAR described herein can be linked to each other in a random order or in a specified order. Optionally, in some embodiments, a short oligonucleotide or polypeptide linker between 2-10 amino acids in length can form the linkage. A glycine-serine doublet provides a particularly suitable linker.
[0145] In one embodiment, the cytoplasmic domain comprises the signaling domain of CD3 zeta and the signaling domain of CD28. In another embodiment, the cytoplasmic domain comprises the signaling domain of CD3 zeta and the signaling domain of 4-1BB. In yet another embodiment, the cytoplasmic domain comprises the signaling domain of CD3 zeta, and the signaling domains of CD28 and 4-1BB.
[0146] In one embodiment, the cytoplasmic domain in a CAR described herein comprises a signaling domain of 4-1BB and a signaling domain of CD3 zeta, where the signaling domain of 4-1BB comprises a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the polypeptide sequence of SEQ ID NO:24, and the signaling domain of CD3 zeta comprises a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:26.
[0147] In one embodiment, the cytoplasmic domain in a CAR described herein is designed to comprise a signaling domain of CD28 and a signaling domain of CD3 zeta, where the signaling domain of CD28 comprises a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the polypeptide sequence of SEQ ID NO:28 and the signaling domain of CD3 zeta comprises a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the polypeptide sequence of SEQ ID NO:26.
[0148] In one embodiment, the cytoplasmic domain in a CAR described herein comprises the signaling domain of 4-1BB and the signaling domain of CD3 zeta, wherein the signaling domain of 4-1BB comprises the amino acid sequence set forth in SEQ ID NO:24, and the signaling domain of CD3 zeta comprises the amino acid sequence set forth in SEQ ID NO:26.
[0149] Further genetic elements Although cell therapy has great promise for the treatment of human diseases, significant toxicity from the cells themselves or their transgene products has hindered clinical exploration. In some embodiments described herein, immune effector cells containing the CAR described herein that are infused into a mammalian subject, e.g., a human, can be removed to regulate the action of such immune effector cells if harmful effects arise from their use. Thus, in certain embodiments, in addition to the therapeutic CD33-specific chimeric antigen receptor described herein, a second gene can also be introduced into the modified immune effector cells described herein. The second gene is, in effect, a "kill switch" that allows for the depletion of CD33 CAR-containing cells. In certain embodiments, the "kill switch" is a HER1 tag or CD20 tag that includes at least an antibody binding epitope of HER1 or CD20, or a functional fragment thereof, and optionally includes a HER1 polypeptide or CD20 polypeptide that includes a signal polypeptide sequence or a fragment thereof.
[0150] In certain embodiments, the second gene is epithelium In some embodiments, the second gene is a truncated human HER1 tag, which is a growth factor receptor (HER1) or a fragment or variant thereof. epithelium HER1 tag, which is growth factor receptor 1 (e.g., HER1t or HER1t-1). Optionally, the second gene is a truncated human epitheliumIt is a variant of growth factor receptor 1. In some embodiments, at least one of HER1, HER1t, and HER1t-1 provides a safety mechanism by allowing depletion of infused CAR-T cells via administration of FDA approved cetuximab or any antibody that recognizes HER1, HER1t, and / or HER1t-1. In some embodiments, the HER1t gene comprises a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the nucleic acid sequence of SEQ ID NO:32. In some embodiments, the HER1t-1 gene comprises a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the nucleic acid sequence of SEQ ID NO:54. Truncated HER1 sequences, such as HER1t and HER1t-1, abolish the potential for EGF ligand binding, EGFR homo- and heterodimerization, and EGFR-mediated signaling, while keeping cetuximab's binding to the receptor intact (Ferguson, K., 2008. A structure-based view of Epidermal Growth Factor Receptor regulation. Annu Rev Biophys, Volume 37, pp. 353-373).
[0151] In a further embodiment of the present invention, the second gene introduced in addition to the therapeutic CD33-specific chimeric antigen receptor is a CD20 tag. Optionally, the CD20 tag is a full-length CD20 polypeptide or a truncated CD20 polypeptide (CD20t-1). Optionally, the CD20 tag, for example, CD20 or CD20t-1, also provides a safety mechanism by allowing the depletion of infused CAR-T cells through administration of FDA-approved rituximab therapy. In certain embodiments, the CD20 tag has a polypeptide sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence of SEQ ID NO:36. In certain embodiments, the CD20 tag is a CD20t-1 tag and has a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence of SEQ ID NO: 56. In some embodiments, the CD20 tag is encoded by a CD20 gene comprising a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO: 35. In some embodiments, the CD20 tag is encoded by a CD20t-1 gene comprising a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO: 57.
[0152] In embodiments, the CAR vector comprising a CAR described herein further comprises a full-length CD20 tag comprising a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:36.
[0153] In embodiments, a gene encoding a kill tag, e.g., a HER1t tag, a HER1t-1 tag, a CD20 tag, or a CD20t-1 tag, is genetically fused to the CD33 CAR at the 3' end in frame via a self-cleaving peptide, e.g., but not limited to, a Thosea asigna virus (T2A) peptide. In embodiments, the T2A peptide has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:30.
[0154] In some embodiments, the kill tag gene is cloned in frame with the CD33 CAR gene into the pFUGW lentiviral plasmid backbone. In other embodiments, both genes are cloned into the Sleeping Beauty transposon vector. In other embodiments, the kill tag is cloned into a separate lentiviral vector. In yet other embodiments, the kill tag, such as HER1t, HER1t-1, CD20, or CD20t-1, is cloned into a separate Sleeping Beauty transposon vector. In certain embodiments, the kill tag has a signal peptide, for example, a GM-CSFRa signal peptide, where the GM-CSFRa signal peptide has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of SEQ ID NO: 16. In certain embodiments, the signal peptide is IgK having a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO: 34. Optionally, the signal peptide can be selected from IgE and CD8α, variants and fragments thereof.
[0155] An exemplary vector encoding the CAR and kill tag described herein is shown in FIG.
[0156] Exemplary CAR open reading frames Exemplary CAR and human CD33 receptor open reading frames encompassed by the methods and compositions described herein are in Table 1.
[0157] [Table 1]
[0158] Provided in embodiments herein is an isolated nucleic acid encoding a CAR, wherein the CAR comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, or SEQ ID NO:53.
[0159] In each of the embodiments listed in Table 1 involving "hM195scFv," the antigen-binding portion of the CAR is hM195scFv comprising a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 8. In several embodiments, the hM195scFv has a GM-CSFRa signal peptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 16.
[0160] In each of the embodiments in Table 1 involving "CD8a," the transmembrane region of the CAR comprises a CD8 alpha transmembrane domain comprising a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 18, and the stalk domain is CD8a comprising a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 22.
[0161] In each of the embodiments in Table 1 involving "CD28m," the intracellular domain of the CAR comprises CD28 with an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:28.
[0162] In each of the embodiments in Table 1 with "T2A," the CAR ORF comprises a self-cleaving Thoseaasigna virus (T2A) peptide, allowing for the production of multiple gene products from a single vector. In embodiments, the T2A peptide has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:30.
[0163] In the embodiments in Table 1 with "HER1t," the CAR ORF is a truncated human T cell that provides a safety mechanism by allowing depletion of infused CAR-T cells via administration of FDA-approved rituximab therapy. epitheliumThe HER1t gene described herein may comprise a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of SEQ ID NO: 31. In Table 1, unless otherwise stated, the HER1t tag has a GM-CSFRa signal peptide ("GM-CSFRsp") (SEQ ID NO: 16). In certain embodiments, the HER1t tag can be replaced with another tag, for example, HER1t-1 or CD20t-1. In the embodiment in Table 1 with "IgKsp", the signal peptide is IgK having an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of SEQ ID NO: 34.
[0164] In some embodiments in Table 1, including those with "4-1BB," the ORF of the CAR comprises a costimulatory molecule having a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:24.
[0165] In some embodiments in Table 1 with "FL CD20", the CAR ORF comprises a full-length CD20 tag comprising a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 36. CD20 provides a safety mechanism by allowing depletion of infused CAR-T cells via administration of FDA-approved rituximab therapy. In certain embodiments in Table 1, the CAR ORF can be under the control of an inducible promoter for gene transcription. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, the inducible promoter can be a small molecule ligand-inducible, two-polypeptide, ecdysone receptor-based gene switch, such as the RHEOSWITCH® gene switch.
[0166] Cytokines In some embodiments, the CAR described herein is administered to a subject together with one or more additional therapeutic agents, including but not limited to cytokines.In some cases, the cytokine comprises at least one chemokine, interferon, interleukin, lymphokine, tumor necrosis factor, or a variant or combination thereof.In some cases, the cytokine is an interleukin. In some cases, the interleukin is at least one of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, and functional variants and fragments thereof. In some embodiments, the cytokine may be membrane-bound or secreted. In some embodiments, the cytokine is soluble IL-15, soluble IL-15 / IL-15Rα complex (e.g., ALT-803). In certain cases, the interleukin may comprise membrane-bound IL-15 (mbIL-15) or a fusion of IL-15 with IL-15Rα. In some embodiments, the mbIL-15 is a membrane-bound chimeric IL-15 that can be co-expressed with the engineered immune effector cells described herein. In some embodiments, the mbIL-15 comprises full-length IL-15 (e.g., a native IL-15 polypeptide), or a fragment or variant thereof, fused in-frame with full-length IL-15Rα, or a functional fragment or variant thereof. In some cases, the IL-15 is indirectly linked to the IL-15Rα via a linker. In some cases, the mbIL-15 is as described in Hurton et al., "Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells," PNAS 2016.In some cases, the cytokine is expressed in the same immune effector cell as the CAR. In some embodiments, the cytokine described above can be under the control of an inducible promoter for gene transcription. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, the inducible promoter can be a small molecule ligand-inducible, two-polypeptide, ecdysone receptor-based gene switch, such as the RHEOSWITCH® gene switch.
[0167] In further embodiments, immune effector cells expressing a CAR described herein express membrane-bound IL-15 ("mIL-15 or mbIL-15"). In aspects of the invention, mbIL-15 comprises a fusion protein of IL-15 and IL-15Rα. In further embodiments, mbIL-15 comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:37.
[0168] In some embodiments, mbIL-15 is expressed with a cell tag, such as HER1t, HER-1t-1, CD20t-1, or CD20, as described herein. mbIL-15 can be expressed in frame with HER1t, HER-1t-1, CD20t-1, or CD20.
[0169] In some embodiments, mbIL-15 can be under the control of an inducible promoter for gene transcription. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, the inducible promoter can be a small molecule ligand-inducible, two polypeptide, ecdysone receptor-based gene switch, such as the RHEOSWITCH® gene switch.
[0170] Viral-Based Delivery Systems The present invention also provides a delivery system, such as a virus-based system, that is inserted with the nucleic acid of the present invention. Representative viral expression vectors include, but are not limited to, adenovirus-based vectors (e.g., the adenovirus-based Per.C6 system, available from Crucell, Inc. (Leiden, Netherlands)), lentivirus-based vectors (e.g., the lentivirus-based pLPI, available from Life Technologies (Carlsbad, Calif.)), and retrovirus vectors (e.g., pFB-ERV with pCFB-EGSH), herpes viruses. In an embodiment, the viral vector is a lentivirus vector. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer, since they allow long-term, stable integration of transgenes in daughter cells and their propagation. Lentivirus vectors have the additional advantage over vectors derived from oncoretroviruses, such as murine leukemia viruses, in that they can transduce non-proliferating cells, such as hepatocytes. Lentivirus vectors also have the additional advantage of low immunogenicity. Generally, and in embodiments, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers (e.g., WO 01 / 96584, WO 01 / 29058, and U.S. Pat. No. 6,326,193).
[0171] In some embodiments, a lentiviral vector is provided that comprises a backbone and a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising: (a) a CD33 antigen-binding domain; (b) a stalk domain; (c) a transmembrane domain; (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; and (e) a CD3 zeta signaling domain. Optionally, the vector comprises a truncated form epithelium Further included are nucleic acids encoding growth factor receptors (HER1t or HER1t-1), CD20t-1, or full length CD20.
[0172] In some cases, the skeleton and (1) amputation type epithelium Provided is a vector comprising a growth factor receptor, e.g., HER1t or HERt-1, or a functional variant thereof, and (2) a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0173] In some cases, vectors are provided that include a scaffold and a nucleic acid sequence encoding (1) full-length CD20, a truncated CD20, or a variant thereof, and (2) a chimeric antigen receptor (CAR) that includes (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0174] In some embodiments, the nucleic acid encoding the CD33-specific CAR is cloned into a lentivirus vector containing backbone components. Exemplary backbone components include, but are not limited to, pFUGW and pSMPUW. The pFUGW lentiviral vector backbone is a self-inactivating (SIN) lentiviral vector backbone that removes unwanted HIV-1 viral sequences, resulting in reduced potential for neoplasia, harmful mutations, and reproduction of infectious particles. In some embodiments, the vector encoding the CD33 CAR also encodes mbIL-15 within a single construct. In some embodiments, the CD33 CAR and mbIL-15 are encoded on two separate lentiviral vectors. In some embodiments, mbIL-15 is encoded as a truncated form of the lentiviral vector. epitheliumIt is expressed with a growth factor receptor tag. In some embodiments, the CD33 CAR can be co-expressed with mbIL-15 and a cell tag from a single lentiviral vector. In a further embodiment, the CD33 CAR can be under the control of an inducible promoter. In another embodiment, the mbIL-15 can be under the control of an inducible promoter. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, the inducible promoter can be a small molecule ligand-inducible, two-polypeptide, ecdysone receptor-based gene switch, such as the RHEOSWITCH® gene switch.
[0175] In one embodiment, the CD33 CAR described herein comprises an anti-CD33 scFv, a human CD8 hinge and transmembrane domain, and a human 4-1BB signaling domain and a human CD3 zeta signaling domain. In another embodiment, the CD33 CAR of the invention comprises an anti-CD33 scFv, a human CD8 hinge and transmembrane domain, a human 4-1BB signaling domain and a human CD3 zeta signaling domain, and optionally a truncated epitheliumand a growth factor receptor (HER1t or HER1t-1) tag. Other suitable vectors include integrating expression vectors, which may be randomly integrated into the DNA of a host cell or may contain recombination sites that allow specific recombination of the expression vector with the host cell chromosome. Such integrating expression vectors may use endogenous expression control sequences of the host cell chromosome to provide expression of the desired protein. Examples of site-specific integrating vectors include components of the cre-lox system, such as the flp-in system from Invitrogen (Carlsbad, Calif.) (e.g., pcDNA™5 / FRT) or the cre-lox system that can be found in the pExchange-6 Core Vectors from Stratagene (LaJolla, Calif.). Examples of vectors that randomly integrate into host cell chromosomes include, for example, pcDNA3.1 (when introduced in the absence of T antigen) from Invitrogen (Carlsbad, Calif.), and pCI or pFN10A(ACT)FLEXI™ from Promega (Madison, Wis.). Additional promoter elements, such as enhancers, regulate the frequency of transcription initiation. Typically, promoter elements are located within the region 30-110 bp upstream of the start site, although many promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements is often flexible so that promoter function is preserved even when elements are inverted or displaced relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can increase to a distance of 50 bp before activity begins to decay. It is believed that individual elements may function synergistically or independently to activate transcription, depending on the promoter.
[0176] One example of a suitable promoter is the cytomegalovirus (CMV) immediate early promoter sequence, which is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operably linked to it.
[0177] Another example of a suitable promoter is human elongation growth factor 1 alpha 1 (hEF1a1). In some embodiments, the vector constructs comprising the CARs described herein comprise a functional variant of hEF1a1.
[0178] However, other constitutive promoter sequences may also be used, including, but not limited to, simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) LTR (long terminal repeat) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter, as well as human gene promoters, such as, but not limited to, actin promoter, myosin promoter, hemoglobin promoter, and creatine kinase promoter. Furthermore, the present invention is not intended to be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the present invention. The use of an inducible promoter provides a molecular switch capable of turning on expression of a polynucleotide sequence to which it is operably linked when such expression is desired, or turning off expression when expression is not desired. Examples of inducible promoters include, but are not limited to, metallothionein promoter, glucocorticoid promoter, progesterone promoter, and tetracycline promoter.
[0179] The expression vector introduced into cells to assess the expression of the CAR or portions thereof described herein may also contain a selectable marker gene or a reporter gene, or both, to facilitate the identification and selection of expressing cells from the cell population desired to be transfected or infected via the viral vector. In other aspects, the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Either the selectable marker or the reporter gene may be flanked by appropriate regulatory sequences to allow expression in the host cell. Useful selectable markers include, for example, antibiotic resistance genes, such as the neomycin resistance gene (neo) and the ampicillin resistance gene. In some embodiments, truncated forms of the selectable marker may be used. epithelium A growth factor receptor (HER1t or HER1t-1) tag can be used as a selectable marker gene.
[0180] Reporter genes can be used to identify potentially transfected cells and assess the functionality of regulatory sequences. In general, reporter genes are genes that are not present in or expressed by recipient organisms or tissues and code for a polypeptide whose expression is manifested by some easily detectable property, such as enzymatic activity. At a suitable time after the DNA is introduced into the recipient cells, the reporter gene expression is assayed. Suitable reporter genes include luciferase, beta-galactosidase, chloramphenicol acetyltransferase, genes encoding secreted alkaline phosphatase, or green fluorescent protein genes (e.g., Ui-Tei et al., FEBS Letters 479: 79-82 (2000)). Suitable expression systems are well known and can be prepared using known techniques or purchased commercially. In general, the construct with the smallest 5' flanking region that shows the highest level of reporter gene expression is identified as the promoter. Such promoter regions can be linked to a reporter gene and used to assess agents for their ability to modulate promoter-driven transcription.
[0181] In embodiments, the vectors described herein may contain the hEF1a1 promoter to drive expression of the transgene, a bovine growth hormone polyA sequence to enhance transcription, and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), as well as LTR sequences from the pFUGW plasmid.
[0182] Methods for introducing and expressing genes into cells are well known. In the context of expression vectors, the vectors can be easily introduced into host cells, such as mammalian cells, bacterial cells, yeast cells, or insect cells, by any method in the art. For example, the expression vectors can be introduced into host cells by physical means, chemical means, or biological means.
[0183] The physical method for introducing polynucleotide into host cells, such as immune effector cells, includes calcium phosphate precipitation, lipofection, gene gun, microinjection, electroporation, etc. The method for making cells containing vectors and / or exogenous nucleic acids is well known in the art. For example, see Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (2001)). In some embodiments, the method for introducing polynucleotide into host cells is calcium phosphate transfection or polyethyleneimine (PEI) transfection.
[0184] Biological methods for introducing a polynucleotide of interest into host cells, such as immune effector cells, include the use of DNA vectors and RNA vectors.Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian cells, such as human cells.Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, etc.See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.
[0185] Chemical means for introducing polynucleotides into host cells include macromolecular complexes, nanocapsules, microspheres, beads, and colloidal dispersion systems such as lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
[0186] When using a viral delivery system, an exemplary delivery vehicle is a liposome. Lipid formulations can be used for the introduction of nucleic acid into host cells (in vitro, ex vivo, or in vivo). In another embodiment, the nucleic acid can be associated with lipid. The nucleic acid associated with lipid can be encapsulated in the aqueous liposome interior, interspersed within the lipid bilayer of the liposome, can be attached to the liposome via a linking molecule that associates with both the liposome and the oligonucleotide, can be incorporated into the liposome, can be complexed with the liposome, can be dispersed in a solution containing lipid, can be mixed with lipid, can be combined with lipid, can be contained as a suspension in lipid, can be contained or complexed with micelles, or can be otherwise associated with lipid. The composition related to lipid, lipid / DNA, or lipid / expression vector is not limited to any particular structure in solution. For example, the composition can be present in a bilayer structure as a micelle, or can be present in a bilayer structure with a "collapsing" structure. The composition may also simply be dispersed in the solution, and may possibly form aggregates that are not uniform in size or shape.Lipids are fatty substances that may be natural or synthetic.For example, lipids include the fatty droplets that occur naturally in cytoplasm, as well as the class of compounds that contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, aminoalcohols, and aldehydes.
[0187] Lipids suitable for use can be purchased from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be purchased from Sigma, St. Louis, Mo., dicetyl phosphate ("DCP") can be purchased from K & K Laboratories (Plainview, NY), cholesterol ("Choi") can be purchased from Calbiochem-Behring, and dimyristyl phosphatidylglycerol ("DMPG") and other lipids can be purchased from Avanti Polar Lipids, Inc. (Birmingham, Ala.). Lipid stock solutions in chloroform or chloroform / methanol can be stored at about -20°C. Chloroform is used as the only solvent because it evaporates more readily than methanol. "Liposome" is a general term that encompasses a variety of single and multi-layered lipid vehicles formed by the creation of bilayers or lipid aggregates of encapsulated lipids. Liposomes can be characterized as having a vesicular structure with a phospholipid bilayer membrane and an internal aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. Multilamellar liposomes form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo autotransition before forming a closed structure, incorporating water and dissolved solutes between the lipid bilayers (Ghosh et al., Glycobiology 5: 505-10 (1991)). However, compositions with structures in solution that differ from the normal vesicular structure are also encompassed. For example, lipids may adopt micellar structures or exist as heterogeneous aggregates of lipid molecules. Lipofectamine-nucleic acid complexes are also contemplated.
[0188] Non-viral-based delivery systems The nucleic acid encoding the CAR described herein can also be introduced into immune effector cells using a non-viral-based delivery system, such as the "Sleeping Beauty (SB) transposon system," which refers to a synthetic DNA transposon system for introducing DNA sequences into vertebrate chromosomes.Exemplary SB transposon systems are described, for example, in U.S. Patent Nos. 6,489,458 and 8,227,432, and illustrated in FIG. 3. The Sleeping Beauty transposon system is composed of Sleeping Beauty (SB) transposase and SB transposon.
[0189] DNA transposons translocate from one DNA site to another in a simple cut-and-paste fashion. Transposition is the precise process of cutting out a defined DNA segment from one DNA molecule and moving it to another site within the same DNA molecule or genome, or within a different DNA molecule or genome. Like other Tc1 / mariner-type transposases, SB transposase also inserts the transposon into a TA dinucleotide base pair in the recipient DNA sequence. The insertion site can be another site within the same DNA molecule or another DNA molecule (or chromosome). There are approximately 200 million TA sites in mammalian genomes, including the human genome. The TA insertion site is duplicated during the process of transposon integration. This duplication of the TA sequence is a hallmark of transposition and is used in some experiments to confirm the mechanism. The transposase can be encoded within the transposon or it can be provided by another source, in which case the transposon is a non-autonomous element. Non-autonomous transposons are most useful as genetic tools because they cannot be excised and reinserted independently after insertion. SB transposons are envisioned to be used as non-viral vectors for gene transfer and gene therapy into vertebrate genomes. Briefly, the Sleeping Beauty (SB) system (Hackett et al., Mol Ther 18:674-83, (2010)) is adapted to genetically modify T cells (Cooper et al., Blood 105:1622-31, (2005)).This involved two steps: (i) electrotransfer of DNA plasmids expressing the SB transposon [i.e., chimeric antigen receptor (CAR)] and SB transposase to redirect T cell specificity (Jin et al., Gene Ther 18:849-56, (2011); Kebriai et al., Hum Gene Ther 23:444-50, (2012)), and (ii) propagation and expansion of T cells stably expressing the integrated sequences in contact with designer artificial antigen presenting cells (AaPCs) derived from the K562 cell line (also known as AaPCs (Activating and Propagating Cells)). In one embodiment, the SB transposon system comprises coding sequences encoding tdIL-15, IL-21, and / or chimeric antigen receptor. Such systems are described, for example, in Singh et al., Cancer Res (8):68 (2008). April 15, 2008 and Maiti et al., J Immunother. 36(2): 112-123 (2013), which are incorporated by reference in their entireties.
[0190] In certain embodiments, the CD33 CAR and mbIL-15 described herein are encoded in a transposon DNA plasmid vector, and the SB transposase is encoded in a separate vector. In certain embodiments, the CD33 CAR described herein is encoded in a transposon DNA plasmid vector, mb-IL15 is encoded in a second transposon DNA plasmid vector, and the SB transposase is encoded in a third DNA plasmid vector. In some embodiments, mbIL-15 is encoded by a kill tag, such as HER1t, HRt-1, CD20, or CD20t-1.
[0191] Regardless of the method used to introduce exogenous nucleic acid into a host cell or otherwise expose the cell to an inhibitor of the present invention, various assays can be performed to confirm the presence of the recombinant DNA sequence in the host cell. Such assays include "molecular biological" assays well known to those skilled in the art, such as Southern and Northern blotting, RT-PCR and PCR; "biochemical" assays, such as immunological means (ELISA and Western blot), or assays to detect the presence or absence of specific peptides, such as those described herein for identifying drugs, which are within the scope of the present invention.
[0192] In several embodiments, the CD33 CAR and other genetic elements are delivered into cells using the SB11 transposon system, the SB100X transposon system, the SB110 transposon system, the piggyBac transposon system (see, e.g., Wilson et al, "PiggyBac Transposon-mediated Gene Transfer in Human Cells," Molecular Therapy 15:139-145 (2007) which is incorporated by reference in its entirety), and / or the piggyBat transposon system (see, e.g., Mitra et al., "Functional characterization of piggyBat from the bat Myotis lucifugus unveils an active mammalian DNA transposon," Proc. Natl. Acad. Sci USA 110:234-239 (2013)). Additional transposase and transposon systems are provided in U.S. Pat. Nos. 7,148,203, 8,227,432, U.S. Patent Publication No. 2011 / 0117072, Mates et al., Nat Genet, 41(6):753-61 (2009). doi: 10.1038 / ng.343. Epub 2009 May 3, Gene Ther., 18(9):849-56 (2011). doi: 10.1038 / gt.2011.40. Epub 2011 Mar 31, and Ivics et al., Cell. 91(4):501-10, (1997), each of which is incorporated herein by reference in its entirety.
[0193] In other embodiments, CD33 CAR and other genetic elements such as cytokines, mbIL-15, and / or HER1t / HER1t-1 / CD20 / CD20t-1 tags can be integrated into the DNA of immune effector cells through recombinase and expression vector integration. Such vectors can be randomly integrated into the DNA of the host cell or can contain recombination sites that allow specific recombination of the expression vector with the host cell chromosome. Such integrating expression vectors can use endogenous expression control sequences of the host cell chromosome to provide expression of the desired protein. In some embodiments, the presence of sequences on the donor polynucleotide that are homologous to sequences flanking the integration site facilitates integration targeting. For example, integration targeting using the donor polynucleotides described herein can be achieved according to techniques used to create gene knockouts or knockins by conventional transfection methods, such as by homologous recombination. In other embodiments, integration targeting is promoted by both the presence of sequences on the donor polynucleotide that are homologous to sequences flanking the integration site and contacting the cell with the donor polynucleotide in the presence of a site-specific recombinase. Site-specific recombinase, or simply recombinase, refers to a polypeptide that catalyzes conservative site-specific recombination between its compatible recombination sites. Site-specific recombinase as used herein includes naturally occurring polypeptides, as well as derivatives, mutants, and / or fragments that retain activity, and naturally occurring polynucleotides, derivatives, mutants, and / or fragments that encode a recombinase that retain activity.
[0194] Recombinase can be introduced into target cells before, simultaneously with, or after the introduction of targeting vector. Recombinase can also be directly introduced into cells as protein, for example, using liposomes, particle coating, or microinjection. Alternatively, polynucleotides, DNA or messenger RNA, encoding recombinase can be introduced into cells using appropriate expression vectors. The components of targeting vectors described above are useful in constructing expression cassettes containing sequences encoding the recombinase of interest. However, expression of recombinase can also be regulated in other ways, for example, by placing expression of recombinase under the control of a regulatable promoter (i.e., a promoter whose expression can be selectively induced or suppressed).
[0195] Recombinases can be from the integrase family or resolvase family. The integrase family of recombinases has more than 100 members, including, for example, FLP, Cre, and lambda integrase. The integrase family is also called the tyrosine family or lambda integrase family, and uses the catalytic hydroxyl group of tyrosine for nucleophilic attack on the phosphodiester bond of DNA. Typically, members of the tyrosine family first nick DNA, which then forms a double-strand break. Examples of tyrosine family integrases include Cre integrase, FLP integrase, SSV1 integrase, and lambda (λ) integrase. In the resolvase family, also known as the serine recombinase family, a conserved serine residue forms a covalent link to the DNA target site (Grindley, et al., (2006) Ann Rev Biochem 16:16).
[0196] In one embodiment, the recombinase is an isolated polynucleotide sequence comprising a nucleic acid sequence encoding a recombinase selected from the group consisting of SPβc2 recombinase, SF370.1 recombinase, Bxb1 recombinase, A118 recombinase, and ΦRv1 recombinase. Examples of serine recombinases are described in detail in U.S. Patent No. 9,034,652, which is incorporated herein by reference in its entirety.
[0197] Recombinases for use in the practice of the present invention can be recombinantly produced and purified as previously described. Polypeptides having the desired recombinase activity can be purified to the desired purity by methods known in the art for protein purification, including, but not limited to, ammonium sulfate precipitation of proteins, size fractionation, affinity chromatography, HPLC, ion exchange chromatography, heparin agarose affinity chromatography (e.g., Thorpe & Smith, Proc. Nat. Acad. Sci. 95:5505-5510, 1998).
[0198] In one embodiment, the recombinase can be introduced into the eukaryotic cell containing the recombination junction site where recombination is desired by any suitable method. Methods for introducing functional proteins into cells are well known in the art, for example, by microinjection or other methods. The introduction of purified recombinase protein confirms the transient presence of the protein and its function, which is often the preferred embodiment. Alternatively, the gene encoding the recombinase can be included in an expression vector used to transform the cell, in which the polynucleotide encoding the recombinase is operably linked to a promoter that mediates the expression of the polynucleotide in the eukaryotic cell. The recombinase polypeptide can also be introduced into the eukaryotic cell by messenger RNA encoding the recombinase polypeptide. It is generally preferred that the recombinase is present only as long as it is necessary for the insertion of the nucleic acid fragment into the genome to be modified. Thus, the lack of persistence associated with most expression vectors is not expected to be detrimental. The recombinase gene can be introduced before, at the same time as, or after the introduction of the exogenous polynucleotide of interest. In one embodiment, the recombinase gene is present in the vector carrying the polynucleotide to be inserted, and the recombinase gene can also be incorporated within the polynucleotide.
[0199] In one embodiment, a method for site-specific recombination includes providing a first recombination site and a second recombination site and contacting the first recombination site and the second recombination site with a recombinase polypeptide of a prokaryotic cell resulting in recombination between the recombination sites, wherein the recombinase polypeptide is capable of mediating recombination between the first recombination site and the second recombination site, wherein the first recombination site is attP or attB and the second recombination site is attB or attP, and wherein if the first recombination junction site is attB, the second recombination junction site is attP, and if the first recombination junction site is attP, the second recombination junction site is attB, and wherein the recombinase is a phage recombinase of Listeria monocytogenes, a phage recombinase of Streptococcus pyogenes, a phage recombinase of Bacillus subtilis, or a phage recombinase of Bacillus subtilis. The phage recombinase is selected from the group consisting of a phage recombinase from Mycobacterium subtilis, a phage recombinase from Mycobacterium tuberculosis, and a phage recombinase from Mycobacterium smegmatis.
[0200] Further embodiments provide for the introduction of a site-specific recombinase into the cell whose genome is to be modified. One embodiment is a method for obtaining site-specific recombination in a eukaryotic cell, comprising the steps of providing a eukaryotic cell comprising a first recombination junction site and a second recombination junction site, and contacting the first recombination junction site and the second recombination junction site with a recombinase polypeptide of a prokaryotic cell, resulting in recombination between the recombination sites, wherein the recombinase polypeptide is capable of mediating recombination between the first recombination junction site and the second recombination junction site, wherein the first recombination junction site is a recombination junction site of a phage genome (attP) or a recombination junction site of a bacterial genome (attB), and the second recombination junction site is attB or attP, and if the first recombination junction site is attB, the second recombination junction site is attP, and if the first recombination junction site is attP, the second recombination junction site is attB, In one embodiment, the recombinase is selected from the group consisting of A118 recombinase, SF370.1 recombinase, SPβc2 recombinase, ΦRv1 recombinase, and Bxb1 recombinase. In one embodiment, the recombinase results in integration.
[0201] Cells containing CD33 CAR and vector Provided herein is a modified cell expressing the CAR described herein. In certain embodiments, the modified cell described herein is an immune effector cell. In some embodiments, the modified cell described herein is an immune effector cell. epitheliumImmune effector cells are provided that contain a vector comprising a growth factor receptor (HER1t or HER1t-1) and (2) a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[0202] In certain embodiments, the antibody comprises: (a) a CD33 antigen-binding domain; (b) a stalk domain; (c) a transmembrane domain; (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; (e) a CD3 zeta signaling domain; and (f) a truncated form of the antibody. epithelium Immune effector cells containing a chimeric antigen receptor (CAR) containing a growth factor receptor (HER1t or HER1t-1) are presented.
[0203] In some embodiments herein, there is provided an immune effector cell comprising: (1) a cell tag for use as a kill switch, a selection marker, a biomarker, or a combination thereof; and (2) a chimeric antigen receptor (CAR) comprising: (a) a CD33 antigen-binding domain; (b) a stalk domain; (c) a transmembrane domain; (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; and (e) a CD3 zeta signaling domain. In some embodiments, the cell tag is HER1t, HER1t-1, CD20t-1, or CD20.
[0204] In some embodiments, the immune effector cells are T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), and regulatory T cells. In some embodiments, the cells exhibit anti-tumor immunity when the CD33 antigen-binding domain binds to CD33.
[0205] Engineered immune effector cells The immune effector cell is modified to express one or more heterologous genes or polypeptides as described herein.The immune effector cell is modified to express CD33 CAR as described herein and at least one of HER1t tag, HER1t-1 tag, CD20 tag, and CD20t-1 tag.Optionally, the immune effector cell is modified to express CD33 CAR, mbIL-15, and at least one of HER1t tag, HER1t-1 tag, CD20 tag, and CD20t-1 tag as disclosed herein.
[0206] As used herein, a "T cell" or "T lymphocyte" is a type of lymphocyte that plays a central role in cell-mediated immunity. A "T cell" or "T lymphocyte" can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T cell receptor (TCR) on the cell surface.
[0207] In some embodiments, the engineered immune effector cell is an engineered immune cell, including T cells and / or natural killer cells. T cells or T lymphocytes are subtypes of white blood cells involved in cell-mediated immunity. Exemplary T cells include helper T cells, cytotoxic T cells, TH17 cells, stem cell memory T cells (TSCM), naive T cells, memory T cells, effector T cells, regulatory T cells, or natural killer T cells.
[0208] Helper T cells (TH cells) assist other white blood cells in immune processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. Sometimes TH cells are known as CD4+ T cells, due to the expression of CD4 glycoprotein on the cell surface. Helper T cells become activated when presented with peptide antigens by MHC class II molecules expressed on the surface of antigen-presenting cells (APCs). Upon activation, helper T cells divide rapidly and secrete small proteins called cytokines that regulate or support active immune responses. These cells can differentiate into one of several subtypes, including TH1, TH2, TH3, TH17, Th9, or TFH, which secrete different cytokines to facilitate different kinds of immune responses. Signaling from APCs directs T cells toward specific subtypes.
[0209] Cytotoxic T cells (TC cells or CTLs) destroy virus-infected and tumor cells and are also involved in transplant rejection. These cells are also known as CD8+ T cells because they express the CD8 glycoprotein on their surface. These cells recognize their targets by binding to antigens associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, CD8+ cells can be inactivated into an anergic state, thereby preventing autoimmune diseases.
[0210] Memory T cells are a subset of antigen-specific T cells that persist for a long time after an infection has cleared. Upon re-exposure to their cognate antigen, memory T cells rapidly expand into large numbers of effector T cells, thereby providing the immune system with a "memory" for past infections. Memory T cells include subtypes: stem cell memory T cells (TSCM), central memory T cells (TCM cells), and two types of effector memory T cells (TEM and TEMRA cells). Memory cells can be CD4+ or CD8+ cells. Memory T cells can express the cell surface proteins CD45RO, CD45RA, and / or CCR7.
[0211] Regulatory T cells (Treg cells), formerly known as suppressor T cells, play a role in maintaining immune tolerance. The primary role of regulatory T cells is to block T cell-mediated immunity, terminating immune responses and suppressing autoreactive T cells that have escaped the negative selection process in the thymus.
[0212] Natural killer T cells (NKT cells) bridge the adaptive and innate immune systems. Unlike conventional T cells, which recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigens presented by a molecule called CD1d. Upon activation, these cells can perform functions ascribed to both Th and Tc cells (i.e., production of cytokines and release of cytolytic / cell-killing molecules). NKT cells can also recognize and eliminate some tumor cells and cells infected with herpes viruses.
[0213] Natural killer (NK) cells are a type of cytotoxic lymphocyte of the innate immune system. In some cases, NK cells provide the first line of defense against viral infection and / or tumor formation. NK cells can detect MHC presented on infected or cancerous cells, triggering cytokine release and subsequently inducing lysis and apoptosis. NK cells can also detect stressed cells in the absence of antibodies and / or MHC, allowing for a rapid immune response.
[0214] Dosage of Engineered Immune Effector Cells In some embodiments, an amount of modified immune effector cells is administered to a subject in need thereof, the amount being determined based on efficacy and potential to induce cytokine-associated damaging effects. In some cases, the amount of modified immune effector cells is about 10 modified immune effector cells per kg. 5 ~about 10 9 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 5 ~about 10 8 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 5 ~about 10 7 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 6 ~about 10 9 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 6 ~about 10 8 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 7 ~about 10 9 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 5 ~about 10 6 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg.6 ~about 10 7 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 7 ~about 10 8 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 8 ~about 10 9 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 9 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 8 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 7 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 6 In some cases, the amount of engineered immune effector cells is about 10 engineered immune effector cells per kg. 5 Includes pieces.
[0215] In some embodiments, the engineered immune effector cells are CAR-T cells that are CD33-specific CAR-T cells. In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 5 ~about 10 9 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 5 ~about 10 8 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 5 ~about 10 7 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 6 ~about 10 9 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 6 ~about 10 8In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 7 ~about 10 9 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 5 ~about 10 6 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 6 ~about 10 7 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 7 ~about 10 8 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 8 ~about 10 9 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 9 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 8 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 7 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 6 In some cases, the amount of CD33-specific CAR-T cells is about 10 CAR-T cells per kg. 5 Includes pieces.
[0216] Source of immune effector cells In certain aspects, embodiments described herein include methods of generating and / or expanding redirected, antigen-specific immune effector cells (e.g., T cells, NK cells, or NK T cells) that include transfecting cells with an expression vector containing a DNA (or RNA) construct encoding a CAR and then, optionally, stimulating the cells with feeder cells, recombinant antigen, or antibodies against the receptor to expand the cells. In certain aspects, the cells (or cell populations) engineered to express a CAR are stem cells, iPS cells, immune effector cells, or progenitors of these cells.
[0217] Sources of immune effector cells can include both allogeneic and autologous sources. In some cases, immune effector cells can also be differentiated from stem cells or induced pluripotent stem cells (iPSCs). Thus, cells for modification according to the embodiments can be isolated from umbilical cord blood, peripheral blood, human embryonic stem cells, or iPSCs. For example, allogeneic T cells can be modified to contain chimeric antigen receptors (and, optionally, to lack functional TCRs). In some aspects, immune effector cells are primary human T cells, such as T cells derived from human peripheral blood mononuclear cells (PBMCs). PBMCs can be collected from peripheral blood, or from bone marrow or umbilical cord blood after stimulation with G-CSF (granulocyte colony stimulating factor). After transfection or transduction (e.g., with an expression construct for a CAR), the cells can be immediately infused or cryopreserved. In certain embodiments, after transfection, the cells can be propagated ex vivo as a bulk population for days, weeks, or months within about 1, 2, 3, 4, 5, or more days after gene transfer into the cells. In further embodiments, after transfection, the transfected cells are cloned and clones that confirm the presence of a single expression cassette or plasmid, integrated or maintained in an episome, and the expression of a chimeric antigen receptor are expanded ex vivo. The clones selected for expansion confirm the ability to specifically recognize and lyse target cells expressing the antigen. The recombinant T cells can be expanded by stimulation with IL-2 or other cytokines that bind to the common gamma chain (e.g., IL-7, IL-12, IL-15, IL-21, and other cytokines). The recombinant T cells can be expanded by stimulation with artificial antigen-presenting cells. Recombinant T cells can also be expanded in contact with artificial antigen-presenting cells, or with antibodies such as OKT3, which crosslink CD3 on the surface of T cells.Subsets of the recombinant T cells can be further selected by using magnetic bead-based isolation and / or fluorescence activated cell sorting techniques and further cultured with AaPCs. In a further embodiment, the genetically modified cells can be cryopreserved.
[0218] T cells can also be obtained from a number of sources, including bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments of the invention, any number of T cell lines available in the art can be used. In certain embodiments of the invention, T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to those skilled in the art, such as Ficoll® separation. In several embodiments, cells from an individual's circulating blood can be obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one embodiment, the cells collected by apheresis are washed to remove the plasma fraction and the cells are placed in an appropriate buffer or medium for the processing steps in question. In one embodiment of the invention, the cells are washed with phosphate buffered saline (PBS). In alternative embodiments, the wash solution lacks calcium, may lack magnesium, and may lack many, but not all, divalent cations. An initial activation step in the absence of calcium results in enhanced activation. As one of skill in the art will readily appreciate, the wash step can be accomplished by methods known to those of skill in the art, such as using a semi-automated "flow-through" centrifuge (e.g., Cobe 2991 cell processor, Baxter CytoMate, or Haemonetics Cell Saver 5) following the manufacturer's instructions. After washing, the cells can be resuspended in a variety of biocompatible buffers, such as, for example, Ca2+-free PBS, Mg2+-free PBS, Plasmalyte A, or other saline solutions with or without buffer. Alternatively, the apheresis sample can be removed of undesired components and the cells can be resuspended directly in culture medium.
[0219] In another embodiment, T cells are isolated from peripheral blood lymphocytes by lysing red blood cells and depleting monocytes, for example, by centrifugation through a PERCOLL® gradient or by counterflow centrifugal elutriation. + , CD28+ , CD4 + , CD8 + , CD45RA + , and CD45RO +Specific subpopulations of T cells, such as T cells, can also be further isolated by positive or negative selection methods. For example, in one embodiment, T cells are isolated by incubation with anti-CD3 / anti-CD28 (i.e., 3×28) conjugated beads, such as DYNABEADS® M-450 CD3 / CD28 T, for a time sufficient for the desired T cell positive selection. In one embodiment, the time is about 30 minutes. In a further embodiment, the time ranges from 30 minutes to 36 hours, or longer, and any integer value therebetween. In a further embodiment, the time is at least 1, 2, 3, 4, 5, or 6 hours. In yet another embodiment, the time is 10 to 24 hours. In one embodiment, the incubation time is 24 hours. The use of longer incubation times, such as 24 hours, for the isolation of T cells from patients with leukemia can increase cell yield. In any situation where T cells are in low numbers compared to other cell types, such as in the situation of isolating tumor infiltrating lymphocytes (TILs) from tumor tissue or immune-compromised individuals, longer incubation times can be used to isolate T cells. Furthermore, the use of longer incubation times can also increase the efficiency of capturing CD8+ T cells. Thus, by simply shortening or lengthening the time to allow T cells to bind to CD3 / CD28 beads, and / or increasing or decreasing the ratio of beads to T cells (as further described herein), subpopulations of T cells can be preferentially positively or negatively selected at the beginning of culture, or at other times during the process. In addition, by increasing or decreasing the ratio of anti-CD3 and / or anti-CD28 antibodies on the beads or other surfaces, subpopulations of T cells can be preferentially positively or negatively selected at the beginning of culture, or at other desired times. Those skilled in the art will recognize that multiple rounds of selection can also be used in the context of the present invention. In certain embodiments, it may be desirable to perform a selection procedure and use the "unselected" cells in the activation and expansion steps. The "unselected" cells can also be subjected to additional rounds of selection.
[0220] Enrichment of T cell populations by negative selection can be achieved by a combination of antibodies directed to surface markers unique to the negatively selected cells. One method is cell sorting and / or selection via negative magnetic immunoadhesion or flow cytometry using a cocktail of monoclonal antibodies directed to cell surface markers present on the negatively selected cells. For example, CD4 + To enrich cells by negative selection, the monoclonal antibody cocktail typically includes antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In certain embodiments, the cocktail typically includes antibodies against CD4 + , CD25 + , CD62L hi , G.I.T.R. + , and FoxP3 + It may be desirable to enrich or positively select for regulatory T cells expressing IL-1. Alternatively, in certain embodiments, regulatory T cells can be depleted by anti-CD25 conjugated beads or other similar selection methods.
[0221] The concentration and surface of cells (e.g., particles such as beads) can be varied to isolate the desired cell population by positive or negative selection. In certain embodiments, it may be desirable to significantly reduce the volume in which the beads and cells are mixed together (i.e., increase the concentration of cells) to ensure maximum contact between the cells and the beads. For example, in one embodiment, a concentration of 2 billion cells per ml is used. In one embodiment, a concentration of 1 billion cells per ml is used. In a further embodiment, a concentration of more than 100 million cells per ml is used. In a further embodiment, a cell concentration of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells per ml is used. In yet another embodiment, a cell concentration of 75, 80, 85, 90, 95, or 100 million cells per ml is used. In further embodiments, a concentration of 125 or 150 million cells per ml may be used. The use of higher concentrations may result in increased cell yield, cell activation, and cell expansion. Furthermore, the use of higher cell concentrations allows for more efficient capture of cells that may have low expression of the target antigen of interest, such as CD28-negative T cells, or cells derived from samples with many tumor cells (i.e., leukemic blood, tumor tissue, etc.). Such cell populations may have therapeutic value and would be desirable to obtain. For example, the use of higher cell concentrations may result in more efficient capture of CD8 T cells, which normally have low expression of CD28. + Allows for more efficient selection of T cells.
[0222] In a related embodiment, it may be desirable to use a low concentration of cells. The mixture of T cells and surface (e.g., particles such as beads) is significantly diluted to minimize particle-cell interactions. This selects for cells expressing high amounts of the desired antigen that bind to the particles. For example, CD4 + T cells express high levels of CD28 and dilute concentrations of CD8 + T cells are captured more efficiently. In one embodiment, the cell concentration used is 5×10 cells per ml. 6In another embodiment, the concentration used is about 1 x 10 cells per ml. 5 1 x 10 cells per ml 6 The number of bits may be any integer value between these.
[0223] In other embodiments, cells can be incubated on a rotator at varying speeds, at 2-10° C. or at room temperature, for varying lengths of time.
[0224] The stimulated T cells can also be frozen after a washing step. After a washing step that removes plasma and platelets, the cells can be suspended in a freezing solution. While many freezing solutions and freezing parameters are known in the art and would be useful in this context, one method involves the use of PBS containing 20% DMSO and 8% human serum albumin, or culture medium containing 10% dextran 40 and 5% dextrose, 20% human serum albumin, and 7.5% DMSO, or other suitable cell freezing medium containing, for example, Hespan and Plasmalyte A, and then the cells are frozen to -80°C at a rate of 1°C per minute and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing may be used, as well as rapid uncontrolled freezing at -20°C or in liquid nitrogen.
[0225] In certain embodiments, cryopreserved cells are thawed, washed, and rested at room temperature for 1 hour prior to activation using the methods of the invention, as described herein.
[0226] Certain embodiments also provide for the collection of blood samples or apheresis products from a subject at a time period prior to the time when the expanded cells described herein may be required. Thus, the source of cells to be expanded can be collected at any time point required, and the desired cells, such as T cells, can be isolated and frozen for subsequent use in T cell therapy for any number of diseases or conditions that would benefit from T cell therapy, such as the T cell therapy described herein. In one embodiment, blood samples or apheresis are generally taken from healthy subjects. In certain embodiments, blood samples or apheresis are generally taken from healthy subjects who are at risk of developing disease, but have not yet developed disease, and the cells of interest are isolated and frozen for subsequent use. In certain embodiments, the T cells can be expanded, frozen, and used at a later time point. In certain embodiments, samples are collected from patients immediately after diagnosis for certain diseases described herein, but prior to any treatment. In further embodiments, the cells are isolated from a blood sample or apheresis derived from the subject prior to any number of reasonable treatment modalities, including, but not limited to, treatment with agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies, cytoxan, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and irradiation. These drugs inhibit either the calcium-dependent phosphatase, calcineurin (cyclosporine and FK506), or the p70S6 kinase (rapamycin), which is important in growth factor-induced signal transduction (Liu et al., Cell 66:807-815, (1991); Henderson et al., Immun 73:316-321, (1991); Bierer et al., Curr. Opin. Immun 5:763-773, (1993)).In a further embodiment, the cells are isolated for a patient and frozen for subsequent use with (e.g., prior to, concurrently with, or following) bone marrow or stem cell transplantation, chemotherapy agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide, or T cell depleting therapy using antibodies such as OKT3 or CAMPATH. In another embodiment, the cells can be pre-isolated and frozen for subsequent use for treatment following B cell depleting therapy, such as agents reactive with CD20, e.g., Rituxan.
[0227] In a further embodiment of the present invention, T cells are obtained directly from the patient after treatment. In this regard, it has been observed that after certain cancer treatments, particularly with drugs that impair the immune system, and immediately after treatment during the period when the patient usually recovers from the treatment, the quality of the T cells obtained may be optimal or improved in their ability to expand ex vivo. Similarly, after ex vivo modification using the methods described herein, these cells may be in a favorable state for extended engraftment and in vivo expansion. Thus, within the context of the present invention, it is envisioned to recover blood cells, including T cells, dendritic cells, or other cells of the hematopoietic lineage, during this recovery period. Furthermore, in certain embodiments, mobilization (e.g., mobilization with GM-CSF) and conditioning regimens can be used to create conditions favorable for repopulation, recirculation, regeneration, and / or proliferation of certain cell types in the subject, particularly in a defined time window after treatment. Exemplary cell types include T cells, B cells, dendritic cells, and other cells of the immune system.
[0228] T cell activation and expansion Either before or after the T cells are engineered to express a CAR as described herein, the T cells can be engineered to express a CAR as described, for example, in any of the methods described in U.S. Pat. Nos. 6,352,694, 6,534,055, 6,905,680, 6,692,964, 5,858,358, 6,887,466, 6,905,681, 7,144,575, 7,067 ... The cells can be activated and expanded generally using the methods described in U.S. Patent Application Publication No. 20060121005, U.S. Pat. Nos. 7,318, 7,172,869, 7,232,566, 7,175,843, 5,883,223, 6,905,874, 6,797,514, 6,867,041, and U.S. Patent Application Publication No. 20060121005.
[0229] In general, the T cells described herein are expanded by contact with a surface to which is attached an agent that stimulates CD3 / TCR complex-associated signals and a ligand that stimulates costimulatory molecules on the T cell surface. In particular, a population of T cells can be stimulated by contact with an anti-CD3 antibody, or an antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface as described herein, or by contact with a protein kinase C activator (e.g., bryostatin) with a calcium ionophore, or the like. To costimulate accessory molecules on the T cell surface, a ligand that binds to the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody under appropriate conditions to stimulate the proliferation of the T cells. CD4 + T cells or CD8 +To stimulate the proliferation of T cells, they can be contacted with anti-CD3 antibody and anti-CD28 antibody. Examples of anti-CD28 antibody include 9.3, B-T3, XR-CD28 (Diaclone, Besancon, France), and can be used as well as other methods generally known in the art (Berg et al., Transplant Proc. 30(8):3975-3977, (1998); Haanen et al., J. Exp. Med. 190(9):13191328, (1999); Garland et al., J. Immunol Meth. 227(1-2):53-63, (1999)).
[0230] In certain embodiments, the primary and costimulatory signals for T cells are provided by different protocols. For example, the agents providing each signal may be in solution or may be coupled to a surface. When coupled to a surface, the agents may be coupled to the same surface (i.e., in a "cis" configuration) or to separate surfaces (i.e., in a "trans" configuration). Alternatively, one agent may be coupled to a surface and the other agent in solution. In one embodiment, the agent providing the costimulatory signal is bound to a cell surface and the agent providing the primary activation signal is in solution or coupled to a surface. In certain embodiments, both agents are in solution. In another embodiment, the agents may be in soluble form and then crosslinked to a surface, such as a cell expressing an Fc receptor or antibody or other binding agent that binds the agent. In this regard, see, e.g., U.S. Patent Application Publication Nos. 20040101519 and 20060034810 for artificial antigen presenting cells (aAPCs) contemplated for use in the present invention in activating and expanding T cells.
[0231] In one embodiment, the two agents are immobilized on the same bead, i.e., "cis", or on separate beads, i.e., "trans". By way of example, the agent providing the primary activation signal is an anti-CD3 antibody or an antigen-binding fragment thereof, and the agent providing the costimulatory signal is an anti-CD28 antibody or an antigen-binding fragment thereof, and both agents are co-immobilized with equal molecular weights on the same bead. In one embodiment, the CD4 + For T cell expansion and proliferation, a 1:1 ratio of each antibody bound to beads is used. In certain aspects of the invention, a ratio of anti-CD3:CD28 antibodies bound to beads is used such that an increase in T cell expansion is observed compared to the expansion observed using a 1:1 ratio. In one particular embodiment, an increase of about 1 to about 3 times is observed compared to the expansion observed using a 1:1 ratio. In one embodiment, the ratio of CD3:CD28 antibodies bound to beads ranges from 100:1 to 1:100 and all integer values therebetween. In one aspect of the invention, more anti-CD28 antibodies are bound to the particles than anti-CD3 antibodies, i.e., the ratio of CD3:CD28 is less than 1. In certain embodiments of the invention, the ratio of anti-CD28 antibodies to anti-CD3 bound to beads is greater than 2:1. In one particular embodiment, a ratio of CD3:CD28 bound to beads of 1:100 is used. In another embodiment, a 1:75 ratio of CD3:CD28 bound to beads is used. In a further embodiment, a 1:50 ratio of CD3:CD28 bound to beads is used. In another embodiment, a 1:30 ratio of CD3:CD28 bound to beads is used. In some embodiments, a 1:10 ratio of CD3:CD28 bound to beads is used. In another embodiment, a 1:3 ratio of CD3:CD28 bound to beads is used. In yet another embodiment, a 3:1 ratio of CD3:CD28 bound to beads is used.
[0232] Particle to cell ratios of 1:500 to 500:1 and any integer value therebetween can be used to stimulate T cells or other target cells. As one skilled in the art can readily appreciate, the particle to cell ratio can depend on the particle size compared to the target cells. For example, small sized beads can only bind to a few cells, whereas larger beads can bind to many cells. In certain embodiments, the cell to particle ratio ranges from 1:100 to 100:1 and any integer value therebetween, and in further embodiments, the ratio includes 1:9 to 9:1 and any integer value therebetween, which can also be used to stimulate T cells. The ratio of anti-CD3 / anti-CD28 coupled particles to T cells resulting in stimulation of T cells can vary as mentioned above, but certain values include 1:100, 1:50, 1:40, 1:30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, and 15:1, with one ratio being at least 1:1 particle to T cell ratio. In one embodiment, a particle to cell ratio of 1:1 or less is used. In one particular embodiment, the particle:cell ratio is 1:5. In further embodiments, the particle to cell ratio can vary depending on the stimulation day. For example, in one embodiment, the ratio of particles to cells is 1:1 to 10:1 on day 1, and additional particles are added to cells every day or every other day thereafter for up to 10 days, resulting in a final ratio of 1:1 to 1:10 (based on cell count on the day of addition). In a particular embodiment, the ratio of particles to cells is 1:1 on the first stimulation day, and adjusted to 1:5 on the third and fifth stimulation days. In another embodiment, particles are added every day or every other day to a final ratio of 1:1 on day 1, and 1:5 on the third and fifth stimulation days. In another embodiment, the ratio of particles to cells is 2:1 on the first stimulation day, and adjusted to 1:10 on the third and fifth stimulation days.In another embodiment, particles are added every day or every other day to a final ratio of 1:1 on the first day and 1:10 on the third and fifth stimulation days.Those skilled in the art will understand that various other ratios may also be suitable for use in the present invention.In particular, the ratio will vary depending on the size of the particles and the size and type of cells.
[0233] In further embodiments described herein, immune effector cells such as T cells are combined with drug-coated beads, the beads and cells are then separated, and the cells are then cultured. In alternative embodiments, the drug-coated beads and cells are not separated prior to culture, but are cultured together. In further embodiments, the beads and cells are first concentrated by applying a force, such as a magnetic force, resulting in increased ligation of cell surface markers, thereby inducing stimulation of the cells.
[0234] By way of example, anti-CD3 and anti-CD28 conjugated paramagnetic beads (3x28 beads) can be contacted with T cells to ligate cell surface proteins. In one embodiment, cells (e.g., 10 T cells) can be contacted with anti-CD3 and anti-CD28 conjugated paramagnetic beads (3x28 beads) to ligate cell surface proteins. 4 ~10 9) and beads (e.g., DYNABEADS® M-450 CD3 / CD28 T paramagnetic beads, or MACS® MicroBeads from Miltenyi Biotec, in a 1:1 ratio) in a buffer, e.g., PBS (without divalent cations such as calcium and magnesium). Again, one skilled in the art can readily appreciate that any cell concentration may be used. For example, target cells may be extremely rare in a sample, comprising only 0.01% of the sample, or the entire sample (i.e., 100%) may comprise the desired target cells. Thus, any cell number is within the context of the present invention. In certain embodiments, it may be desirable to significantly reduce the volume in which the particles and cells are mixed together (i.e., increase the concentration of cells) to ensure maximum contact between the cells and the particles. For example, in one embodiment, a concentration of approximately 2 billion cells per ml is used. In another embodiment, a concentration of more than 100 million cells per ml is used. In further embodiments, a cell concentration of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells per ml is used. In yet another embodiment, a cell concentration of 75, 80, 85, 90, 95, or 100 million cells per ml is used. In further embodiments, a concentration of 125 or 150 million cells per ml may be used. The use of high concentrations may result in increased cell yield, cell activation, and cell expansion. Furthermore, the use of high cell concentrations allows for more efficient capture of cells that may have low expression of the target antigen of interest, such as CD28-negative T cells. In certain embodiments, such cell populations may have therapeutic value and would be desirable to obtain. For example, the use of high cell concentrations may result in increased cell yield, cell activation, and cell expansion. + Allows for more efficient selection of T cells.
[0235] In one embodiment described herein, the mixture can be cultured for a few hours (about 3 hours) to about 14 days, or any integer value therebetween. In another embodiment, the mixture can be cultured for 21 days. In one embodiment of the present invention, the beads and T cells are cultured together for about 8 days. In another embodiment, the beads and T cells are cultured together for 2-3 days. Several cycles of stimulation may also be desired, such that the culture period of the T cells is 60 days or more. Suitable conditions for culturing T cells include a suitable medium (e.g., Minimum Essential Medium or RPMI Medium 1640, or X-vivo 15 (Lonza)) that may contain factors necessary for growth and survival, including serum (e.g., fetal bovine serum or human serum), interleukin 2 (IL-2), insulin, IFN-gamma, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGFβ, and TNF-alpha, or any other additives known to those skilled in the art for the growth of cells. Other additives for cell growth include, but are not limited to, detergents, plasmanates, and reducing agents such as N-acetylcysteine and 2-mercaptoethanol. The medium may contain RPMI 1640, AIM-V, DMEM, MEM, alpha-MEM, F-12, X-Vivo 15 and X-Vivo 20, Optimizer, amino acid supplements, sodium pyruvate, and vitamins, serum-free or supplemented with an appropriate amount of serum (or plasma), or a defined set of hormones, and / or cytokines in amounts sufficient for T cell growth and expansion. Antibiotics, such as penicillin and streptomycin, are only included in experimental cultures and are not included in cell cultures that are infused into subjects. Target cells are maintained under conditions necessary to support growth, such as appropriate temperature (e.g., 37°C) and atmosphere (e.g., air + 5% CO2).
[0236] T cells exposed to varying stimulation times can exhibit different characteristics. For example, a typical blood product or apheresis peripheral blood mononuclear cell product may exhibit either cytotoxic T cell populations or suppressor T cell populations (TC , CD8 + ) a larger population of helper T cells (T H , CD4 + Ex vivo T cell expansion by stimulation of CD3 and CD28 receptors occurs primarily in T cells before about day 8-9. H cells, but after about 8-9 days, more and more T C Thus, depending on the purpose of the treatment, the subject may be administered a population of T cells that includes a population of T cells. H It may also be advantageous to infuse a population of T cells containing T C When an antigen-specific subset of cells has been isolated, it may be beneficial to expand this subset to a greater extent.
[0237] Furthermore, in addition to the CD4 and CD8 markers, other phenotypic markers also vary significantly, but for the most part, in a reproducible manner during the course of the cell expansion process, thus allowing the ability to tailor the activation of T cell products for specific purposes.
[0238] In some cases, the immune effector cells (e.g., T cells) of the embodiments are co-cultured with AaPCs (activating and propagating cells) to support the expansion and growth of the cells. AaPCs can also be referred to as artificial antigen presenting cells (aAPCs). For example, antigen presenting cells (APCs) are useful in preparing the therapeutic compositions and cell therapy products of the embodiments. In one aspect, AaPCs can be transgenic K562 cells. For general guidance on the preparation and use of antigen presenting systems, see, for example, U.S. Patent Nos. 6,225,042, 6,355,479, 6,362,001, and 6,790,662, U.S. Patent Publication Nos. 2009 / 0017000 and 2009 / 0004142, and WO 2007 / 103009, each of which is incorporated by reference. In yet further aspects of the embodiment, the culturing of the transgenic CAR cells comprises culturing the transgenic CAR cells in the presence of dendritic cells or AaPCs (activating and propagating cells) that stimulate the expansion of immune effector cells expressing the CAR. In yet further aspects, the AaPCs comprise a CAR-binding antibody or fragment thereof expressed on the surface of the AaPCs. The AaPCs may optionally comprise additional molecules that activate or co-stimulate T cells. The additional molecules may optionally comprise membrane-bound Cγ cytokines. In yet further aspects, the AaPCs are inactivated or irradiated, or have been checked for and confirmed to be free of infectious agents. In yet further aspects, the culturing of the transgenic CAR cells in the presence of the AaPCs comprises culturing the transgenic CAR cells in a medium that comprises a soluble cytokine, such as IL-15, IL-21, and / or IL-2. The cells can be cultured at ratios of about 10:1 to about 1:10, about 3:1 to about 1:5, about 1:1 to about 1:3 (immune effector cells to AaPCs), or any range derivable therein. For example, co-cultures of T cells and AaPCs can be at ratios of about 1:1, about 1:2, or about 1:3.
[0239] In one embodiment, the AaPCs may express CD137L. In other embodiments, the AaPCs may further express CD19, CD64, CD86, or mIL15. In certain embodiments, the AaPCs may express at least one anti-CD3 antibody clone, such as, for example, OKT3 and / or UCHT1. In one embodiment, the AaPCs may be inactivated (e.g., irradiated). In one embodiment, the AaPCs may be tested for and confirmed to be free of infectious agents. Methods for producing such AaPCs are known in the art. In one embodiment, culturing the CAR-modified T-cell population with the AaPCs may include culturing the cells at a ratio of about 10:1 to about 1:10, about 3:1 to about 1:5, about 1:1 to about 1:3 (T cells to AaPCs), or any range derivable therein. For example, the co-culture of T cells and AaPCs can be at a ratio of about 1:1, about 1:2, or about 1:3. In one embodiment, the culturing step can further include culturing with an aminobisphosphonate (e.g., zoledronic acid).
[0240] In further aspects, the population of transgenic CAR cells is cultured and / or stimulated for no more than 7, 14, 21, 28, 35, 42, 49, 56, 63, or 70 days. In certain embodiments, the stimulation comprises co-culture of the transgenic CAR T cells with AaPCs, which promotes the proliferation of CAR-positive T cells. In another aspect, the population of transgenic CAR cells is stimulated for no more than 1 stimulation, 2 stimulations, 3 stimulations, 4 stimulations, 5 stimulations, 5 stimulations, 6 stimulations, 7 stimulations, 8 stimulations, 9 stimulations, or 10 stimulations. In some cases, the transgenic cells are not cultured ex vivo in the presence of AaPCs. In some special cases, the method of the embodiment further comprises enriching the cell population for immune effector cells (e.g., T cells) expressing the CAR after the transfection and / or culturing steps. The enrichment step may include fluorescence activated cell sorting (FACS) and sorting for cells expressing the CAR. In a further aspect, sorting for cells expressing the CAR includes the use of a CAR-binding antibody. The enrichment step may also include depletion of CD56+ cells. In yet a further aspect of the embodiment, the method further includes a cryopreserved sample for the population of transgenic CAR cells.
[0241] Optionally, AaPCs are incubated with peptides of optimal length that allow direct binding of the peptide to MHC molecules without further processing. Alternatively, the cells may express the antigen of interest (i.e., in the case of MHC-independent antigen recognition). Additionally, optionally, APCs are incubated with a specific CAR polypeptide or a general CAR polypeptide (e.g., uAaPCs (universal activating and propagating CAR polypeptide)). The AaPC system may express antibodies that bind to T cells. Such methods are disclosed in WO 2014 / 190273, which is incorporated herein by reference. In addition to the peptide-MHC molecule or antigen of interest, the AaPC system may also include at least one exogenous supporting molecule. Any suitable number and combination of supporting molecules may be utilized. The supporting molecules may be selected from supporting molecules such as costimulatory molecules and adhesion molecules. Exemplary costimulatory molecules include CD70 and B7.1 (B7.1 was formerly known as B7 and also as CD80), which bind to, among others, CD28 and / or CTLA-4 molecules on the surface of T cells, thereby regulating, for example, T cell expansion, Th1 differentiation, short-term T cell survival, and interleukin (IL-1) expression. The adhesion molecules may include carbohydrate-binding glycoproteins such as selectins, transmembrane-binding glycoproteins such as integrins, calcium-dependent proteins such as cadherins, and single-pass transmembrane immunoglobulin (Ig) superfamily proteins such as intercellular adhesion molecules (ICAMs), which promote cell-cell or cell-matrix contact. Exemplary adhesion molecules include ICAMs, such as LFA-3 and ICAM-1. Techniques, methods, and reagents useful for the selection, cloning, preparation, and expression of exemplary support molecules, including costimulatory molecules and adhesion molecules, are exemplified, for example, in U.S. Pat. Nos. 6,225,042, 6,355,479, and 6,362,001, which are incorporated herein by reference.
[0242] The cells selected to become AaPCs are preferably defective in intracellular antigen processing, intracellular peptide trafficking, and / or intracellular peptide loading of MHC class I or class II molecules, or are poikilothermic (i.e., less sensitive to temperature stimuli than mammalian cell lines), or have both defective and poikilothermic properties. Preferably, the cells selected to become AaPCs also lack the ability to express at least one endogenous counterpart (e.g., endogenous MHC class I or class II molecules, and / or endogenous support molecules as described above) to the exogenous MHC class I or class II molecules and support molecule components introduced into the cells. Furthermore, AaPCs preferably retain the defective and poikilothermic properties that the cells possessed prior to their modification to generate AaPCs. Exemplary AaPCs constitute or are derived from TAP (transporter associated with antigen processing)-deficient cell lines, such as insect cell lines. An exemplary poikilothermic insect cell line is a Drosophila cell line, such as the Schneider 2 cell line (see, e.g., Schneider 1972). Exemplary methods for the preparation, growth, and culture of Schneider 2 cells are provided in U.S. Patent Nos. 6,225,042, 6,355,479, and 6,362,001.
[0243] In one embodiment, the AaPCs are also subjected to a freeze-thaw cycle. In an exemplary freeze-thaw cycle, the AaPCs can be frozen by contacting a suitable receptacle containing the AaPCs with an appropriate amount of liquid nitrogen, solid carbon dioxide (i.e., dry ice), or similar cryogenic material so that freezing occurs rapidly. The frozen APCs are then thawed by removal of the AaPCs from the cryogenic material and exposure to ambient room temperature conditions, or by utilizing a lukewarm water bath or warm hands to facilitate a shorter thawing time, in an accelerated thawing process. In addition, prior to thawing, the AaPCs can be frozen and stored for extended periods of time. The frozen AaPCs can also be thawed and then lyophilized prior to further use. Preferably, preservatives that may adversely affect the freeze-thaw procedure, such as dimethyl sulfoxide (DMSO), polyethylene glycol (PEG), and other preservatives, are absent from the medium containing the AaPCs undergoing the freeze-thaw cycle, or are essentially removed, such as by introducing the AaPCs into a medium essentially lacking such preservatives.
[0244] In further embodiments, the heterologous nucleic acid and the nucleic acid endogenous to the AaPC can be inactivated by crosslinking such that essentially no cell proliferation, replication, or expression of the nucleic acid occurs after inactivation. In one embodiment, the AaPC is inactivated at a time subsequent to the expression of exogenous MHC and supporting molecules, the presentation of such molecules on the surface of the AaPC, and the loading of the selected peptide or peptides onto the presented MHC molecules. Thus, such inactivated AaPC loaded with selected peptides are essentially rendered incapable of proliferation or replication, but retain the presentation function of the selected peptide. Preferably, crosslinking also results in AaPCs that are essentially free of contaminating microorganisms, such as bacteria and viruses, without substantially reducing the antigen presenting cell function of the AaPC. Thus, crosslinking helps to alleviate concerns regarding the safety of cell therapy products developed using AaPCs, while maintaining important AaPC functions. For methods related to crosslinking and AaPCs, see, for example, US Patent Publication No. 20090017000, which is incorporated herein by reference.
[0245] In certain embodiments, modified antigen presenting cells (APCs) are further provided. Such cells can be used to propagate immune effector cells ex vivo, for example, as described above. In a further aspect, the modified APCs themselves can be administered to a patient, thereby stimulating the expansion and proliferation of immune effector cells in vivo. The modified APCs of the embodiments themselves can be used as therapeutic agents. In other embodiments, the modified APCs can be used as therapeutic agents that can stimulate the activation of endogenous immune effector cells specific to a target antigen and / or increase the activity or prolong the persistence of adoptively transferred immune effector cells specific to a target antigen.
[0246] The term "modified APC" as used herein refers to a cell that comprises at least a first transgene, the first transgene encoding an HLA. Such modified APCs may further comprise a second transgene for expression of an antigen, such that the antigen is presented on the surface of the APC in complex with the HLA. In some aspects, modified APCs may be a cell type that presented the antigen (e.g., a dendritic cell). In further aspects, modified APCs may be made from a cell type that does not normally present antigen, such as a T cell or a precursor of a T cell (referred to as a "T-APC"). Thus, in some aspects, modified APCs of embodiments comprise a first transgene encoding a target antigen and a second transgene encoding a human leukocyte antigen (HLA), such that the HLA is expressed on the surface of the modified APC in complex with an epitope of the target antigen. In certain specific aspects, the HLA expressed in the modified APC is HLA-A2.
[0247] In some aspects, the modified APC of the embodiment may further comprise at least a third transgene encoding a costimulatory molecule. The costimulatory molecule may be a costimulatory cytokine, which may be membrane-bound Cγ cytokine. In certain aspects, the costimulatory cytokine is IL-15, such as membrane-bound IL-15. In some further aspects, the modified APC may comprise an edited (or deleted) gene. For example, an inhibitory gene, such as PD-1, LIM-3, CTLA-4, or TCR, may be edited to reduce or eliminate the expression of the gene. The modified APC of the embodiment may further comprise a transgene encoding any target antigen of interest. For example, the target antigen may be an infectious disease antigen or a tumor-associated antigen (TAA).
[0248] In one embodiment of the present disclosure, the immune effector cells described herein are modified at a point-of-care facility. Optionally, the point-of-care facility is in a hospital or institution (e.g., a medical institution) near the subject. Optionally, the immune effector cells are modified by modifying / introducing chimeric receptors and / or cytokines into the immune effector cells, and then rapidly infused into the subject. In some embodiments, such immune effector cells are modified with vectors described herein via electroporation. In other embodiments, the vectors can be non-viral or viral vectors. In one case, the non-viral vectors include the Sleeping Beauty transposon system. Optionally, the modified immune effector cells do not undergo a propagation and activation step. Optionally, the modified immune effector cells do not undergo an incubation or culturing step. In other cases, the immune effector cells are modified by modifying / introducing chimeric receptors and cytokines into the immune effector cells, and then rapidly infused into the subject. In other cases, immune effector cells are modified by modifying / introducing chimeric receptors and cytokines into the cells, and then rapidly infused into the subject within at least 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours. In other cases, NK cells or T cells are modified by modifying / introducing chimeric receptors and cytokines into the cells, and then rapidly infused into the subject within 0 days, <1 day, <2 days, <3 days, <4 days, <5 days, <6 days, or <7 days. In some cases, the source of immune effector cells can include both allogeneic and autologous sources. In one case, the immune effector cells can be T cells or NK cells. In one case, the chimeric receptor can be CD33 CAR. In another embodiment, the cytokine can be mbIL-15. In another embodiment, the immune effector cell expressing the CD33 CAR can include a HER1t tag or a HER1t-1 tag.In another case, the HER1t tag can comprise SEQ ID NO: 32 or 54, or a variant or fragment thereof. In one case, the mbIL-15 is mbIL-15 according to SEQ ID NO: 37, or a variant or fragment thereof. In another case, the mbIl-15 can also comprise a HER1t tag or a HER1t-1 tag. In yet another case, the expression of the CD33 CAR and / or mbIL-15 is modulated by a gene switch expression system as described herein.
[0249] Therapeutic applications In some embodiments herein, immune effector cells (e.g., T cells) are described that are transduced by lentiviral vectors (LVs). For example, the LVs encode CARs that combine the antigen recognition domain of CD33 with the stalk domain of CD8 alpha hinge and its variants, the intracellular domain of CD3 zeta, CD28, 4-1BB, or any combination thereof with the intracellular domain of CD3 zeta. Thus, in some cases, the transduced T cells can induce CAR-mediated T cell responses.
[0250] In some embodiments described herein, the use of CAR is presented to redirect the specificity of primary T cells to the CD33 tumor antigen.Thus, the present invention also provides a method for stimulating a T cell-mediated immune response to a target cell population or target tissue in a mammal, comprising administering to the mammal a T cell expressing a CAR, wherein the CAR comprises a binding moiety that specifically interacts with CD33, a stalk domain, e.g., a zeta chain portion comprising the intracellular domain of human CD3 zeta, and a costimulatory signaling region.
[0251] In one embodiment, the present disclosure includes a type of cell therapy in which T cells are genetically modified to express the CD33-specific CAR of the present invention, and the CAR T cells are infused into a recipient in need thereof. The infused cells can kill tumor cells in the recipient. Unlike antibody therapy, CAR T cells can replicate in vivo, resulting in long-term persistence that can lead to sustained tumor control.
[0252] In one embodiment, the CAR T cells described herein are capable of undergoing robust T cell expansion in vivo and can persist for extended periods of time, hi another embodiment, the CAR T cells of the present invention evolve into specific memory T cells that can be reactivated to inhibit further tumor formation or growth.
[0253] The CAR-modified T cells described herein can also be used as a kind of vaccine for ex vivo immunization and / or in vivo treatment of a mammal. In some embodiments, the mammal is a human. With respect to ex vivo immunization, the immune effector cells are administered to a mammal after at least one of the following in vitro procedures: i) cell expansion, ii) introduction of a nucleic acid encoding a CAR into the cells, and / or iii) cryopreservation of the cells.
[0254] Ex vivo procedures are well known and are discussed more fully below. Briefly, cells are isolated from a mammal (e.g., human) and genetically modified (i.e., transduced or transfected in vitro) with a vector expressing a CAR disclosed herein. The CAR-modified cells can be administered to a mammalian recipient to provide a therapeutic benefit. The mammalian recipient can be a human, and the CAR-modified cells can be autologous to the recipient. Alternatively, the cells can be allogeneic, syngeneic, or xenogeneic to the recipient.
[0255] Procedures for ex vivo expansion of hematopoietic stem and progenitor cells are described in U.S. Pat. No. 5,199,942, which is incorporated herein by reference, and can be applied to the cells of the present invention. Other suitable methods are known in the art, and therefore the present invention is not limited to any particular method of ex vivo expansion of cells. Briefly, ex vivo culture and expansion of T cells includes (1) recovering CD34+ hematopoietic stem and progenitor cells from a mammalian peripheral blood collection or extramedullary explant, and (2) expanding such cells ex vivo. In addition to the cellular growth factors described in U.S. Pat. No. 5,199,942, other factors such as flt3-L, IL-1, IL-3, and c-kit ligand can also be used to culture and expand cells.
[0256] In addition to using cell-based vaccines for ex vivo immunization, the present invention also provides compositions and methods for in vivo immunization to elicit an immune response directed against an antigen in a patient.
[0257] In general, cells activated and expanded as described herein can be used in the treatment and prevention of diseases occurring in immune-compromised individuals. In particular, the CAR-modified T cells of the present invention are used in the treatment of myeloid malignancies, such as acute myeloid leukemia (AML). In certain embodiments of the present invention, the cells are used in the treatment of patients at risk of developing AML. Thus, the present invention provides a method for treating or preventing AML, comprising administering to a subject in need thereof a therapeutically effective amount of the CAR-modified T cells of the present invention. In some embodiments, the cells activated and expanded as described herein can be used in the treatment of relapsed or refractory AML.
[0258] In brief, the pharmaceutical composition of the present invention may comprise the target cell population described herein in combination with one or more pharma- ceutical or physiologically acceptable carriers, diluents, or excipients.Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline, carbohydrates such as glucose, mannose, sucrose, or dextran, mannitol, proteins, amino acids such as polypeptides or glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), and preservatives.In some embodiments, the compositions of the present invention are formulated for intravenous administration.
[0259] The pharmaceutical compositions described herein can be administered in a manner appropriate for the disease to be treated (or prevented). The number and frequency of administration are determined by factors such as the condition of the patient and the type and severity of the patient's disease, but the appropriate dosage can be determined by clinical trials.
[0260] When referring to an "immune effective amount," an "antitumor effective amount," a "tumor inhibiting effective amount," or a "therapeutic amount," the exact amount of the composition of the invention to be administered can be determined by a physician, taking into account the individual differences in the patient's (subject's) age, weight, tumor size, extent of infection or metastasis, and condition. In general, pharmaceutical compositions comprising T cells as described herein are administered in amounts of 10 cells per kg of body weight, including all integer values within these ranges. 4 ~10 9 10 cells per kg of body weight 5 ~10 6 It may be stated that the T cell composition may be administered in a single dose. The T cell composition may also be administered multiple times at these doses. The cells may be administered by using infusion methods commonly known in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319:1676 (1988)). The optimal dosage and treatment regime for a particular patient may be readily determined by one skilled in the medical arts by monitoring the patient for signs of disease and adjusting the treatment accordingly.
[0261] In certain embodiments, it may be desirable to administer activated T cells to a subject, then subsequently redraw blood (or perform apheresis), activate T cells derived therefrom in accordance with the present invention, and reinfuse the patient with these activated, expanded T cells. This process may be performed multiple times, every few weeks. In certain embodiments, T cells may be activated from a blood draw of 10cc to 400cc. In certain embodiments, T cells may be activated from a blood draw of 20cc, 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc, or 100cc. Without being bound by theory, the use of this multiple draw / multiple reinfusion protocol may be used to single out certain T cell populations. In another embodiment, it may be desirable to administer the subject composition of activated T cells following lymphodepletion of the patient via radiation or chemotherapy.
[0262] Administration of the compositions described herein can be performed in any convenient manner, including aerosol inhalation, injection, ingestion, transfer, implantation, or transplantation. The compositions described herein can be administered to a patient subcutaneously, intradermally, intratumorally, intralymph node, intramedullary, intramuscularly, intravenously (iv), or intraperitoneally. In one embodiment, the T cell compositions of the present invention are administered to a patient by intradermal or subcutaneous injection. In another embodiment, the T cell compositions of the present invention are administered by iv injection. The T cell compositions can be directly injected into a tumor, lymph node, or site of infection.
[0263] The dosage of the above treatments administered to patients will vary with the exact nature of the condition being treated and the recipient of the treatment. Scaling of dosages for human administration can be performed according to accepted practices in the art. For example, the above treatment doses can be 1×10 CAR+ cells per kg. 4 5 x 10 CAR+ cells per kg 6An exemplary dose can range from 1 x 10 CAR+ cells per kg. 4 1 x 10 CAR+ cells per kg 5 3 x 10 CAR+ cells per kg 5 1 x 10 CAR+ cells per kg 6 or 5 x 10 CAR+ cells per kg 6 Thus, the appropriate dose can be adjusted for an adult patient and for a pediatric patient.
[0264] Alternatively, a typical amount of immune effector cells administered to a mammal (e.g., a human) can range, for example, from 1 million to 100 billion cells, although amounts below or above this exemplary range are also within the scope of the invention. For example, a dose of host cells of the invention can range from about 1 million to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the preceding values), about 10 million to about 100 billion cells (e.g., about 20 million cells, about 30 million cells, about 40 million cells, about 60 million cells, about 70 million cells, about 80 million cells, about 90 million cells, about 100 million cells, about 150 million cells, about 200 million cells, about 300 million cells, about 400 million cells, about 500 million cells, about 600 million cells, about 700 million cells, about 800 million cells, about 90 ...00 million cells, about 150 million cells, about 200 million cells, about 300 million cells, about 400 million cells, about 10 billion cells, about 25 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, or a range defined by any two of the preceding values), about 100 million cells to about 50 billion cells (e.g., about 120 million cells, about 250 million cells, about 350 million cells, about 450 million cells, about 650 million cells, about 800 million cells, about 900 million cells, about 3 billion cells, about 30 billion cells, about 45 billion cells, or a range defined by any two of the preceding values).
[0265] The therapeutic or prophylactic efficacy can be monitored by periodic evaluation of the treated patient.For repeated administration for several days or more, depending on the condition, the treatment is repeated until the desired suppression of disease symptoms occurs.However, other dosage regimens may be useful and are within the scope of the present invention.The desired dosage can be delivered by a single bolus administration of the composition, by multiple bolus administrations of the composition, or by continuous infusion administration of the composition.
[0266] The compositions comprising immune effector cells expressing the disclosed nucleic acid sequences or vectors comprising these nucleic acid sequences can be administered with one or more additional therapeutic agents that can be co-administered to a mammal. "Co-administering" refers to administering one or more additional therapeutic agents and a composition comprising the host cells or vectors of the present invention close enough together to enhance the effect of the one or more additional therapeutic agents, or vice versa. In this regard, the immune effector cells described herein or compositions comprising the vectors described herein can be administered simultaneously with one or more additional therapeutic agents, administered first and the one or more additional therapeutic agents administered second, or vice versa. Alternatively, the compositions comprising the disclosed immune effector cells or vectors described herein and the one or more additional therapeutic agents can be administered simultaneously.
[0267] Examples of therapeutic agents that may be included in compositions (or included in kits) or co-administered with the host cells of the invention and / or vectors of the invention are interleukins, cytokines, interferons, adjuvants, and chemotherapeutic agents. In some embodiments, the additional therapeutic agent is IFN-alpha, IFN-beta, IFN-gamma, GM-CSF, G-CSF, M-CSF, LT-beta, TNF-alpha, growth factors, and hGH, ligands of the human Toll-like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10.
[0268] Bcl-2 inhibitors, STAT3 inhibitors, or STAT5 inhibitors are also included in the composition or co-administered therewith (or included in the kit). Cancer cells may overexpress anti-apoptotic proteins such as Bcl-2, or may have persistent activation of pathways (i.e., STAT5 and STAT3) that result in an unusually high level of resistance to natural apoptosis mediators or pharmacological agents. Combining pharmacotherapy approaches with immunotherapy approaches to use more than one apoptotic pathway is envisioned to increase tumor cell death and reduce resistance to treatment. The use of small molecule inhibitors may shift the balance of pro-apoptotic and anti-apoptotic molecules in tumor cells sufficiently to sensitize tumor cells to death or reduce resistance to killing upon encounter with tumor-specific T cells. Elevated Bcl-2 expression has been found in hematological malignancies such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), and solid tumors (i.e., melanoma, breast cancer, and ovarian cancer). Prolonged activation of STAT3 or STAT5 has been observed in AML, CLL, chronic myeloid leukemia, large granular lymphocytic leukemia, and leukemia cell lines. Small molecule inhibitors targeting Bcl-2, STAT3, or STAT5 are envisioned to be included in, co-administered with, and / or co-cultured with the compositions of the present invention. One bcl-2 inhibitor is ABT-737. This compound is part of the BH3 mimetic small molecule inhibitor (SMI) group that targets these Bcl-2 family proteins but not A1 or Mcl-1. ABT-737 differs from conventional BCL-2 inhibitors due to its apparently greater affinity for Bcl-2, Bcl-xL, and Bcl-w. ABT-199, a so-called BH3 mimetic drug, is designed to block the function of Bcl-2 protein in patients with chronic lymphocytic leukemia.
[0269] STAT3 and STAT5 inhibitors include, but are not limited to, STAT3 and STAT5 inhibitors described in Fagard et al., STAT3 inhibitors for cancer therapy, JAK-STAT, 2:1 (2013), e22882, DOI: 10.4161 / jkst.22882 and Furqan, et al., Journal of Hematology & Oncology 2013, 6:90 doi:10.1186 / 1756-8722-6-90. In addition to JAK / STAT pathway effectors, there are also three major classes of negative regulators: SOCS (suppressors of cytokine signaling), PIAS (protein inhibitors of activated stats), and PTPs. Tyrosine phosphatases neutralize the activity of JAK. The best characterized of these regulators is SHP-1, the product of the mouse mosweetin gene. SHP-1 contains two SH2 domains and can bind to phosphorylated JAK or phosphorylated receptors to facilitate the dephosphorylation of these activated signaling molecules.Other tyrosine phosphatases, such as CD45, are believed to play a role in regulating JAK / STAT signaling through a subset of receptors.Therefore, it is envisioned that the JAK / STAT pathway is a drug target for the composition of the present disclosure.
[0270] "Antifoaming agents" reduce foaming during processing that can result in coagulation of the aqueous dispersion, air bubbles in the finished film, or generally impair processing. Exemplary antifoaming agents include silicon emulsion or sorbitan sesquoleate.
[0271] "Antioxidants" include, for example, butylated hydroxytoluene (BHT), sodium ascorbate, ascorbic acid, sodium metabisulfite, and tocopherol. In certain embodiments, antioxidants enhance chemical stability when needed.
[0272] The formulations described herein may benefit from antioxidants, metal chelators, thiol-containing compounds, and other general stabilizing agents. Examples of such stabilizers include, but are not limited to, (a) about 0.5% to about 2% w / v glycerol, (b) about 0.1% to about 1% w / v methionine, (c) about 0.1% to about 2% w / v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w / v ascorbic acid, (f) 0.003% to about 0.02% w / v polysorbate 80, (g) 0.001% to about 0.05% w / v polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc, or (n) combinations thereof.
[0273] "Binders" impart cohesive properties and include, for example, alginic acid and its salts; cellulose derivatives such as carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (e.g., Klucel®), ethylcellulose (e.g., Ethocel®), and microcrystalline cellulose (e.g., Avicel®); microcrystalline dextrose; amylose; magnesium aluminum silicate; polysaccharide acids; bentonite; gelatin; polyvinylpyrrolidone / vinyl acetate copolymer; crospovidone; povidone; starch; alfalfa; starches; sugars such as tragacanth, dextrin, sucrose (e.g., Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (e.g., Xylitab®), and lactose; natural or synthetic gums such as acacia, tragacanth, ghatti gum, mucilage of isapol husk, polyvinylpyrrolidone (e.g., Polyvidone® CL, Kollidon® CL, Polyplasdone® XL-10), arabogalactan from larch, Veegum brand), polyethylene glycol, waxes, sodium alginate.
[0274] "Carriers" or "carrier materials" include any excipients commonly used in medicines and are to be selected based on their compatibility with the compounds disclosed herein, such as ibrutinib and anti-cancer compounds, and the release profile characteristics of the desired dosage form. Exemplary carrier materials include, for example, binders, suspending agents, disintegrants, fillers, surfactants, solubilizers, stabilizers, lubricants, humectants, diluents, and the like. "Pharmaceutically compatible carrier materials" may include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerin, magnesium silicate, polyvinylpyrrolidone (PVP), cholesterol, cholesterol esters, sodium caseinate, soy lecithin, taurocholic acid, phosphatidylcholine, sodium chloride, tricalcium phosphate, dipotassium phosphate, cellulose and cellulose conjugates, sugars, sodium stearoyl lactylate, carrageenan, monoglycerides, diglycerides, pregelatinized starch, and the like. See, e.g., Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).
[0275] "Dispersing agents" and / or "viscosity modulating agents" include materials that control the diffusion and homogeneity of drugs through liquid media or granulation or blending methods. In some embodiments, these agents also enhance the effectiveness of coating or eroding matrices. Exemplary diffusion enhancers / dispersing agents include, for example, hydrophilic polymers, electrolytes, Tween® 60 or Tween® 80, PEG, polyvinylpyrrolidone (PVP; commercially known as Plasdone®), and, for example, hydroxypropylcellulose (e.g., HPC, HPC-SL, and HPC-L), hydroxypropylmethylcellulose (e.g., HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M), sodium carboxymethylcellulose (carboxymethylcellulose), cellulose acetate (Citrate), cellulose esters (Citrate), cellulose esters (Citrate), cellulose esters (Citrate), cellulose acetate ... Sodium), carbohydrate-based dispersants such as methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), amorphous cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinylpyrrolidone / vinyl acetate copolymer (S630), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68®, Pluronics F88®, and Pluronics F108®, which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (e.g., Tetronic, also known as Poloxamine 908® (BASF Corporation, Parsippany, NJ), which are tetrafunctional block copolymers derived from the sequential addition of propylene oxide and ethylene oxide to ethylenediamine). 908 (registered trademark), polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyvinylpyrrolidone / vinyl acetate copolymer (S-630), polyethylene glycol (e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400), sodium carboxymethylcellulose, methylcellulose, polysorbate 80, sodium alginate, Examples include gums such as gum tragacanth and gum acacia, guar gum, xanthans including xanthan gum, sugars, cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, polysorbate 80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone, carbomer, polyvinyl alcohol (PVA), alginates, chitosan, and combinations thereof.Plasticizers such as cellulose or triethylcellulose can also be used as dispersants. Particularly useful dispersants in liposomal and self-emulsifying dispersions are dimyristoyl phosphatidylcholine, natural phosphatidylcholine derived from chicken eggs, natural phosphatidylglycerol derived from chicken eggs, cholesterol, and isopropyl myristate.
[0276] Combinations of one or more erosion promoters with one or more diffusion promoters may also be used in the compositions.
[0277] The term "diluent" refers to a compound that is used to dilute the compound of interest prior to delivery. Diluents can also be used to stabilize the compound, as they can provide a more stable environment. In the art, salts dissolved in buffers (which can also control or maintain pH) are used as diluents, including but not limited to phosphate buffered saline solutions. In certain embodiments, diluents increase the bulk of the composition to facilitate compression or create sufficient bulk for homogeneous blending for capsule filling. Such compounds include, for example, lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel®; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugars such as Di-Pac® (Amstar); mannitol, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate stearate, sucrose-based diluents, powdered sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; mannitol, sodium chloride; inositol, bentonite, and the like.
[0278] "Bulking agents" include compounds such as lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starch, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
[0279] "Lubricants" and "glidants" are compounds that prevent, reduce, or inhibit adhesion or friction of materials. Exemplary lubricants include, for example, stearic acid, calcium hydroxide, talc, sodium stearyl fumarate, hydrocarbons such as mineral oils or hydrogenated vegetable oils such as hydrogenated soybean oil (Sterotex®), higher fatty acids and their alkali metal and alkaline earth metal salts such as aluminum, calcium, magnesium, zinc, etc., stearic acid, sodium stearate, glycerol, talc, wax, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, polyethylene glycol (e.g., PEG-4000) or methoxypolyethylene glycol such as Carbowax™, sodium oleate, sodium benzoate, glyceryl behenate, polyethylene glycol, magnesium or sodium lauryl sulfate, colloidal silica such as Syloid™, Cab-O-Sil®, starch such as corn starch, silicone oil, surfactants, etc.
[0280] A "plasticizer" is a compound used to soften the microencapsulated material or film coating to make the microencapsulated material less brittle. Suitable plasticizers include, for example, polyethylene glycols such as PEG 300, PEG 400, PEG 600, PEG 1450, PEG 3350, and PEG 800, stearic acid, propylene glycol, oleic acid, triethylcellulose, and triacetin. In some embodiments, the plasticizer may also function as a dispersing agent or humectant.
[0281] "Solubilizing agents" include compounds such as triacetin, triethyl citrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate, sodium doccusate, vitamin E TPGS, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, n-butanol, isopropyl alcohol, cholesterol, bile salts, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide.
[0282] "Stabilizers" include compounds such as any antioxidant, buffer, acid, preservative, etc.
[0283] "Suspending agents" include polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, vinylpyrrolidone / vinyl acetate copolymer (S630), polyethylene glycol (e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400), sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose stearate acetate, Polysorbate 80, hydroxyethylcellulose, sodium alginate, e.g., gums such as gum tragacanth and gum acacia, guar gum, xanthans including xanthan gum, sugars, cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, compounds such as polysorbate 80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone, and the like.
[0284] "Surfactants" include compounds such as sodium lauryl sulfate, sodium docusate, Tween 60 or Tween 80, triacetin, vitamin E TPGS, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbate, poloxamer, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, e.g., Pluronic® (BASF). Some other surfactants include polyoxyethylene glycerol fatty acid esters and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkyl ethers and alkyl phenyl ethers, e.g., octoxynol 10, octoxynol 40. In some embodiments, surfactants can be incorporated to enhance physical stability or for other purposes.
[0285] "Viscosity enhancing agents" include, for example, methylcellulose, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose stearate acetate, hydroxypropylmethylcellulose phthalate, carbomer, polyvinyl alcohol, alginates, acacia, chitosan, and combinations thereof.
[0286] "Moisturizing agents" include compounds such as oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium docusate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, Tween 80, Vitamin E TPGS, ammonium salts, and the like.
[0287] Kits and Compositions One aspect of the present disclosure relates to kits and compositions comprising a first vector comprising a coding region encoding the CD33-specific CAR of the present invention and optionally a gene incorporated for safety reasons, such as HER1t or HER1t-1 and functional variants thereof, or CD20 or CD20t-1 and functional variants thereof. These kits and compositions may comprise multiple vectors, each encoding a different protein or subset of proteins. These vectors may be viral, non-viral, episomal or integrative vectors. In some embodiments, the vector is a transposon, such as a sleeping beauty transposon.
[0288] In some embodiments, the kits and compositions include not only the vector, but also cells and agents such as interleukins, cytokines, interleukins, and chemotherapeutic agents, adjuvants, moisturizers, or emulsifiers. In one embodiment, the cells are T cells. In one embodiment, the kits and compositions include IL-2. In one embodiment, the kits and compositions include IL-21. In one embodiment, the kits and compositions include a Bcl-2 inhibitor, a STAT3 inhibitor, or a STAT5 inhibitor. In several embodiments, the kits include IL-15 or mbIL-15.
[0289] In certain embodiments herein, kits and products are disclosed for use in one or more methods described herein.Such kits include a carrying case, package, or container that is compartmentalized to receive one or more containers, such as vials, test tubes, etc., each of which contains one of the individual elements used in the methods described herein.Suitable containers include, for example, bottles, vials, syringes, and test tubes.In one embodiment, the container is formed from various materials, such as glass or plastic.
[0290] The products presented herein contain packaging materials. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, test tubes, bags, containers, bottles, and any packaging materials suitable for the selected formulation and intended mode of administration and treatment.
[0291] For example, the container comprises CAR-T cells (e.g., CD33-specific CAR-T cells as described herein), and optionally, in addition, cytokines and / or chemotherapeutic agents as disclosed herein. Such kits optionally include a statement or labeling or instructional content identification regarding their use in the methods described herein.
[0292] The kit typically includes a label listing the contents and / or instructions for use, as well as a package insert with instructions for use. Typically, a set of instructions will also be included.
[0293] In some embodiments, the indicia is affixed to or associated with the container. In one embodiment, the indicia is affixed to the container when letters, numbers, or other symbols forming the indicia are bonded, molded, or etched into the container itself, and the indicia is also associated with the container when present in a receptacle or carrying case that holds the container, for example, as a package insert. In one embodiment, the indicia is used to indicate that the contents are to be used for a specific therapeutic application. The indicia also indicates instructions for the use of the contents, such as in the methods described herein.
[0294] array Table 2 provides a representative list of certain sequences that are included in the embodiments presented herein.
[0295] [Table 2-1]
[0296]
Table 2-2
[0297]
Table 2-3
[0298]
Table 2-4
[0299]
Table 2-5
[0300]
Table 2-6
[0301]
Table 2-7
[0302]
Table 2-8
[0303]
Table 2-9
[0304]
Table 2-10
[0305]
Table 2-11
[0306] [Table 2-12]
[0307] [Table 2-13]
[0308] [Table 2-14]
[0309] [Table 2-15]
[0310] [Table 2-16]
[0311] [Table 2-17] EXAMPLES
[0312] These examples are presented for illustrative purposes only and are not intended to limit the scope of the claims presented herein.
[0313] [Example 1] Delivery of CD33 CAR via lentiviral vector: CD33 CAR lentiviral vector was constructed based on HIV-1 derived vector backbone. The HER1t gene was genetically fused to CD33 CAR via an in-frame, self-cleaving, Thosea asigna virus 2A peptide (T2A) at the 3' end. Both genes were cloned into the pFUGW lentiviral plasmid backbone described below.
[0314] The use of VSV-G (vesicular stomatitis virus glycoprotein (VSV-G)) as a substitute for the HIV-1 envelope protein for the CD33 CAR lentivirus resulted in improved vector stability, target cell targeting, and transduction efficiency (Cronin, J., Zhang, X. & Reiser, J., Altering the tropism of lentiviral vectors through pseudotyping, Curr Gene Ther, 5(4):387-98 (2005)).
[0315] During production, CD33 CAR viral particles were assembled and budded from the surface of transfected HEK293T cells. VSV-G protein was provided by the pMND-VSVG helper plasmid, vector core and enzyme proteins were provided by the pΔ8.9 so (GagPol) helper plasmid, and Rev protein, required for efficient transport and packaging of the RNA genome into viral particles, was provided by the pRSV-Rev plasmid. All other HIV-1 accessory proteins, including Vpu, Vif, Vpr, Nef, and Tat, were deleted from the CD33 CAR vector.
[0316] The pFUGW lentiviral vector backbone is a SIN lentiviral vector backbone.
[0317] Regulatory elements The LV-CD33 CAR vector contained the human elongation factor 1 alpha 1 (EF1A1) promoter and bovine growth hormone polyA sequence, as well as the Kozak ribosomal initiation sequence, driving the expression of the transgene. The vector also used the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) as well as the LTR sequence from the pFUGW plasmid. The origin of replication was based on the pUC19 plasmid. Figure 2 shows the lentiviral vector map of the CD33 CAR.
[0318] [Example 2] How to generate CD33 CAR vectors The LV-CD33 CAR vector was assembled from three sources: (1) The following was obtained from an already constructed vector and digested with restriction enzymes PacI and BlpI: (a) pFUGW backbone components (b) Human elongation factor 1 alpha 1 promoter (EF1A1) promoter and enhancer driving anti-CD33 scFv with GM-CSFR alpha signal peptide (c) CD8α hinge and transmembrane domains (2) The 4-1BB signaling domain module was obtained as a synthetic gene; (3) A region containing CD3ζ, T2A transcription linker, GM-CSFRalpha signal peptide, HER1t depletion marker, bovine growth hormone polyA, and flanking cloning sites was amplified by PCR.
[0319] Using the homology regions engineered into each cassette, the three DNA cassettes were annealed together in an in vitro assembly reaction. The resulting lentiviral vector contained the transgenes of interest (CD33 CAR and HER1t) in reverse orientation to the lentiviral genome. After transformation into Stbl4 E. coli strain, positive colonies were identified by colony PCR and the three inserts were verified by Sanger sequencing. All plasmid sequences were verified by Illumina Next Generation Sequencing.
[0320] Vectors were produced in HEK-293T cells in DMEM with 10% FBS using calcium phosphate precipitation transfection of four plasmids, the LV-CD33 CAR vector plasmid, and three helper plasmids, pΔ8.9 so (GagPol); pMND-VSVG; and pRSV-Rev.
[0321] Approximately 18 hours after plasmid transfection, a complete medium change was performed with culture medium containing benzonase (50 U / mL). Approximately 24 hours after medium change, the vector containing culture supernatant was harvested and labeled as harvest 1. The cells were refed with fresh medium and returned to the incubator. The supernatant of harvest 1 was clarified using a filter and stored overnight at between 2-8°C.
[0322] The next day, cells were observed by microscope and the vector-containing supernatant was harvested again as harvest 2, which was filtered as before. The harvest 1 supernatant was combined with the filtered harvest 2 supernatant and the pooled supernatant was further clarified through a 0.45 μm filter. The clarified vector harvest was purified using anion exchange membrane chromatography, concentrated and diafiltered into the selected medium using a hollow fiber device. The purified LV-CD33 CAR vector was loaded and stored frozen at <-80°C.
[0323] [Example 3] Efficiency of the delivery system Transduction of T cells from healthy donors with LV-CD33 CAR lentiviral vectors typically resulted in 25-50% of cells stably co-expressing CD33 CAR and HER1t 12-14 days after transduction. Figure 4 describes a typical lentiviral transduction scheme for the generation of CAR-T cells. Figure 5 shows representative data for CD33 CAR and HER1t expression from a single T cell from a healthy donor 12 days after lentiviral transduction. Purified human CD3+ T cells were activated using Dynabeads® Human T-Activator CD3 / CD28 beads and then transduced with CD33 CAR lentiviral vectors at a multiplicity of infection (MOI) of 5. Cells were grown in medium containing IL-2 for 12 days after transduction. Twelve days after transduction, flow cytometry analysis was performed to evaluate the expression of CD33 CAR and HER1t, as measured by protein L and cetuximab mAb, respectively.
[0324] Figure 6 confirms the expression of CD33 CAR from lentiviral transduced cells by Western blot. Expanded non-transduced CD33 CAR-T cells or lentiviral transduced CD33 CAR-T cells were cultured and cell lysates were made using RIPA buffer with protease inhibitors. BCA assay was also performed on samples made in donors to normalize the amount of protein loaded onto the gel with reducing conditions. After protein transfer, the membrane was blocked and then probed with 1 μg / ml anti-CD3ζ antibody (clone 8D3) followed by goat anti-mouse horseradish peroxidase detection antibody. Bands were detected by chemiluminescence and captured by a digital imaging system. The 16 kDa band represents endogenously expressed CD3ζ, while the 60 kDa band represents CD33 CAR expressing the CD3ζ signaling moiety. Only CD33 CAR-T cells exhibit a 60 kDa band in addition to the endogenous CD3ζ band, whereas non-transduced cells and Jurkat T cells only display endogenous CD3ζ.
[0325] Figure 7 shows the ex vivo expansion of CD33 CAR-T cells in culture after transduction with lentiviral vectors. The starting cell population was 2.5 x 10 5 Data shown are mean ± SEM from four independent T cell donors. CD33 CAR-T cells were efficiently transduced and expanded ex vivo to levels that meant a clinically relevant dose was achieved.
[0326] [Example 4] Integration of genetic material The delivered genetic material was integrated in the form of a proviral genome. The transgene introduced into T cells using lentiviral transduction was stable over the study period. Figure 8 is a copy number assessment for CD33-CAR-T cells after lentiviral transduction. Droplet digital PCR (ddPCR) was used to determine the number of gene copies integrated into the host genome after lentiviral transduction of human SUPT1 T cells or T cells derived from healthy donor 270169 (D270169) using an MOI of 5. Genomic DNA (gDNA) was obtained at least 14 days after transduction. ddPCR reactions were prepared using Bio-Rad's ddPCR system (QX200TM AutoDG ddPCR system) with Taqman-based primer and probe sets to detect CD33 CAR. Based on the assumption that every cell has two copies of the RNaseP gene, RNaseP was used as a standard reference gene to evaluate copy number variants (CNVs). The expression of CD33 CAR on SUPT1 / CD33 CAR-T cells and D270169 / CD33 CAR-T cells was confirmed by flow cytometry and reported to be about 80% and about 30%, respectively (data not shown). For D270169 / CD33 CAR-T cells, the sample measured in the assay (referred to as "measurement") was derived from a mixed population, but further calculations were performed to determine the copy number of the insert (referred to as "back calculation") of T cells expressing CAR. Data shown is the average copy number per cell ± SD from two experiments.
[0327] [Example 5] Animal and cell culture models to evaluate the efficacy of gene transfer systems The efficiency of lentivirus-mediated gene transfer, as measured by expression of the transferred gene, was assessed by flow cytometry of transduced cells (Figure 5). Expansion of transduced T cells was performed in ex vivo culture medium for 12-14 days post-transduction to achieve a reasonable dose (Figure 7).
[0328] In preclinical analyses, the levels of CD33 CAR observed on the surface of T cells following lentiviral transduction (Figure 8) were sufficient to efficiently and specifically eliminate different CD33-positive target tumor cell lines in vitro (Figure 9), as well as to extend survival of mice bearing CD33-positive tumors to statistically significant levels versus controls (Figure 12). See also Figures 5 and 6 for further supporting data.
[0329] The functional capacity of CD33 CAR-T cells was investigated in both in vitro and in vivo models.
[0330] In vitro studies of CD33 CAR-T cells included cytotoxicity against CD33-expressing AML cell lines as well as a murine EL4 cell line transduced to express human CD33 on its surface, and secretion of IFN-γ, IL-2, and TNF-α cytokines upon coculture with CD33-positive target cells. CD33 CAR-T cells coexpressed the HER1t protein to allow depletion of infused CAR-T cells by administration of cetuximab. The ability of cetuximab to eliminate CD33 CAR-T cells by ADCC was also evaluated in vitro.
[0331] CD33 CAR-T cells were specifically cytotoxic against target cells in a dose-dependent manner (Figure 9). Cytotoxic CD33 CAR-T cells at an effector:target (E:T) ratio of 10:1 (B) and 1:1 (C) were measured by europium release assay over 2 hours. Dose-dependent cytotoxicity by CD33 CAR-T cells against target cells was observed between 10:1 and 1:1 E:T ratios, but significant cytotoxicity was only observed when target cells expressed CD33 on their surface. Non-transduced T cells did not show significant cytotoxicity against any of the target cells tested. Data shown in the graphs are mean ± SEM from 4 different donors. ** p-value < 0.01 and *** The p-value is <0.001.
[0332] CD33 CAR-T cells specifically secreted higher levels of various cytokines compared to non-transduced T cells upon co-culture with various target cell lines (Figure 10). Evaluation of cytokine production from non-transduced T cells and CD33 CAR-T cells after co-culture with various target AML cell lines expressing CD33. Mouse EL4 cell line was used as a negative control for human CD33 expression. T cells were co-cultured overnight at an effector:target (E:T) ratio of 10:1, and culture supernatants were collected for multiplex cytokine analysis using QBeads (Intellicyt). Multiplex analysis of human IFNγ, human IL-2, and human TNF secretion into culture medium was assayed. Following co-culture of CD33 CAR-T cells with target cells expressing CD33, elevated levels of the cytokines IFNγ, IL-2, and TNF were detected when compared to basal expression levels by non-transduced T cells with the same target cells. Values plotted represent the mean ± SD for the test samples in duplicate.
[0333] Cetuximab was able to dose-dependently eliminate CD33 CAR-T cells expressing HER1t on the surface (Figure 11). ADCC was determined by flow cytometry analysis of 7-AAD uptake using PKH26-labeled target cells co-incubated with purified effector NK cells at an E:T ratio of 5:1 for 24 hours. Specific dose-dependent ADCC of cetuximab against CD33 CAR-T cells was observed. Values plotted represent the mean ± SD for the test samples in duplicate.
[0334] The ability of CD33 CAR-T cells to specifically reduce tumor burden was also examined in an in vivo xenograft model in immunodeficient NSG (NOD.Cg-PrkdcscidIL2rgtm1Wjl / SzJ, NODscid gamma) mice using MOLM-13, an AML cell line transduced to express fLUC (MOLM-13 / fLUC), to monitor tumor burden by bioluminescence imaging. Details of the study design are depicted in Table 2. Administration of CD33 CAR-T cells in NSG mice bearing MOLM-13 / fLUC tumors reduced tumor burden and extended median survival to statistically significant levels (P<0.001) when compared with a control treatment group consisting of saline, untransduced T cells, and nonspecific CD19 CAR-T cells generated from the same healthy T cell donor as the CD33 CAR-T cells. CD33 CAR-T cells expanded in vivo in tumor-bearing mice (Figure 14). Flow cytometry analysis of CD33 CAR-T cells in NSG mice prior to injection and detection of CD33 CAR-T cells in various tissues of treated mice was performed to document the persistence and expansion of CAR-T cells in vivo (Figure 14A). Healthy donor T cells were transduced with CD33 CAR lentivirus and expanded ex vivo. Flow cytometry analysis was performed to evaluate the expression level of CD33 CAR prior to injection of CD33 CAR-T cells for treatment. The indicated populations were gated for FSC / SSC / live / CD3+ cells (Figure 14B). Flow cytometry analysis was performed on blood, bone marrow, and spleen samples collected from CD33 CAR-T treated mice bearing MOLM-13 tumors on day 18 (10 days after CD33 CAR-T cell injection by systemic IV injection into the tail vein) to detect the presence of CD33 CAR-T cells. Data from one representative mouse, populations gated based on FSC / SSC / hCD45 / hCD3 expression.
[0335] On day 0, immunodeficient NSG mice were inoculated with 5 × 10 cells of the MOLM-13 cell line modified to express the firefly luciferase (fLUC) gene (MOLM-13 / fLUC). 5 On day 7, tumor-bearing mice were identified by expression of bioluminescence via IVIS imaging and then randomized into various treatment groups. On day 8, mice were treated with saline alone, non-transduced T cells (10 total T cells per mouse) via IV injection. 7 cells), CD33 CAR-T cells without a cell tag or with a HER1t cell tag (10 CD33 CAR-T cells per mouse) 7 cells), or CD19 CAR T cells (10 CD19 CAR-T cells per mouse 7 Additionally, on day 15, another group of mice was treated with CD33 CAR T cells with a HER1t cell tag (10 CD33 CAR+ T cells per mouse). 7 Mice were administered a second dose of CD33 CAR-T cells (1 or 2 doses). Total tumor burden was assessed over the course of the study by fLUC expression using bioluminescence imaging. Survival curves from the various treatment groups are shown in Figure 12. The median survival time of mice in saline, non-transduced T cells, and CD19 CAR-T cells was 15 days. Mice treated with CD33 CAR T cells that did not contain a cell tag also had extended survival, but all mice treated with CD33 CAR-T cells (1 or 2 doses) showed complete survival up to 29 days.
[0336] The average flux values from the ventral and dorsal views are plotted in Figure 13 for the various treatment groups. Values shown are total flux values expressed as photons / second and show the mean ± SEM for each group. The solid upward arrow indicates the day of administration of CAR-T for each group, and the dotted upward arrow on day 15 indicates the second administration of CD33 CAR-T for the 2-dose group.
[0337] [Table 3]
[0338] [Example 6] Cytokine analysis: Plasma samples from mice were collected at specific time points within the protocol or when mice became moribund and were euthanized for humane reasons. To obtain plasma, blood was collected into EDTA collection tubes and then spun at 5,000×g for 15 minutes at room temperature, and the resulting plasma was then introduced into clean collection tubes. Plasma was frozen and stored at −80° C. until assayed. ProcartaPlex® Human Cytokine / Chemokine / Growth Factor Panel 1 Kit (eBioscience) contains the following analytes: Brain-Derived Neurotrophic Factor (BDNF); epitheliumGrowth factor (EGF), eotaxin, fibroblast growth factor 2 (FGF-2), granulocyte / macrophage-colony stimulating factor (GM-CSF), GRO alpha (CXCL1), hepatocyte growth factor (HGF), interferon (IFN) alpha, IFN gamma (IFNγ), interleukin (IL)-1 receptor alpha (IL-1RA), IL-1 alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, interferon gamma-inducible protein 10 (IP-10; also known as CXCL10), leukemia inhibitory factor (LIF), monocyte chemoattractant protein-1 (MCP-1; also known as CCL2), macrophage inflammatory protein 1 alpha (MIP-1 alpha; also known as CCL3), MIP-1 beta (also known as CCL4), beta-nerve growth factor (NGF beta), RANTES (Regulated Antigen-Associated Protein 10 (Regulated Antigen-Associated Protein 10 (Regulated Antigen-Associated Protein 10 (Regulated Antigen-Associated Protein 10)), IL-22, IL-23, IL-27, IL-31, interferon gamma-inducible protein 10 (IP-10; also known as CXCL10), leukemia inhibitory factor (LIF), monocyte chemoattractant protein-1 (MCP-1; also known as CCL2), macrophage inflammatory protein 1 alpha (MIP-1 alpha; also known as CCL3), MIP-1 beta (also known as CCL4), beta-nerve growth factor (NGF beta), RANTES (Regulated Antigen-Associated Protein 10 (Regulated Antigen-Associated Protein 10)), IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-37, IL-38, IL-39, IL-40, IL-41, IL-42, IL-43, IL-44, IL- This is a 45-plex magnetic bead-based kit for the multiplex detection of IL-13 upon Activation Normal T cell Expressed and Secreted, Platelet-Derived Growth Factor BB (PDGF-BB), Placental Growth Factor 1 (PIGF-1), Stem Cell Factor (SCF), Stromal-Derived Factor 1 alpha (SDF-1 alpha, also known as CXCL12 alpha), Tumor Necrosis Factor alpha (TNF alpha), TNF beta (also known as lymphotoxin alpha), Vascular Endothelial Growth Factor alpha (VEGF-A), and Vascular Endothelial Growth Factor D (VEGF-D). The assay was performed according to the manufacturer's specific protocol. Data were collected on a Bio-Rad Bio-Plex® 200 instrument (Bio-Rad, Hercules, CA) running Bio-Plex Manager software version 6.1.
[0339] On day 11, plasma collected from the mice was used to assess the expression of human cytokines and human growth factors. See FIG. 22A. Because the T cells transferred into MOLM-13 and NSG mice are of human origin, the measurement of human cytokines allowed for further insight into the mechanism of action of CAR-T cells acting against tumor cells. In MOLM-13 tumor-bearing mice treated only with saline, some human systemic cytokines were detected, such as MCP-1 and MIP1 beta (data not shown), as well as several other growth factors, but the levels of cytokines such as IFNγ and TNFα were below the detection range (FIG. 22A). MOLM-13 tumor-bearing mice treated with non-transduced T cells also continued to show similar cytokine and growth factor expression patterns compared to the group treated only with saline. The cytokine and growth factor levels seen in the non-transduced T cell group provide a baseline value for the mixture of human T cells and tumor cells in this mouse model system. Analysis of cytokine expression data by CD33-CAR-T cells (whether or not the CAR T cells co-expressed the cell tag) showed significant levels of IFNγ and TNF production, in addition to GM-CSF, IL-10, IL-18, and IP-10. In contrast, administration of CD19-CAR-T cells to MOLM-13 tumor-bearing mice showed modestly elevated levels of cytokines such as GM-CSF, IFNγ, and IL-18 compared to mice treated with saline alone or non-transduced T cells, but the expression levels of these cytokines were not significantly elevated when compared to the levels of the same cytokines detected in mice treated with CD33-CAR-T cells (without the cell tag) or CD33-CAR-T cells (with the cell tag) or CD33-CAR-T cells (with the cell tag; two doses).
[0340] Blood samples were taken at the designated time points of the study to assess the presence of tumor cells as well as adoptively transferred T cells by flow cytometry. As shown in Figure 22B, the presence of MOLM-13 / fLUC cells could be detected in the peripheral blood of mice at day 16. To avoid underestimation or potential loss of CD33 antigen in MOLM-13 cells, CD123 antibody was used to identify tumor cells. MOLM-13 tumor cells were detected in peripheral blood samples obtained from mice administered saline alone, non-transduced T cells, or CD19-CAR-T cells. In addition, transferred T cells were detected in blood from mice administered non-transduced T cells or CD19-CAR-T cells as early as day 16 and day 11 when cell analysis of blood was started. Blood from mice administered CD33-CAR-T cells showed little to no presence of MOLM-13 tumor cells, while a T cell population was clearly present.
[0341] Figure 22C confirms the cytotoxic activity against additional AML tumor cell lines (THP1 and HL60). Further evidence for the redirected cytotoxic function of CD33-CAR-T cells was provided by assessing cytokine expression by immune effector cells upon co-culture with CD33 tumor cells. Several CD33-expressing tumor cell lines were evaluated for induction of IFNγ, TNF (also referred to as TNFα), and IL-2 expression after co-culture with CD33-CAR-T cells. Co-culture of CD33-CAR-T cells with CD33-expressing tumor cells caused a significant increase in IFNγ, TNF, and IL-2 expression compared to non-transduced T cells derived from the same donor (Figure 10). Furthermore, no cytokine expression was detected from the parental EL4 cell line used as a negative control for tumor targeting. Intracellular cytokine staining (ICS) was performed as a further confirmation of target specificity. Whereas CD33-CAR-T cells demonstrated cellular expression of both IFNγ and IL-2 following overnight coculture with CD33-expressing MOLM-13, THP-1, or HL-60 tumor cells, coculture with murine EL4 cells did not demonstrate significant cytokine expression above the levels seen by T cells alone (Figure 23E).
[0342] CD33-CAR-T cells were generated from cells obtained from an AML patient (donor E261) with relapsed AML disease. Briefly, cryopreserved PBMCs from an AML donor were thawed and T cells were selected and expanded using anti-CD3 / anti-CD28 beads. T cells were transduced with CD33-CAR LV particles and expanded in culture. Characterization of this thawed PBMC sample revealed that T cells were present in the PBMC sample from this donor at low frequency and consisted mainly of CD33+ cells (Figure 23A). T cells were isolated, activated and expanded for transduction with LV to generate CD33-CAR-T cells. The remaining cells after T cell isolation were CD33+ (Figure EB) and maintained in culture with the use of the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). For this AML donor, approximately 41% of the T cells expressed CD33-CAR on the cell surface as assessed after 12 days of culture following LV transduction (Figure 23C). Cytotoxic activity was confirmed in flow cytometry-based co-culture assays of CD33-CAR-T cells derived from this donor with MOLM-13 tumor cells or the patient's own CD33-expressing tumor cells. Evaluation of the remaining cell population for CD3 (T cell) and CD33 (tumor) expression on cells by staining at the time points assessed (day 0 and day 3) showed that only co-culture with CD33-CAR-T cells was able to eliminate CD33-expressing tumor cells, whereas no cell killing was observed in the co-culture setting with untransduced (UNT) T cells (Figure 23D).
[0343] In addition, CD33-CAR-T cells generated from AML donors also induced expression of IFNγ and IL-2, as assessed by flow cytometry using intracellular cytokine staining. Intracellular cytokine staining was performed 18 hours after co-culture of CD33-CAR-T cells (derived from AML donor E261) with the indicated tumor cells. T cells were cell surface stained and then stained for the cytokines IFNγ and IL-2 following fixation / permeabilization. Cells were gated based on FSC / SSC / live / CD3 T cells. Whereas co-culture of CD33-CAR-T cells alone or with mouse EL4 tumor cells did not show expression of IFNγ or IL-2, increased expression of both cytokines was observed after co-culture with MOLM-13 or tumor cells derived from specific donor cells (Figure 23E). In addition, cytokine expression from cells expressing CD33-CAR was specifically induced, whereas T cells not expressing CAR did not show cytokine expression.
[0344] [Example 7] Lentiviral CD33 CARs with various signaling domains were constructed and examined for expression. Lentiviral particles with CD33 CAR with only CD3ζ signaling domain, CD33 CAR with CD28-CD3z (referred to as CD28z) signaling domain, or CD33 CAR with CD28-CD3z domain with co-expression of withHER1t were transduced into pre-activated human T cells according to the schematic outlined in Figure 4. Flow cytometry analysis was performed on T cells 12-14 days after transduction. Expression of CD33 CAR was detected via protein L staining and HER1t was detected via cetuximab staining (Figures 15A and 15B).
[0345] To confirm the specificity of the CD33 CAR (with different signaling domains) recognizing its target, co-culture assays were performed on various tumor cell lines. Expression of CD33 on the tested cell lines was displayed (Figure 16A). It should be noted that K562 cells express CD33 endogenously, so expression was observed in K562 / CD123, and the K562 / CD33 cell line was transduced to overexpress CD33. EL4 is a mouse cell line that does not express human CD33. Cytotoxicity was determined by labeling various tumor target cell lines using DELFIA BATDA reagent (DELFIA EuTDA Cytotoxicity Assay; Perkin Elmer), and then co-culturing CD33 CAR T cells or untransduced T cells (UNT) with the labeled tumor cells at an effector:target ratio (E:T) of 20:1. After 2 hours, the supernatant from the assay was harvested, developed by adding DELFIA Europium assay, and read on a time-resolved fluorometer (Figure 16B). Robust IFNγ production was obtained by co-culture of CD33 CAR T cells with CD33-expressing tumor cells using an effector:target (E:T) ratio of 20:1 and incubation for 18 hours, and culture supernatants were harvested and assayed for IFNγ production by ELISA according to the manufacturer's instructions. Untransduced T cells (UNT) showed little to no detectable IFNγ in the co-cultures (Figure 16C).
[0346] Lentiviral transduction of T cells derived from cryopreserved PBMC samples of patients diagnosed with AML was performed similarly to the steps outlined above for transduction of T cells derived from healthy donor T cells. Briefly, anti-CD3 / CD28 beads followed by lentiviral transduction of CD33 CAR-41BBz-T2A-HER1t at varying MOIs was used to activate T cells isolated from PBMC samples. Transduced T cell cultures were expanded over a 14-day culture period. CAR expression, as determined by protein L staining, was assessed throughout the culture expansion period. CD33 CAR levels were observed on the T cell surface (data not shown). Donor autologous CD33-expressing tumor cells as well as AML tumor cell lines were used to confirm the cytotoxic activity of CD33 CAR T cells. In one case, a low E:T ratio was used to set up co-cultures. At various time points, flow cytometry analysis was performed to determine the presence and frequency of T cells, and CD33-expressing tumor cells present in co-culture were evaluated at various time points.The co-culture of CD33 CAR-T cells with autologous CD33-expressing tumor cells confirmed cytotoxic activity, as determined by the reduction or absence of CD33+ tumor cells (data not shown).Similar findings were also observed with known AML tumor cell lines tested, such as MOLM-13.
[0347] [Example 8] CD33 CAR by Sleeping Beauty Various CD33 CAR constructs were constructed and generated in the Sleeping Beauty transposase-transposon system (Figure 3). For example, CD33-CD8a-CD28TM-CD3z constructs were generated with various EF1a promoter lengths (short, medium, and long). CD33 CAR constructs with HER1t cell tags were also generated and examined.
[0348] The CAR construct was introduced into cells via electroporation using a Sleeping Beauty-based transposon system to mediate integration of the construct into the genome. On day 0, 20 million PBMCs were resuspended in 100 μL of Amaxa Human T cell Nucleofector solution (model number: VPA-1002; Lonza, Basel, Switzerland) mixed with 15 μg of transposon and 5 μg of transposase (pKan-CMV-SB11) and electroporated using Program U-14. The next day (day 1), cells were counted and surface stained for CAR expression by protein L staining and HER1t staining using cetuximab. Cells were stimulated with γ-irradiated (100 Gy) or mitomycin C-treated AaPC at a ratio of 1:1. The AaPC cells used were K562-AaPC expressing CD64-CD86-41BBL-CD19-mbIL-15 / IL15Ra-ROR1 antigens with endogenous expression of CD33. CAR T cells were stimulated with AaPC at a ratio of 1:1. Cultures were supplemented with IL-21 (30 ng / ml) only for the first round of stimulation, then with recombinant human IL-2 (50 IU / ml) and IL-21 (30 ng / ml) (PeproTech) for the remaining stimulations. T cell cultures were phenotyped at the end of each stimulation cycle, which typically lasted for 7 days. Cultures were phenotyped for CAR expression using protein L staining or by recombinant CD33 / Fc protein staining detected by multiparameter flow cytometry. Cultures were also closely monitored for proliferation of NK cells (defined as the CD3- CD56+ population), which were removed from CAR T cell cultures using magnetic beads for CD56 (Stem Cell Technologies and / or Miltenyi Biotec) according to the manufacturer's instructions when the percentage exceeded 10% of the total cell population.Flow cytometry was used to assess expression of CD33 CAR from multiple donor PBMCs following stimulation with AaPC.
[0349] To confirm the specificity of the CD33 CAR (with various signaling domains) recognizing its target, co-culture assays were performed on various tumor cell lines. Note that K562 cells endogenously express CD33 and EL4 is a mouse cell line that does not express human CD33. Cytotoxicity was determined by labeling various tumor target cell lines using DELFIA BATDA reagent (DELFIA EuTDA Cytotoxicity Assay; Perkin Elmer) and then co-culturing CD33 CAR T cells or untransduced T cells (UNT) with labeled tumor cells at an effector:target ratio (E:T) of 10:1 and an E:T ratio of 2:1. After 2 hours, the supernatant from the assay was collected and developed by adding DELFIA Europium Assay and read on a time-resolved fluorometer (Figure 17).
[0350] Degranulation assay and intracellular cytokine staining with IFNγ CD107a, also known as lysosomal membrane protein 1 (LAMP-1), is constitutively expressed in the late endosome-lysosomes of cells, but transiently expressed on the cell surface of degranulated cells. A degranulation assay was established to evaluate the ability of CD33 CAR T to recognize different target cells with or without CD33 expression by the simultaneous detection of intracellular IFNγ per cell. Briefly, CD33 CAR T cells were co-cultured with target cells at an E:T ratio of 10:1 in 96-well plates. Target cells included K562 / CD19 (with endogenous CD33 expression), THP-1 and EL-4 (mouse cell lines). At the beginning of co-culture, fluorescently conjugated CD107a antibody or fluorescently conjugated isotype antibody was added together with Transport Inhibitor Cocktail (containing monensin and brefeldin; 1x concentration; eBioscience) and incubated at 37°C for 4 hours. At the end of the incubation period, cells were pelleted in the plate and cell surface antigens were stained for CAR expression and T cell marker detection. After cell surface staining, cells were also stained with Fixable Cell viability dye (eBioscience) according to the manufacturer's instructions, then washed, followed by fixation with Fix / Perm Solution (BD Biosciences). After fixing the samples, cells were washed in Perm / Wash solution (BD Biosciences) and then stained intracellularly with fluorescently conjugated anti-human IFNγ antibody. Samples were washed and then resuspended in the appropriate staining buffer, and data was collected by LSR II flow cytometer (BD Biosciences). As shown in Figure 18, prominent expression of CD107a degranulation was observed only in K562-derived cells and the CD33-expressing THP-1 cell line, whereas minimal degranulation was observed in immune effector cells alone and in co-culture with EL-4. A similar pattern was observed for intracellular IFNγ expression.
[0351] [Example 9] The CAR construct was introduced into cells via electroporation using a Sleeping Beauty-based transposon system to mediate integration of the construct into the genome. On day 0, 20 million PBMCs were resuspended in 100 μL of Amaxa Human T cell Nucleofector solution (model number: VPA-1002; Lonza, Basel, Switzerland) mixed with 15 μg of transposon (for CD33 CAR-CD8-CD28z) and 5 μg of transposase (pKan-CMV-SB11) and electroporated using Program U-14. The next day (day 1), cells were counted and surface stained for CAR expression by protein L staining and HER1t staining using cetuximab. Cells were stimulated with γ-irradiated (100 Gy) or mitomycin C-treated AaPC at a ratio of 1:1. The AaPC cells used were K562-AaPC expressing CD64-CD8641BBL-CD19-mbIL-15 / IL15Ra-ROR1 antigens. CAR T cells were stimulated with AaPC at a ratio of 1:1. Cultures were supplemented with IL-21 (30 ng / ml) only for the first round of stimulation, then with recombinant human IL-2 (50 IU / ml) and IL-21 (30 ng / ml) (Pepro-Tech) for the remaining stimulations. T cell cultures were phenotyped at the end of each stimulation cycle, which typically lasted for 7 days. Cultures were phenotyped for expression of CAR T cells using protein L staining or by recombinant CD33 / Fc protein staining detected by multiparameter flow cytometry. Cultures were also closely monitored for proliferation of NK cells (defined as the CD3- CD56+ population), which were removed from CAR T cell cultures using magnetic beads for CD56 (Stem Cell Technologies and / or Miltenyi Biotec) according to the manufacturer's instructions when the percentage exceeded 10% of the total cell population.Flow cytometry was used to assess expression of CD33 CAR from multiple donor PBMCs following stimulation with AaPCs.Data from representative donors are summarized in Table 3 for CD33 CAR-CD8-CD28z and in Table 4 for CD33-CAR-CD8-4-1BBz with or without the HER1t cell tag. Figure 19 further supports expression of the Sleeping Beauty CD33 CAR-CD28z construct with the HER1t tag.
[0352] Table 4 confirms the expression of the exemplary Sleeping Beauty CD33-CD8a-CD28z CAR in various PBMC donors.
[0353] [Table 4]
[0354] Table 5 confirms the expression of an exemplary Sleeping Beauty CD33-CD8a-41BBz CAR with and without expression of the HER1t tag in various PBMC donors.
[0355] [Table 5]
[0356] [Example 10] Lentiviral transduction of NK cells was also performed with CD33 CAR coupled to various HER1t tags (SEQ ID NOs: 32 and 54) and C20t tags. Figures 25-27 confirm the expression of CD33 CAR and HER1t and CD20t-1 tags on NK cells. Figures 28-29 also confirm that CD33 CAR NK cells efficiently lyse NK-resistant CD33+ AML cells at different E:T ratios. When co-cultured with different target cells, CD33 CAR NK cells produced cytokines (e.g., IFNγ, TNF-a, IL-6, RANTES, GM-CSF, IL-10, MIP-1a, and MIP-1b) (data not shown).
[0357] Unless otherwise defined, all technical and scientific terms and any acronyms used herein have the same meaning as commonly understood by one of ordinary skill in the art of the present invention.
[0358] Although preferred embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are presented for the purpose of example only. Numerous changes, variations, and substitutions will now occur to those skilled in the art without departing from the present disclosure. It should be understood that various alternatives to the embodiments described herein, or combinations of one or more of the embodiments or aspects described therein, may be utilized in the practice of the present disclosure. The following claims define the scope of the present disclosure, and it is intended that methods and structures within the scope of these claims, and their equivalents, be covered thereby. The present invention may include the following aspects. [1] 1. An isolated nucleic acid encoding a chimeric antigen receptor (CAR), the CAR comprising: (a) a CD33 antigen-binding domain, (b) stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; (e) CD3 zeta signaling domain 2. An isolated nucleic acid comprising: [2] the CD33 antigen-binding domain comprises (a) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:8 (hM195scFv); (b) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 9 and 10 (M2H12); (c) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 11 and 12 (DRB2); and (d) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 14 and 15 (My9-6). The isolated nucleic acid of claim 1, comprising at least one of: [3] 3. The isolated nucleic acid of claim 1 or 2, wherein the CD33 antigen-binding domain is a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:8 (hM195scFv). [4] 3. The isolated nucleic acid of claim 1 or 2, wherein the stalk domain is a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 22 (CD8 alpha hinge). [5] 5. The isolated nucleic acid of any one of claims 1 to 4, wherein the costimulatory signaling domain comprises 4-1BB. [6] The isolated nucleic acid of claim 5, wherein the costimulatory signaling domain of 4-1BB comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:24. [7] 6. The isolated nucleic acid of any one of claims 1 to 5, wherein the costimulatory signaling domain comprises CD28. [8] 9. The isolated nucleic acid of claim 7, wherein the costimulatory signaling domain of CD28 comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:28. 9. The isolated nucleic acid of any of claims 1 to 8, wherein the CD3 zeta signaling domain comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:26.
[10] cutting type epithelium 10. The isolated nucleic acid of any one of claims 1 to 9, further comprising a growth factor receptor.
[11] The cutting type epithelium The isolated nucleic acid of claim 10, wherein the growth factor receptor is HER1t and comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 32.
[12] The cutting type epithelium The isolated nucleic acid of claim 10, wherein the growth factor receptor is HER1t-1 and comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:54.
[13] 2. The isolated nucleic acid of claim 1, wherein the CAR comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 39, 41, 43, 45, 47, 49, 51, 53, or 55.
[14] The skeleton and (1) HER1t, HER1t-1, or a truncated form containing at least one of these functional mutants epithelium Growth factor receptors, and (2)(a) a CD33 antigen-binding domain, (b) stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; and (e) CD3 zeta signaling domain Chimeric antigen receptor (CAR) comprising and a nucleic acid sequence encoding the same.
[15] The skeleton and (1) full-length CD20, truncated CD20 (CD20t-1), or functional mutants thereof; and (2)(a) a CD33 antigen-binding domain, (b) stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; and (e) CD3 zeta signaling domain Chimeric antigen receptor (CAR) comprising and a nucleic acid sequence encoding the same.
[16] 16. The vector of claim 14 or 15, which is a lentiviral vector, a retroviral vector, or a non-viral vector.
[17] The cutting type epitheliumThe vector of claim 14, wherein the growth factor receptor comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:32 or SEQ ID NO:54.
[18] 16. The vector of claim 15, comprising a nucleotide sequence encoding a truncated CD20 (CD20t-1), or a functional variant thereof, wherein said CD20t-1 comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:56.
[19] 16. The vector of claim 15, wherein the full-length CD20 comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:36.
[20] 21. The vector of any one of claims 14 to 19, further comprising a nucleotide sequence encoding a self-cleaving Thosea asigna virus (T2A) peptide. 21. The vector of any one of claims 14 to 20, wherein the backbone is a Sleeping Beauty transposon DNA plasmid or pFUGW. [twenty two] 22. The vector of any one of claims 14 to 21, further comprising a promoter. [twenty three] 23. The vector of claim 22, wherein the promoter is hEF1a1. [twenty four] the CD33 antigen-binding domain comprises (a) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:8 (hM195scFv); (b) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 9 and 10 (M2H12); (c) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 11 and 12 (DRB2); and (d) a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NOs: 14 and 15 (My9-6). 24. The vector according to any one of claims 14 to 23, comprising at least one of the following: [twenty five] 25. The vector of any of claims 14 to 24, wherein the CD33 antigen-binding domain is a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:8.
[26] 26. The vector of any of claims 14 to 25, wherein the stalk domain comprises a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 22 (CD8 alpha hinge).
[27] 27. The vector of any of claims 14 to 26, wherein the costimulatory signaling domain comprises 4-1BB.
[28] 29. The vector of claim 27, wherein the costimulatory signaling domain of 4-1BB comprises a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:24. 27. The vector of any one of claims 14 to 26, wherein the costimulatory signaling domain comprises CD28.
[30] 30. The vector of claim 29, wherein the costimulatory signaling domain of CD28 comprises a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:28.
[31] 31. The vector of any of claims 14 to 30, wherein the CD3 zeta signaling domain comprises a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:26.
[32] 32. A vector according to any one of claims 14 to 31, comprising a plasmid.
[33] 32. The vector of claims 14 to 31, wherein each said vector comprises an expression plasmid.
[34] The vector of claim 16, wherein the non-viral vector is a Sleeping Beauty transposon.
[35] An immune effector cell comprising a nucleotide according to any one of claims 1 to 13. Skeleton and (1) Amputation type epithelium An immune effector cell comprising a vector comprising a growth factor receptor (HER1t) and (2) a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[37] (1) A cell tag for use as a kill switch, a selection marker, a biomarker, or a combination thereof, and (2) an immune effector cell comprising a chimeric antigen receptor (CAR) comprising (a) a CD33 antigen-binding domain, (b) a stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both, and (e) a CD3 zeta signaling domain.
[38] The immune effector cell of claim 37, wherein the cell tag comprises HER1t, HER1t-1, CD20t-1, or CD20.
[39] The immune effector cell of claim 38, wherein the cell tag comprises HER1t, and the HER1t comprises the polypeptide sequence of SEQ ID NO: 32.
[40] The immune effector cell of claim 38, wherein the cell tag comprises HER1t-1, and the HER1t-1 comprises the polypeptide sequence of SEQ ID NO: 54.
[41] 35. An immune effector cell comprising a vector according to any one of claims 14 to 34.
[42] 43. The immune effector cell of any one of claims 35 to 41, which is a T cell, a natural killer (NK) cell, a cytotoxic T lymphocyte (CTL), or a regulatory T cell. The immune effector cell of claim 42, wherein the CD33 antigen-binding domain, upon binding to CD33, exhibits anti-tumor immunity.
[44] 1. A method for stimulating a T cell-mediated immune response against a target cell population or target tissue in a human subject in need thereof, comprising administering to the human subject an effective amount of a cell genetically modified to express a CAR, wherein the CAR (a) a CD33 antigen-binding domain, (b) stalk domain, (c) a transmembrane domain, (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both; (e) the CD3 zeta signaling domain, and (f) Cutting type epithelium Growth factor receptor (HER1t) A method comprising:
[45] 45. The method of claim 44, wherein the human has been diagnosed with acute myeloid leukemia (AML).
[46] 46. The method of claim 45, wherein the acute myeloid leukemia is relapsed or refractory AML.
[47] 1. An isolated nucleic acid encoding a chimeric antigen receptor (CAR), the CAR comprising: (a) a CD33 antigen-binding domain with the amino acid sequence of SEQ ID NO:8; (b) a stalk domain with the amino acid sequence of SEQ ID NO: 22; (c) a costimulatory signaling domain comprising CD28 with the amino acid sequence of SEQ ID NO: 28; (d) a HER1 tag comprising at least one of HER1t having the amino acid sequence of SEQ ID NO: 32 and HER1t-1 having the amino acid sequence of SEQ ID NO: 54; (e) a CD3 zeta signaling domain with the amino acid sequence of SEQ ID NO: 26 2. An isolated nucleic acid comprising:
[48] 1. An isolated nucleic acid encoding a chimeric antigen receptor (CAR), the CAR comprising: (a) a CD33 antigen-binding domain with the amino acid sequence of SEQ ID NO:8; (b) a stalk domain with the amino acid sequence of SEQ ID NO: 22; (c) a costimulatory signaling domain comprising 4-1BB with the amino acid sequence of SEQ ID NO: 24; (d) a HER1 tag comprising at least one of HER1t having the amino acid sequence of SEQ ID NO: 32 and HER1t-1 having the amino acid sequence of SEQ ID NO: 54; (e) a CD3 zeta signaling domain with the amino acid sequence of SEQ ID NO: 26 2. An isolated nucleic acid comprising:
[49] 49. A vector comprising any one or more of the polynucleotides of claims 47 and 48.
[50] 50. The vector of claim 49, which is a lentiviral vector, a retroviral vector, or a non-viral vector.
[51] 51. The vector of claim 50, wherein the non-viral vector is a Sleeping Beauty transposon.
[52] 50. The vector of claim 49, which is a plurality of vectors.
[53] A system for expressing a CAR in an immune effector cell, the system comprising one or more vectors encoding the isolated nucleic acid of any one of claims 1 to 13 and 47 to 48.
[54] The system of claim 53, wherein the immune effector cell is a T cell or a NK cell. 55. The system of any one of claims 53 to 54, further comprising nucleic acid encoding at least one further gene.
[56] 56. The system of claim 55, wherein the additional genes comprise cytokines.
[57] 57. The system of claim 56, wherein the cytokine comprises at least one of IL-2, IL-15, IL-12, IL-21, and a fusion of IL-15 with IL-15Rα.
[58] 57. The system of claim 56, wherein the cytokine is in a secreted form.
[59] 57. The system of claim 56, wherein the cytokine is in membrane-bound form.
[60] 60. The system of any one of claims 53 to 59, comprising one vector.
[61] 61. The system of any one of claims 53 to 60, wherein the one or more vectors are lentiviral vectors, retroviral vectors, or non-viral vectors.
[62] 62. The system of claim 61, wherein the non-viral vector is a Sleeping Beauty transposon.
[63] 63. The system of claim 62, further comprising a Sleeping Beauty transposase.
[64] 64. The system of claim 63, wherein the Sleeping Beauty transposase is SB11, SB100X, or SB110.
[65] 65. The system according to any one of claims 53 to 64, wherein the immune effector cells are mammalian cells.
[66] 67. A method of expressing a CAR in an immune effector cell, comprising contacting the immune effector cell with the system of any one of claims 53 to 65. 1. A method of stimulating the proliferation and / or survival of modified T cells, comprising: (a) obtaining a sample of cells from a subject, said sample comprising T cells or precursors of T cells; (b) transfecting the cells with one or more vectors encoding the isolated nucleic acid of any one of claims 1-13 and 47-48, and a vector encoding a transposase, resulting in a population of modified CD33 CAR-expressing T cells; (c) optionally culturing said population of CD33 CAR T cells ex vivo for 2 days or less. The method includes:
[68] 68. The method of claim 67, further comprising transfecting the cells with a vector encoding a cytokine.
[69] 69. The method of claim 68, wherein the cytokine is a fusion protein comprising IL-15 and IL-15Rα.
[70] 70. The method of any one of claims 66 to 69, wherein the one or more vectors are lentiviral vectors, retroviral vectors, or non-viral vectors.
[71] 71. The method of claim 70, wherein the non-viral vector is a Sleeping Beauty transposon.
[72] 72. The method of claim 71, further comprising a Sleeping Beauty transposase.
[73] 73. The method of claim 72, wherein the Sleeping Beauty transposase is SB11, SB100X, or SB110.
Claims
1. The skeleton and (a) a nucleic acid encoding a truncated epidermal growth factor receptor comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:54; and (b)(i) a CD33 antigen-binding domain, (ii) the stalk domain; (iii) a transmembrane domain, (iv) a costimulatory signaling domain comprising 4-1BB and / or CD28, and (v) CD3 zeta signaling domain A nucleic acid encoding a chimeric antigen receptor comprising and a vector comprising:
2. The vector of claim 1 , which is a lentiviral vector, a retroviral vector, or a non-viral vector.
3. 3. The vector of claim 1 or 2, wherein the truncated epidermal growth factor receptor comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:54 or an amino acid sequence that differs from SEQ ID NO:54 by 1 to 20 conservative amino acid substitutions.
4. the CD33 antigen-binding domain comprises: (a) a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:8; (b) (i) a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:9, and (ii) a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:10; (c) (i) a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:11, and (ii) a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:12, and (d) (i) a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO: 13, and (ii) a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:
14. The vector according to any one of claims 1 to 3, comprising at least one of the following:
5. The vector of any one of claims 1 to 4, wherein the costimulatory signaling domain comprises a 4-1BB signaling domain.
6. The vector of any one of claims 1 to 5, wherein the costimulatory signaling domain comprises a CD28 signaling domain.
7. The vector according to any one of claims 1 to 6, wherein the vector is a Sleeping Beauty transposon.
8. (a) the CD33 antigen-binding domain comprises a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:8; (b) the stalk domain comprises a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:22; (c) the costimulatory signaling domain comprises a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:28; and (d) the CD3 zeta signaling domain comprises a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:26: The vector described in claim 1.
9. (a) the CD33 antigen-binding domain comprises a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:8; (b) the stalk domain comprises a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:22; (c) the costimulatory signaling domain comprises a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO: 24; and (d) the CD3 zeta signaling domain comprises a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:26: The vector described in claim 1.
10. The vector of any one of claims 1 to 9, wherein the truncated epidermal growth factor receptor comprises the amino acid sequence of SEQ ID NO:
54.
11. 10. The vector of any one of claims 1 to 9, wherein the truncated epidermal growth factor receptor comprises an amino acid sequence that differs from SEQ ID NO:54 by 1 to 20 conservative amino acid substitutions.
12. A vector described in any one of claims 1 to 11, further encoding a fusion protein comprising (a) IL-15 or a functional variant thereof and (b) IL-15Rα or a functional variant thereof.
13. The vector according to any one of claims 1 to 11, further encoding a fusion protein comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:
37.
14. The vector of any one of claims 1 to 11, further encoding a fusion protein comprising a polypeptide that differs from the amino acid sequence of SEQ ID NO: 37 by 1 to 20 conservative amino acid substitutions.
15. An immune effector cell comprising the vector according to any one of claims 1 to 14.
16. The immune effector cell of claim 15, which is a T cell or a natural killer (NK) cell.
17. The immune effector cell of claim 15 or 16, which is a cytotoxic T lymphocyte or a regulatory T cell.
18. A composition comprising an effective amount of an immune effector cell according to any one of claims 15 to 17 for stimulating a T cell-mediated immune response against a target cell population or a target tissue in a human subject.
19. 20. The composition of claim 18, wherein the human subject has been diagnosed with acute myeloid leukemia (AML).
20. 20. The composition of claim 19, wherein the AML is relapsed or refractory AML.
21. A system for expressing a chimeric antigen receptor in an immune effector cell, comprising: (a) the vector of claim 7; and (b) Sleeping Beauty transposase.
22. The system of claim 21 , wherein the immune effector cell is a T cell or a NK cell.
23. 23. The system of claim 21 or 22, further comprising nucleic acid encoding at least one further gene.
24. 24. The system of claim 23, wherein the further gene encodes a cytokine.
25. 25. The system of claim 24, wherein the cytokine comprises at least one of IL-2, IL-15, IL-12, and IL-21.
26. 1. A method of stimulating the proliferation or survival of an engineered T cell, comprising: (a) transfecting in vitro T cells or progenitor T cells with (i) a vector according to any one of claims 1 to 14, and (ii) a vector encoding a transposase, thereby generating a population of modified T cells expressing a chimeric antigen receptor comprising a CD33 antigen-binding domain; (b) optionally culturing the population of modified T cells ex vivo for two days or less; The method includes:
Citation Information
Patent Citations
Truncate epidermal growth factor receptor (EGFRt) for transduction T cell selection
JP2013509879A
CD33 specific chimeric antigen receptors for cancer immunotherapy
WO2015150526A2
Method and compositions for cellular immunotherapy
WO2015157391A1
Chimeric antigen receptors and methods of making
WO2015123642A1
Treatment of cancer using chimeric antigen receptor
WO2015142675A2
